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ABSTRACT 
The purpose of this study was to investigate several biological markers that may predict the 
response of muscle invasive transitional cell carcinoma TCC of the bladder to radical 
radiotherapy. The specific markers chosen were tumour angiogenesis (CD31 &CD34), 
tumour cell proliferation (K.i-67) and apoptosis (bcl-2), intratumour macrophage infiltration 
(CD68) and p53. 
Archival formalin fixed paraffin embedded pre treatment bladder biopsies from I 0 I 
patients with muscle invasive TCC were obtained. All patients subsequently received 
radical radiotherapy as their only treatment for the disease. 4f.llll sections were graded 
according to the WHO grading system and staged by the TNM classification. Angiogenesis 
(CD3I&CD34) counts were obtained using a 25-point Chalkley eyepiece graticule. Bcl-2 
scored as positive and negative, while p53, Ki-67 and CD68 were estimated using an 
eyepiece graticule. The medical records were examined to assess the response of the 
tumour at the 3-month post radiotherapy cystoscopy and the long-term outcome. Patients 
were classified into two groups in two sections: the first section includes (I) those free of 
disease (no tumour detected in the bladder at the 3-month cystoscopy), (2) those with 
resistant disease (tumour present at 3 months). The second section includes (I) those with 
persistent or recurrent cancer in the bladder (tumour recurred after an initial 3 months 
negative check cystoscopy together with patients with resistant disease at 3 months), (2) 
those free of disease at all subsequent cystoscopies. 
Detailed statistical analysis revealed that there were no association between any of the 
markers examined and the response to radiotherapy. MVD using CD34 was lower in higher 
stage tumours (p=O.OSO). Females, whilst representing only a small fraction (16) of the total 
of patients studied showed an inferior response to radiotherapy when compared to that of 
male patients (p=0.048). Higher median haemoglobin levels for the response group 
(p=0.031) was observed as well as a positive significant correlation between p53 (Ll) 
expression and MIB-1 (LI) (r=0.332, p=O.OOJ). 
The Kaplan-Meier survival analysis shows that the survival time is significantly better for 
those who were exposed longer to radiotherapy (> 33 days) (Log Rank, p=0.0246). There 
was a significantly higher survival time for patients who have CD68 higher than 42.4 (log 
rank, p--D.036). 
The study concluded that none of the selected markers could be used as prognostic value in 
determining patients most suitable for radiotherapy as primary treatment with curative 
intent for their bladder cancer. The finding of a poorer response in females is worthy of 
further study since, hormonal and anatomical influences may be important. 
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INTRODUC¥10N 
INTRODUCTION 
l.l. General consideration 
260,000 new cancers (excluding non-melanoma skin cancers) were registered in the 
United Kingdom in 1997. 
During 1997 10,480 new cases of bladder cancer were registered. These accounts for 
4% of all cancers registered and make bladder cancer the fifth most common cancer in 
the United Kingdom. Only cancer of the lung (38,870 cases), cancer of the breast 
(38,270 cases), cancer of the colon and rectum (34,310 cases) and cancer of the prostate 
(21, 777 cases) are more prevalent. 
Bladder cancer is more common in men than in women, being the fourth most common 
cancer in men and the 8th most common in women. The difference in incidence between 
the sexes is becoming less and this may be related to the increased smoking habits seen 
in women. 
There were I 52,500 deaths due to cancer during 1999 and this accounts for 25% of all 
deaths. Figures collected between 1991 and 1993 indicate that the overall 5 year 
survival for bladder cancer in men was 65.7% and for women 57.6%. Thus during that 
period bladder cancer had the best 5 year survival for all common male cancers and the 
4th best for common female cancers. 
The figures above were taken from the Cancer Research Campaign website 
(www.crc.org.uk). 
It is therefore clear that the commitment required for the management of bladder cancer 
involves a significant part of most urologists' time. 
The majority (90%) of bladder cancers are transitional cell (TCC) cancers. 
Adenocarcinomas, squamous cell carcinomas and a variety of rare cancers make up the 
remainder (Barbara, et al., 1996). 
TCCs may present in a variety of histological grades and stages. The majority are well 
differentiated and superficial on the bladder wall. A minority (approximately 20%), 
however, are less well differentiated and invade into and through the muscular wall of 
the bladder. At the present time the only hope of cure with such tumours is either by 
total removal of the bladder (cystectomy) or external beam radiotherapy (EBRT). 
Although cystectomy is usually considered to have superior results as regards survival, 
the difference is small (5-year survival after cystectomy is 59% for pT2, 25% for pT3 
and 29% for pT4) (Dalbagni, et al., 2001) and radiotherapy has the advantage of organ 
preservation and avoiding surgery. Therefore, there would be a clinical advantage if 
parameters were available to select patients most likely to respond to radiotherapy. 
It is recognised that tumour oxygenation (in part, related to tumour vascularity) IS 
positively correlated with response to radiotherapy (Hopewell et al., 1989). Tumour 
oxygenation requires a neovascular response to the tumour and there is considerable 
direct evidence to support the idea that tumour growth and metastasis require 
neovascularisation. The process by which this neovascularisation occurs is known as 
tumour angiogenesis (Folkman, 1990). Angiogenic stimulators, as well as angiogenic 
inhibitors tightly regulate new vessel growth. As tumour growth and tumour invasion 
depend on this angiogenic response the ability to quantitate the degree of angiogenesis 
within or around a tumour may provide important prognostic information (Weidner et 
al., 1993; Pluda, 1997). Immunohistochemical methods have been developed which are 
capable of quantitating the neovascular response induced by a specific tumour. This 
quantitation has been accomplished by determining the microvessel density within and 
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around a tumour, using antibodies that recognise vascular endothelial cells (Stein et al., 
1998). 
1.1.1 The aetiology of bladder cancer 
Bladder cancer was the first cancer identified as being associated with industrialisation. 
In 1895, Dr. Ludwig Rehn reported on bladder cancer in German workers who 
manufactured aniline dyes. Later, this was shown to be related to the presence of 2-
naphthyl-amine in the dyes. Since then, many additional chemicals, along with 
environmental agents, have been identified as causes of bladder cancer (Ciayson et al., 
1970; Price, 1971; Cohen et al., 1992). 
Although a number of aetiological factors are associated with the development of 
bladder cancer, in industrialised countries cigarette smoking is by far the most 
significant environmental carcinogen today (Chiu et al., 2001). A fourfold increased 
risk for the development of bladder cancer has been reported in cigarette smokers 
(Clavel et al., 1989). The type and number of cigarettes, and use of filters have each 
been shown to be related, in a dose response manner, to the development of bladder 
cancer. Also time since cessation of smoking has been related to a reduction in its 
development (Vineis et al., 1998). 
Controversy exists as to whether coffee and other caffeine-containing beverages are 
involved in urinary tract carcinogenesis (Cohen et al., 1992). The results of 
epidemiological studies show marked variation, with studies indicating either no risk or 
a slight increase in relative risk. Interpretation of the studies is often difficult because of 
the presence of confounding factors, especially cigarette smoking. Experimental studies 
have failed to demonstrate that caffeine is carcinogenic to the urinary bladder 
(Johansson, et al., 1997). Also, both long-term carcinogenicity studies and multistage 
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studies have been negative for caffeine (Sternberg, 1999). The genotoxicity of caffeine 
also remains uncertain and is largely dependent on the type of assay being used and the 
caffeine concentrations attained in the assay system. The evidence strongly favours the 
conclusion that caffeine is not mutagenic in humans (Johansson, et al., 1997). 
Treatment with cytostatic drugs, especially cyclophosphamide, is associated with the 
risk of bladder cancer, as is the treatment of tissues lying close to the bladder with 
radiotherapy e.g. for uterine cancer (Tuttle et al., 1988; Kleinerman et al., 1995). 
In developing countries, especially in the Middle East and parts of Africa, infections 
with organism Schistosoma Haematobium is responsible for a high incidence of bladder 
cancer although 75% of these cases are squamous cell carcinomas rather than 
transitional cell carcinoma (EI-Bolkainy, 1983; Cohen et al., 1992). 
Certain areas of the Balkan countries, including the former Yugoslavia and Bulgaria, 
have increased death rates due to nephropathy. These patients also have a high 
prevalence of urothelial tumours involving both upper and lower urinary tracts. So far, 
extensive research has failed to reveal specific aetiologic factors responsible for the 
cancers in these patients. A mycotoxin and ochratoxin may induce nephropathy in pigs 
similar to the Balkan type in humans. It is unclear whether this compound is involved in 
the human disease or is related to the urothelial malignancies (Cohen et al., 1992). 
Certain regions of the Island of Taiwan have an increased incidence of peripheral 
vascular disease commonly referred to as "Blackfoot disease". Individuals suffering 
from this condition have an increased incidence of urinary tract malignancy (Johansson, 
et al., 1997; Yang et al., 2002). Arsenic has been suggested to be the culprit responsible 
for the vascular disease process and may also be involved in the development of 
urothelial cancer. A similar relationship between high levels of arsenic exposure and 
bladder cancer has been reported from Argentina and Chile (Hopenhayn-Rich, et al., 
1996). 
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Dietary factors in experimental animals and humans have been observed to influence 
the development of bladder cancer. It has been observed that individuals with greater 
vitamin A or carotene consumption have a lower incidence of bladder cancer than those 
with low consumption of the vitamin. To some extent, experimental studies have 
supported this view and have formed the basis for the use of retinoids as potential 
chemopreventive agents in patients with a previous papillary transitional cell carcinoma 
(Johansson, et al., 1997; Ross et al., 1996). 
N-nitrosamines are chemicals that can produce bladder cancer in rodents (Magee et al., 
1967). Nitrosamines can be formed in vivo from ingested nitrates and secondary amines 
by nitrate-reducing bacteria in the human bladder. Vitamin C can block this in vivo 
nitrosamine formation, but there is little epidemiological information at present 
available on the relationship between N-nitroso compounds or vitamin C intact and 
bladder cancer risk (Ross et al., 1996). 
Exposure to drinking water in areas with a high pesticide usage is associated with an 
increased risk of development of bladder cancer (Cohen et al., 1992; Lamm and Torti, 
1996), although the reason for this is unclear. 
There has been a suggestion that artificial sweeteners, especially sodium saccharin and 
cyclamate, are associated with increased risk of bladder cancer (Cohen et al., 1992). A 
large number of epidemiological studies have been performed to evaluate the 
relationship between exposure to these sweeteners and the development of bladder 
cancer in humans but have failed as yet to find such a relationship. 
Individuals who are immune-suppressed as a result of disease, such as genetic 
immunodeficiencies and acquired immunodeficiency syndrome (AIDS), or as a result of 
treatment, such as transplant patients, have an increased risk of developing 
malignancies. 
5 
Patients who receive a solid organ transplant have a threefold to fourfold increased risk 
of developing a malignancy (Penn, 2000). Three previous cases of bladder carcinoma 
after heart transplant have been reported (Maier and Grimm, 1994; Baldwin and Ruckle, 
1995; Stein et al., 1995). In these cases, the patients were diagnosed with bladder 
carcinoma 4 to 5 years after transplantation. The investigators of these reports 
speculated that chronic immunosuppression played a role in the development of the 
bladder carcinoma. In addition, 12 cases of bladder carcinoma in renal transplant 
patients have been also reported (Gifford et al., 1998). In most resent report by Berger 
et al., in 2002, reported the first case of transitional cell carcinoma of the bladder in a 
lung transplant recipient. Although, a direct causal relationship between the two cannot 
be established, the presentation of the tumour 1.5 years after lung transplantation 
suggests that chronic immunosuppression was a contributing factor. 
The human papilloma virus (HPV) family has been implicated in the development of 
bladder cancer (Zur, 1996). The presence of HPV DNA in squamous and transitional 
cell carcinoma of the bladder has been detected in 0-80% of tumours examined 
(Griffiths et al., 2000). Nevertheless, most studies report low HPV numbers (<10%) 
(Simoneau et al., 1999; Soulitzis et al., 2002), suggesting that HPV plays an important 
role in a small portion of bladder cancer cases. 
Urinary tract calculi have also been associated with an increased risk of bladder cancer 
(Burin et al., 1995; LaVecchia and Airoldi, 1999). This is likely to be due to repeated 
abrasion of the urothelium with regenerative hyperplasia and is frequently associated 
with squamous cell carcinoma rather than transitional cell carcinoma. 
Advanced techniques based on the molecular biology of bladder cancer have detected 
chromosomal aberrations correlating directly to mechanisms of carcinogenesis and 
tumour progression. Karyotyping reveals numeric alterations of the chromosomes 7, 8, 
9 and structural aberrations ofthe chromosomes 1, 5, 9, 11, l3 and 17, which finally, on 
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the molecular level, lead to alterations of the cellular activity and function of proto-
oncogenes and tumour suppressor genes and to modulated cellular signaling and 
transcription. The loss of specific chromosomal regions in urothelial carcinoma can 
result in structurally altered and therefore inactivated tumour-suppressor genes or 
activated carcinogenic oncogenes (Brauers et al., 2000). 
Numerical chromosomal aberrations in urothelial carcinoma mostly affect chromosome 
9 (Sandberg and Berger, I994). A complete deletion of chromosome 9 is present in 
about SO% of all bladder cancer specimens, but is rarely the only cytogenetic event and, 
in the majority of cases, is accompanied by various structural and numerical alterations 
of other chromosomes (Sandberg and Berger, I994). 
Structural chromosomal aberrations in transitional cell carctnoma mostly affect 
chromosomes 9, II, I7, I8, 3 and S (Brewster et al., 1994; Sandberg and Berger, I994). 
Several oncogenes and tumour suppressor genes, such as p I6, p2I (W AF I /CIP I), Rb I, 
ras, c-erbB-1 and pS3 are involved in the development and progression of bladder 
cancer (Brauers et al., 2000). 
1.1. 2 The epidemiology of bladder cancer 
Bladder cancer is one of the most common diseases treated by urologists. This is due to 
its high incidence (S1h most common cancer in the United Kingdom) and its tendency to 
recur anywhere the urinary tract is covered with transitional cell epithelium. 
Most bladder cancers in the UK and United States are transitional cell carcinomas. It is 
the sixth most common cause of death from malignant disease in men and the I Oth most 
common cause in women in the UK, with a mortality rate of 126 and 59 per million 
population, respectively (Working Group on Urological Cancer, 1996) and in I999 
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4850 bladder cancer deaths ( 4% all cancer deaths) were reported (ere website ). In 1997 
a total of 10,480 new bladder cancer cases was reported (ere website). 
In the South-Western Region of England, carcinoma of the bladder also ranks fifth 
among malignancies, with a crude annual incidence rate of 30.8 per I 00,000 for men 
and 11.5 per 100,000 for women (Thome et al., 1994). Between 1997-2007 the 
incidence is predicted to rise by 9% and the number of deaths by 10% (South and West 
Cancer Intelligence Unit, 1997). In the South and West, as nationally, there are clear 
upward incidence trends for both sexes (South and West Cancer Intelligence Unit, 
1997). 
The incidence of the disease has been increasing progressively since 1955.Yearly 
incidence continues to rise despite improved awareness of cancer-related carcinogens, 
both at home and in the workplace. 
Bladder cancer is the fourth most commonly diagnosed malignancy in men and the 
eighth most commonly diagnosed malignancy in women in the USA. In 2000, 
approximately 50,000 new cases were diagnosed, and over 10,000 deaths were 
attributed to the disease (Metts et al., 2000). 
The median age at diagnosis is 64 years, and the disease is rarely diagnosed before the 
age of 40. As the society ages, it will become even more significant as the fourth 
leading cause of cancer death in men aged over 89 years (Hassen et al., 2000). 
There is a marked male predominance in transitional cell carcinoma; the male to female 
ratio is at least 3: I (Brauers et al., 2000). However, recent reports have suggested an 
increased incidence of women presenting with muscle invasive cancer. Reasons for this 
trend are unclear but may be related to the increasing smoking habits in women (Hassen 
et al., 2000). 
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1.1.3 The histopathology of bladder cancer 
Familiarity with the histological and cytological features of the normal urinary bladder 
histology is essential to the understanding of the pathology of bladder cancer, leading to 
accurate tumour grading and staging that will ultimately determine the oncological 
management of these urothelial malignancies (Barbara, et al., 1996). The wall of the 
urinary bladder (Fig. 1) consists of the mucosa (lining epithelium and lamina propria), 
muscularis mucosae and muscularis propria (detrusor muscle). At the bladder neck, the 
bladder is fixed by ligaments. The rest of the bladder is loosely contained by perivesical 
fat and on its superio-posteror aspect, the dome, it is covered by peritoneum. 
The urinary tract (bladder, ureters, and renal pelvis) is lined by a specialised transitional 
epithelium, the urothelium (Fig. 2), which protects the subepithelial tissue from 
endogenous and exogenous chemical and bacterial toxins. The normal urothelium is of 
variable thickness and the number of urothelial layers is dependent on the degree of 
organ distension. Normally, this epithelium ranges from three to seven cell layers in 
thickness. An increase in number is abnormal but not necessary neoplastic. The 
urothelium is composed of 2 distinct cell types, the superficial and underlying 
intermediate and basal cells. The superficial cell layer is a highly protective layer with 
large, and occasionally multinucleated specialized umbrella cells. They are modified to 
maintain the integrity of the mucosa during expansion and contraction. They have a 
rigid surface membrane, which maintains its shape even after exfoliation. Beneath the 
urothelial basement membrane is the lamina propria, consisting of loose connective 
tissue that contains delicate bundles of smooth muscle, the muscularis mucosae. The 
muscularis mucosae is a variably developed layer of thin smooth muscle fibres that may 
be complete, incomplete or attenuated (Reuter, 1992; Ro, et al., 1987). 
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Fig. 1. Histology of the normal bladder. 
L= Lumen, Ep= Epethelium (urothelium), LP= Lamina propria, Mus= muscularis 
propna. 
Fig. 2. Transitional epithelium: epithelium cell layers 
L 
L= Lumen, Uro= urothelium, LP= Lamina propria. 
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Whether or not a muscularis mucosae is always found in the bladder is a contentious 
ISSUe. 
The wispy smooth muscle bundles of the muscularis mucosae are characteristically 
thinner than those of the muscularis propria, an important feature when assessing 
bladder biopsies. AJso the muscularis mucosae is associated with large medium sized 
arterial and venous blood vessels. Both the lamina propria and submucosa usually 
consist of loose fibrous tissue, but may contain variable amounts of adipose tissue 
(Bochner, et al., 1995), another potential source of diagnostic confusion. 
The muscularis propria (detrusor muscle) consists of large bundles of muscle fibres 
associated with scant loose connective tissue. The arrangement of these bundles varies 
at different locations, for example they are more uniform and densely packed in the 
bladder neck, than elsewhere. 
The urothelium shows a range of both non-neoplastic and neoplastic abnormalities, that 
should be accurately identified. 
Von Brunn's nests (Fig. 3) contain well circumscribed urothelial aggregates that arise 
by a process of budding or migration of the overlying non-neoplastic urothelium. They 
may or may not be attached to the surface epithelium and are so common that they are 
considered as normal features of the bladder mucosa. 
The term cystitis cystica (Fig. 4) is used to describe the histological feature of central 
degeneration ofVon Brunn's nests, forming small cystic cavities lined by urothelium or 
cuboidal epithelium. 
Cystitis glandularis is a similar entity that exists in 2 forms, the typical type and the 
intestinal type. It is composed of glandular structure within the lamina propria, that are 
lined by a large of cuboidal or columnar cells surrounded by urothelial cells. When the 
lining cells are overtly mucin-producing, the features are of the intestinal type of cystitis 
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Fig. 3. Von Brunn's nests: 
Fig. 4. Cystitis cystica: 
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glandularis. If this is diffuse it is known as intestinal metaplasia and is commonly seen 
in chronically irritated bladders, and this is associated with a risk of adenocarcinoma. 
Approximately 95% of bladder tumours are of epithelial origin, the remainder being 
mesenchymal tumours (Table 1). 
Neoplasms differentiating toward normal urothelium are called transitional cell 
neoplasms and these may arise any where along the urinary tract that is lined by 
urothelium. 
In a series of about 1000 cases, the location of tumour within the bladder is listed as 
follows: lateral walls, 37%; posterior wall, 18%; trigone, 12%; bladder neck, 11%; 
ureteric orifices, I 0%; dome, 8%; and anterior wall, 4% (Stephenson, et al., 1990). 
They have also been reported within bladder diverticula and even arising from 
regenerated urothelium over a lyophilised dura patch (Selli, et al., 1986). The pattern of 
growth of these tumours may be exophytic or endophytic, or a combination of both 
(Murphy, 1983). When exophytic, the tumour may adopt a papillary configuration (with 
a central fibrovascular cores) or a solid (nodular) appearance. When growing 
endophytically (especially if well-differentiated), it may result in nested formations in 
the lamina propria, which may be under diagnosed as von Brunn's nests or cystitis 
glandularis/cystica (Murphy, et al., 1992; Talbert, 1989). 
Classically TCC tumours are divided empirically into two categories, superficial and 
muscle invasive tumours. Confusingly, superficial tumours include those that have may 
have invaded lamina propria but not detrusor muscle whilst invasive tumours are those 
that have invaded into muscularis propria or beyond. 
Superficial tumours account for approximately 80% of tumours at presentation (Abel, 
1988; Metts et al., 2000). They are generally amenable to bladder conservative therapy 
with disease controlled by transurethral resection (TUR), diathermy, laser and 
photodynamic therapy, intravesical chemotherapy and intravesical BCG. 
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Table 1. World health organization: Histological Classification of Urinary Bladder Tumours 
Metastatic 
Epithelial tumours Nonepithelial Miscellaneous tumours tumours and Unclassified Epithelial abnonnalities Tumourlike lesions tumours secondary tumours 
extensions 
a. Transitional cell a. Benign a. Pheochromocytoma a. Papiloma (polypoid) a. Follicular cystitis 
papilloma b. Malignant b. Lymphoma cystitis b. Malakoplakia 
b. Transitional cell 1. Rhabdomy- c. Carcinosarcoma b. Von Brunn's nests c. Amyloidosis 
papilloma, inverted Osarcoma d. Malignant melanoma c. Cystitis cystica d. Fibrous (fibroepit-
type 2. Others e. Others d. glandular metaplasia helial) polyp. 
C. Squamous cell e. Nephrogenic adenoma e. Endometriosis. 
papilloma f. Squamous metaplasia f. Cysts. 
d. Transitional cell 
carcinoma 
e. Variants of 
transitional cell 
carcinoma 
I. With squamous 
metaplasia 
2. With glandular 
metaplasia 
3. With squamous 
and glandular 
metaplasia 
f. Squamous cell 
carcinoma 
g. Adenocarcinoma 
h. Undifferentiated 
carcinoma 
Only a small percentage of these evolve into tumours that invade the deep muscle and 
have the potential to metastasise (5% ofTa and 20% ofTl). 
The muscle invasive carcinomas account for approximately I 5-20% of bladder tumours 
and require more aggressive treatment, either radical surgery or radiotherapy (Harland, 
1994; Burchardt et al., 2000). They are usually invasive at presentation, only 10-20% 
are preceded by lower stage tumours (Bostwick, 1992). 
Clinical metastases are existent in approximately 5% of cases at presentation 
(Whit more, et al., 1988; Burchardt et al., 2000). In these tumours the extent of invasion 
also influence treatment local extension beyond the bladder may lead to unresectability. 
The most important histological features influencing treatment are the degree of tumour 
differention (grade) and the depth of invasion (stage). In particular the determination of 
the invasion of muscularis propria or beyond. 
IS 
1.1.4 Tumour grade 
No uniformly accepted grading system for bladder cancer exists. Most commonly the 
criteria of the 1973 World Health Organization are used (Mostofi, et al., 1973), grading 
urothelial carcinomas into I, 2 or 3. 
Papilloma is a rare and high debatable entity. The controversy involves the existence of 
diagnostic criteria for this tumour. Some feel it would be better to extend this diagnosis 
to include the WHO gradel urothelial carcinomas (Fig. 5). 
Grade 1 tumours have a thickened urothelium containing more than seven cell layers. 
The cells show mild nuclear pleomorphism and mitotic figures are rare. The nuclear 
polarity and architecture of the urothelium is retained. There is no necrosis (Fig. 6). 
Grade 2 tumours are formed from urothelium that may be of increased, decreased or 
normal thickness. There is a greater degree of nuclear pleomorphism with scattered 
mitotic figures. The urothelial architecture is disturbed with loss of nuclear polarity. 
Necrosis is rare (Fig. 7). 
Grade 3 tumours may have a solid growth pattern and are composed of highly 
pleomorphic cells with frequent bizarre mitotic figures (Friedell, et al., 1980). There is 
architectural anarchy, often associated with necrosis (Fig. 8). 
Within any given tumour there may be heterogeneity of grade, and the grade assigned 
should represent the highest grade present. 
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Fig. 5. Papilloma of the urinary bladder: (a) This benign tumour is composed of 
several papillary projections that consist of a core of connective tissue lined on the 
surface by transitional epithelium that does not differ significantly from the normal 
epithelium of the urinary bladder. (b) This papilla has a central vascular core which is 
lined with cells that do not exceed the thickness of the normal contracted urinary 
bladder. 
Fig. 6. Transitional cell carcinoma, grade 1: thickened transitional cell epithelium 
that shows relative uniformity of cells and only mild loss of polarity. 
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Fig. 7. Transitional cell carcinoma, grade ll: The surface layer of this bladder tumour 
appears disorganized. The cells show variation in size and shape and the polarity of the 
nuclei has been lost. 
Fig. 8. Transitional cell carcinoma, grade Ill: The tumour is composed of cells that 
show marked pleomorphism, and only vaguely resemble transitional epithelium 
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1.1. 5 Tumour stage 
Tumour staging gives an indication of the extent of spread of the cancer and relies on 
information obtained from physical examination, radiological studies, endoscopy, 
examination under anaesthesia, biopsy, transurethral resection of the bladder tumour 
(TURBT), and other pertinent evaluations. 
Clinical staging may be defined as an assessment of the extent of tumour invasion using 
clinical methods (including biopsy and TURB specimens), but not including definitive 
partial or total cystectomy material. 
Pathological (surgical) staging is based on definitive surgical exploration and 
histopathological assessment of the extent of the primary tumour in a cystectomy 
specimen. Pathological staging of the tumour does not necessarily include full 
histopathological evaluation of the regional lymph nodes or potential sites of distant 
metastases. 
The two most commonly used staging systems of bladder cancer include the Jewett and 
Strong system and the tumour-node-metastases (TNM) staging system. 
The TNM system delineates exophytic and superficial growth patterns and also allows 
for separate classifications of patterns of spread outside the bladder (Table 2). Hence, it 
is more frequently used today (Sobin et al., 1997). 
Up to 80% of urothelial carcinomas are non invasive at presentation (pTa). The 
presence of stromal invasion (pT I) does have therapeutic and prognostic significance. It 
is debatable as to whether it is necessary to separate those invading the papillary cores 
only (pTl a) from those extending into the lamina propria (pTl b). However, 
microinvasion, defined as invasion of Smm or less into the lamina propria was found to 
be associated with a significantly increased risk of metastatic cancer (Farrow and Utz, 
1982). The importance of accurately assessing the depth of invasion cannot be 
underestimated. 
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Table 2. TNM Classification of U rinarv Bladder Cancer: 
The latest TNM system for staging bladder cancer was developed by the UICC in 1997 
T- Tumour N - Regional Lymph 
M - Distant Metastasis 
Nodes 
TX - Primary tumour cannot be NX - Regional lymph nodes MX - Distant metastasis 
evaluated cannot be evaluated cannot be evaluated 
TO - No primary tumour NO -No regional lymph MO - No distant 
node metastasis 
metastasis 
Ta - Noninvasive papillary 
carcmoma Nl - Metastasis in a single Ml - Distant metastasis lymph node< 2 cm in size 
TIS - Carcinoma in situ 
("flat tumour") N2 - Metastasis in a single 
lymph node> 2 cm, but < 5 
Tl - Tumour invades cm in size, or Multiple 
connective tissue under the lymph nodes < 5 cm in size 
epithelium (surface layer) 
NJ - Metastasis in a lymph 
T2 - Tumour invades node> 5 cm in size 
muscle 
T2a - Superficial 
muscle affected (inner 
half) 
T2b - Deep muscle 
affected (outer half) 
TJ - Tumour invades 
perivesical (around the 
bladder) fatty tissue 
T3a - microscopically 
T3b - macroscopically 
(e.g., visible tumour 
mass on the outer 
bladder tissue) 
T4 - Tumour invades any of 
the following: prostate, 
uterus, vagina, pelvic wall, 
abdominal wall 
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It is critical not to confuse the thin wispy muscle bundles of muscularis mucosae with 
those of detrusor muscle, as this will lead to overstaging of the tumour. Muscle invasion 
pT2 should only be diagnosed when tumour is seen invading thick muscle bandies. In 
TURBT specimens it is not possible to distinguish between invasion into the inner half 
ofthe muscularis propria (pT2a) and involvement ofthe outer half(pT2b). Fat may also 
been seen in between muscle bundles of the muscularis propria or within the )amine 
propria and submucosa and should not be confused with perivesical fatty tissue. 
Analysis of treatment outcomes indicated that the most important determination 1s 
whether the tumour is organ-confined. To reflect the clinical importance of this, the 
classification has now changed. Pathologic T3 tumours are now defined as those that 
extend beyond the bladder to involve the perivesical fat, either microscopically (T3a), or 
macroscopically (TJb). It is believed that these changes will reflect survival differences 
found in patients with extravesical involvement by bladder tumours. Involvement of the 
prostate gland (pT4a) should be further defined as to whether it is confined to the 
prostatic urethra, involves the periurethral crypts or directly invades the prostatic tissue. 
Tumour fixed to the pelvic sidewall or invading the anterior abdominal wall is classified 
as T4b disease. These tumours are associated with the worst prognosis and cystectomy 
is not normally a treatment option. Figure 9 shows the relationship between the location 
and the depth of the tumour and the stage. 
Carcinoma in situ (CIS) deserves special mention. CIS (Fig. I Oa& I Ob) is defined as high 
grade, flat, non-invasive, transitional cell carcinoma, often involving large portions of 
the bladder urothelium. CIS, although superficial by definition, tends to be aggressive, 
and may lead to metastatic disease (Metts et al., 2000). It commonly occurs most often 
in association with bladder tumours of other types. Treatment depends on the extent of 
the tumour. 
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Fig. 9. The following illustration shows the relationship between the location 
and depth of the tumour and the stage. 
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Transurethral resection may be adequate in localized cases, but BCG and intravesical 
chemotherapy remain standard treatments. In patients with extensive CIS the risk of 
progression to invasive disease is up to 80% at 5 years (Utz and Farrow, 1984). 
Risk of progression is related to grade and stage. The rate of progression for grade I is 
approximately 2%, 11% for grade 11 and 45% for grade Ill. Approximately 4% with Ta 
tumours progress, compared with 30% of patients with Tl tumours (Sternberg, 1999). 
The association of CIS with low stage, low grade tumours has been linked with increase 
risk of subsequent progression and muscle invasion. Up to 78% of patients with diffuse 
CIS, progress to muscle-invasive or metastatic disease (Dalbagni et al., 2000). In muscle 
invading bladder cancers, there is a 50% risk of distant metastases (Sternberg, 1999). 
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Fig. lOa. Carcinoma in situ: The normal transitional epithelium has been replaced by 
thickened epithelium composed of cells that have hyperchromic nuclei and vary in size 
and shape. The nuclei show no polarization. These flat carcinoma-in-situ lesions are 
prone to endophytic growth and invasion of the bladder wall. 
Figure lOb: Carcinoma in-situ. The nuclei are dark-staining and they vary markedly 
in their size and shape and involve the full thickness of the epithelium. 
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1.1.6 Diagnostic procedures 
The most common presenting symptom of bladder cancer is painless haematuria 
occurring in 80-90% of cases (Varkarakis et al., 1974). The symptom complex of 
bladder irritability (urinary frequency and urgency) and dysuria may occur and usually 
is associated with diffuse carcinoma in situ or invasive bladder cancer. The frequency 
may be due to sensory urgency, in which the bladder volume is normal, or in some 
cases due to an absolute reduction in the size of the bladder. Urinary infection is not 
uncommonly found in association with bladder cancer. Other signs and symptoms of 
bladder cancer include flank pain from ureteral obstruction, lower extremity oedema (as 
a result of lymphatic obstruction by the tumour), and a pelvic mass. Occasionally, 
patients present with symptoms of advanced disease, such as weight loss and abdominal 
or bone pain. 
With the exception of young sexually active females with blood associated with a 
urinary infection, haematuria should be fully investigated. In patients under the age of 
40 where the risk of malignancy is minimal, initial referral to a nephrologist is 
advisable. 
Since transitional cells line the urinary tract starting at the kidney, down the ureter, into 
the bladder and includes most of the urethra, the entire urinary tract needs to be 
evaluated for transitional cell cancer. 
Intravenous urography (IVU) should be performed to exclude upper tract obstruction 
and upper tract tumours. Larger bladder cancers may be seen as a filling defect on the 
bladder films but the sensitivity in detecting bladder cancer is poor and cystoscopy is 
always indicated. 
Ultrasound scanning of the upper tracts will also diagnose upper tract obstruction but 
has a lower sensitivity than IVU for diagnosing upper tract transitional cell tumours. It 
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should however be performed as it is more sensitive than IVU in detecting renal cell 
carcinoma. 
Computerised tomography (CT) and magnetic resonance imaging (MRI) are generally 
not used in the initial diagnosis but are of value in staging tumours and planning prior to 
cystectomy and radiotherapy. 
Cystoscopy is the definitive investigation at which mucosal abnormalities can be 
carefully documented and biopsies are taken (Fig. 11). If a bladder tumour is found it 
should be resected down to the bladder wall and separate biopsies of the base, including 
some detrusor muscle, taken in order that the pathologist can look for deep muscle 
invasion. At the end of resection a bimanual pelvic examination should be performed to 
enable clinical staging to be recorded. 
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Fig. 11. Surgeon's view of tumour (direct visualization of the tumour): 
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1.1. 6.1 Urine cytology and other diagnostic tests 
Since the tumours are bathed in urine attempts to diagnose a tumour non-invasively by 
means of urine analysis have been investigated. This would carry considerable benefits 
both for the patient who would avoid an uncomfortable operation, and would be cost 
effective for the purchasers of health care. 
Voided urine cytology is the standard noninvasive tumour specific marker (Wiener et 
al., 1993). Although in the hands of expert cytopathologists cytology is highly specific 
and sensitive for detecting carcinoma in situ, it is not sensitive for detecting low grade 
disease (Wiener et al., 1993; Malik et al., 1999). Furthermore, despite defined criteria 
for detecting malignant cells, variability among those interpreting cytology findings is 
significant. Some pathologists prefer a bladder wash (barbotage) specimen to a voided 
urine specimen to increase the yield of exfoliated cells. However, bladder wash is an 
invasive procedure and a fair number of cytopathologists discourage introducing 
instrumentation artifacts that may yield cells resembling low grade bladder cancer. 
These limitations force urine cytology to be only an adjunct to cystoscopy for detecting 
bladder cancer. 
Wiener et al., reported no difference in the sensitivity of cytology when barbotage or 
voided urine specimens were used (each 59% sensitivity) (Wiener et al., 1998). The 
sensitivity rates in that study for detecting low to high grades I (17%), 2 (61%) and 3 
(90%) bladder cancer emphasize that the sensitivity of cytology for detecting low grade 
bladder cancer is poor. Recently Konety et al., reported that in patients without a history 
of bladder cancer the diagnostic value of bladder barbotage urine cytology is 
insignificant and, therefore, it is not cost-effective as part of a routine evaluation 
(Konety et al., 1999). These results raise questions regarding the tabor involved, 
procedure associated morbidity and the cost required to obtain bladder wash specimens. 
The specificity of urine cytology in several studies was 90% to 95% (Leyh et al., 1999; 
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Takashi et al., 1999; Pode et al., 1999). Overall urine cytology is highly specific for 
detecting bladder cancer and yet except for high grade cancer detection it is not 
sensitive. Another problem with urine cytology is that it requires a trained 
cytopathologist. Since many clinicians do not have access to trained cytopathologists, 
many urologists do not have confidence in this diagnostic assay. Therefore, urine 
cytology in its present form cannot replace cystoscopy as a method for detecting and 
monitoring bladder cancer. 
Over the past few years, a number of new tests have been devised to aid the diagnosis of 
bladder cancer. These tests include the bladder-tumour-associated antigen test (BTA""), 
the BT A stat test, the BT A TRAK test, the fibrin/fibrinogen degradation products test 
(FDP""), and the NMP22TM assay. All of these tests can be performed on urine samples. 
Flow cytometry (FCM) measures the DNA content of cell nuclei and thereby gives an 
indication of the number of cells synthesized DNA and their proliferative activity. 
Melamed (I 984) proposed that the presence of more than 15% aneuploid cells 
(compared to diploid) should define malignancy in the urothelium. In general, diploid 
tumours tend to be GI, Ta or Tl and tetraploid or aneuploid tumours are more likely to 
be poorly differentiated or invading muscle (Badalament et al., 1987; Griffiths et al., 
1995; Tribukait et al., 1982). Study carried out by Badalament et al., showed in 228 
patients that FCM varied according toT category; it was greater in TIS and T1 than in 
Ta. Comparison with cytology in a subset of I 03 patients showed that the overall 
sensitivity of a single FCM examination was 78%, and that the sensitivity was 
significantly greater than voided urine cytology for all three categories of superficial 
bladder cancer. Cytology was positive when FCM was negative in 31103 patients. 
The nuclear matrix protein (NMP) 22 immunoassay measures a nuclear matrix protein 
released from urothelial cells into the urine. Nuclear matrix proteins determine nuclear 
morphology and regulate DNA replication and gene expression (Getzenberg et al., 
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1997). NMP 22 has been developed as a quantitive test (Carpinito et al., 1996; 
Miyanaga et al., 1997), to predict the presence of TCC or the likehood of recurrence 
(Soloway et al., 1996). Miyanaga et al., found raised NMP 22 levels (> 10.0 U/ml) in 
81% (38/47) of patients with bladder cancer, compared with 36% (74/207) of patients 
following endoscopic resection of their tumour, or benign controls. Soloway et al., 
reported that 86% of patients with post-transurethral resection levels less than IOU/ml 
had no recurrence at the first 3-month cystoscopy, compared with levels of NMP 22 
greater than IOU/ml in post-transurethral resection urine that suggested a high risk of 
recurrence (Soloway et al., 1996). These authors have suggested that this may prompt 
more aggressive management if NMP 22 levels are elevated following surgery. As a 
diagnostic test, NMP 22 was reported to have a sensitivity of 61% compared with 33% 
for voided urine cytology (Akaza et al., 1997). 
Several other studies have been done to determine the sensitivity and specificity of the 
NMP22 test. When evaluating these studies, it should be noted that although the 
manufacturer recommends 10 units per ml. as a cutoff limit for NMP22, others have 
used various cutoff limits of 3.6 to 12.0 units per ml. for calculating sensitivity and 
specificity. In these studies a wide range of sensitivity (47% to 100%) has been reported 
for NMP22 to detect bladder cancer but in many the value was between 60% and 70% 
(Wiener et al., 1998; Leyh et al., 1999; Ramakumar et al., 1999; Sharma et al., 1999; 
Banos et al., 1998; Miyanaga et al., 1999; Hughes et al., 1999; Zippe et al., 1999; Del 
Nero et al., 1999; Witjes et al., 1998). The NMP22 test appears to detect all grades of 
bladder cancer with similar sensitivity. In the studies of Del Nero and Landman et al., 
NMP22 had overall 81% to 83% sensitivity for detecting bladder cancer, and 69% to 
86%, 86% to 97% and 90% to 98% sensitivity for detecting grades I to 3 bladder 
cancer, respectively (Del Nero et al., 1999; Landman et al., 1998). In another study of 
Wiener et al NMP22 had an overall sensitivity of 48% (Wiener et al., 1998). The 
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sensitivity rate for detecting grades 1 to 3 bladder cancer were 52%, 45% and 50%, 
respectively. In various studies the specificity of NMP22 is between 60% and 70%, 
although in one specificity was 90% (Landman et al., 1998; Mahnert et al., 1999; 
Heicappell et al., 1999). 
The bladder tumour antigen (BTA) test has been evaluated extensively. This is a latex 
agglutination test that detects the presence of basement membrane complexes in urine. 
Although more sensitive than cytology, the BT A test has been superseded by the BT A 
STAT test by the same manufacturers. This test measures complement factor H-related 
proteins in the urine (Kinders et al., 1997). Leyh et al., in his study found overall 
sensitivity of the new test for diagnosing bladder cancer to be 72% compared with 28% 
for cytology (Leyh et al., 1997). Sarosdy et al., compared BTA ST AT with BTA in 181 
archived urine samples and found superior sensitivity for BTA STAT (66% versus 
59%) but equal specificity (Sarosdy et al., 1997). In other studies the overall sensitivity 
of the BT A STAT was 57% to 83% (Wiener et al., 1998; Leyh et al., 1999; Sharma et 
al., 1999). In 2 studies that evaluated the sensitivity ofBT A ST AT test by tumour grade 
sensitivity was 13% to 48%, 36% to 67% and 63% to 80% for detecting grades I to 3 
disease, respectively (Leyh et al., 1999; Gutierrez et al., 1998; Nasuti et al., 1999). 
Specificity of the BTA ST AT in healthy individuals was reported to be 97%, whereas in 
patients with a history of bladder cancer it was 57% to 73%. It is important to note that 
the specificity of the BTA STAT in patients with benign genitourinary conditions, such 
as infection, renal disease, genitourinary trauma, cystitis, renal or bladder calculi, 
nephritis and renal stones, is only 46% (Leyh et al., 1999). Furthermore, the BT A ST AT 
has been shown to have an 84% false-positive rate in patients with signs and symptoms 
of dysuria, incontinence and haematuria (Nasuti et al., 1999). It is not surprising that 
several genitourinary conditions that cause haematuria yield a false-positive result on 
the BTA STAT. In haematuria complement factor H in blood reacts with antihuman 
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complement factor H related protein monoclonal antibodies to yield a false-positive 
reaction on the BTA STAT. 
The BT A TRAK test, which is a quantitative enzyme immunoassay using monoclonal 
antibodies to bind bladder tumour antigen in urine (Ishak et al., 1997). Comparison with 
BTA in 108 archived samples showed improved sensitivity for BTA TRAK: sensitivity 
for grades I, 2 and 3 tumours were 55%, 67% and 85%, compared with 41%, 58% and 
70% forBTA. 
In several studies the sensitivity of the BT A TRAK is 62% to 77% when using 14 units 
per ml. as the cutoff (Thomas et al., 1999; Mahnert et al., 1999; Abbate et al., 1998; 
Irani et al., 1999; Heicappell, et al., 1999; Ellis et al., 1997). Thomas et al., reported 
that the sensitivity of the BT A TRAK for detecting grades 1 to 3 tumours was 48%, 
59% and 88%, respectively. Sensitivity of the BTA TRAK varies considerably 
depending on the cutoff limit. Mahnert et al., demonstrated that while the BTA TRAK 
had 62% sensitivity and 54% specificity for detecting bladder cancer at 14 units per ml. 
cutoff, it had only 13% sensitivity when the cutoff was 1,300 units per ml., at which 
point the specificity of the test for benign urological conditions was 95%. Overall 
specificity ofthe BTA TRAK in various studies was 48% to 70%. 
Measurement of fibrinogen degradation products in urine is the basis of the Aura-Tek 
FDP dipstick rapid immunoassay. Two studies have shown the test to be significantly 
better than cytology for the detection of bladder cancer. Overal sensitivity of 69-84% 
and specificity of 78-79% compared with 33-39% sensitivity for cytology (Johnston et 
al., 1997; Schmetter et al., 1996). 
Telomerase is a ribonucleoprotein enzyme that is present in almost all cancer cells but 
not in benign tissue (Lee et al., 1997; Muller et al., 1997). Telomerase can be measured 
in the urine or bladder washings (Kavaler et al., 1997; Lance et al., 1997) by a 
tluorescein-labelled PCR (polymerase chain reaction) based technique, or highly 
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sensitive telomeric repeat amplification protocol (TRAP assay) (Lance et al., 1997; 
Muller et al., 1997). Several studies have shown that telomerase is a promising marker 
for detecting bladder cancer. The overall sensitivity oftelomerase for detecting bladder 
cancer is between 70% and 86% (Ramakumar et al., 1999; Kavaler et al., 1998; Lee et 
al., 1998; Dalbagni et al., 1997). Series using bladder wash specimens or combined 
results of bladder wash and voided urine have indicated that the sensitivity of 
telomerase for detecting bladder cancer is as high as 95% (Lee et al., 1998). However, 
in other studies sensitivity has been as low as 46% (Dalbagni et al., 1997). Although 
telomerase has high sensitivity for detecting all grades of bladder tumours, its sensitivity 
is much higher for detecting high grade disease. In various series the sensitivity of 
telomerase for detecting grades 1 to 3 bladder tumours was 56% to 79%, 72% to 85% 
and 85% to I 00%, respectively (Land man et al., 1998; Ramakumar et al., 1999; Yokota 
et al., 1998). The overall specificity of telomerase for bladder cancer detection is often 
between 60% and 70% (range 60% to 90%) (Ramakumar et al., 1999; Landman et al., 
1998; Kavaler et al., 1998; Yokota et al., 1998; Lee et al., 1998; Mayfield et al., 1998). 
The majority of false-positive cases involve chronic or severe inflammatory disease 
(Mayfield et al., 1998). This finding is not surprising since telomerase is expressed in 
proliferative cells, such as activated lymphocytes (Greider et al., 1996). 
There are a number of other potentially useful "markers" for bladder cancer diagnosis, 
including blood group antigens, inducers of immune response which may help to predict 
the invasive potential of surface tumours; and urine markers, such as M344 antigen, 
autocrine motility factors, glycosaminoglycans, scatter factor, and microsatellite 
analysis. 
Lokeshwar and Soloway in a recent study concluded that currently noninvasive bladder 
cancer tests cannot replace cystoscopy, although some have shown a promise of being 
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clinically useful. One or a combination of these tests-markers may prove to be a 
"prostate specific antigen" for bladder cancer (Lokeshwar and Soloway, 2001). 
1. 1. 6. 2 Bladder cancer screening 
If screening methods could detect bladder cancers destined to become muscle invading 
while they are still superficial (and therefore amenable to successful therapy), it is likely 
that a significant reduction in morbidity and mortality would result. Practically all 
bladder cancers will cause haematuria at some point, but haematuria is often 
intermittent, even when caused by serious disease. Repeated testing for haematuria is 
needed, and once one specimen is positive, further evaluation should be done to 
determine its cause. Screening for haematuria can be done by microscopic urinalysis or 
by using a chemical reagent strip (stix testing) to test for haemoglobin. Significant 
microscopic haematuria will be missed by microscopy unless a centrifuged urine sample 
is examined. Routine urine analysis in microbiological laboratories does not include 
centrifugation before microscopy. Conversely, "stix" testing (which test for both intact 
red blood cells and free haemoglobin) is so sensitive that it can be positive when an 
insignificant amount of blood is present. 
Two screening studies of the general population using haematuria home testing have 
been published. Messing and colleagues and Britton and associates solicited from 
general-practice patient care rosters all middle-aged and elderly men residing in 
geographically defined regions [south central Wisconsin and Leeds, England] who were 
not believed to have urologic malignancies or other known causes of haematuria, and 
requested them to test their urine I 0-14 times at home with reagent strips for 
haemoglobin (Messing et al., 1992; Messing et al., 1995; Britton et al., 1989; Britton et 
al., 1992). If the result was positive even once, the subjects were asked to undergo 
formal urologic evaluation including intravenous urography, cytology, and cystoscopy. 
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The two studies had similar findings. Fifteen to 20% of the screened populations had 
haematuria. Of those who completed the workup, 6-8% were found to have urothelial 
cancers. Overall, 1.2-1.3% of those screened had bladder cancer diagnosed. Neither 
study had a prospective, randomized control population. 
The Wisconsin study looked at state tumour registry data to compare the screening 
participants' outcomes with those of an unscreened population. Additionally, pathology 
materials from all men screened in whom bladder cancer developed and from all men 
age over 50 years old in Wisconsin (not screened) in whom bladder cancer developed 
during I year of the study were compared by a referee pathologist. In both populations, 
roughly the same percentage had low-grade (grade I, 2) superficial bladder cancers 
56.8% unscreened, 52.4% screened). Approximately 45% of the cancers (43.2% 
unscreened, 47.6% screened) were high grade. The proportion of muscle-invasive 
tumours was significantly higher in the unscreened population: 23.9% of all cancer 
registry patients versus 4.9% of all screened cancers. By 24 months after diagnosis, 
16.4% of the unscreened patients who developed bladder cancer had died of bladder 
cancer. In contrast, none of the 21 men participating in the screening study in whom 
bladder cancer was detected has died of bladder cancer after 4-9 years of follow up 
(Messing et al., 1998). It would seem that screening allowed the successful diagnosis of 
cancers destined to become muscle invasive at preinvasive stages. Compared with other 
diseases for which screening has been accepted as beneficial and worth the expense ( eg, 
mammography for breast cancer in postmenopausal women, fecal occult blood testing 
or colonoscopy for colorectal cancer, and blood pressure checks for hypertension), 
bladder cancer screening with chemical reagent strips appears to be quite cost-effective 
(Lawrence et al., 1995). Because this was not a prospective, randomised, controlled 
study, certain biases must be considered (Messing et al., 1989; Messing et al., 1992; 
Messing et al., 1995). Lead time bias (the interval between when it could be diagnosed 
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if you looked for it and when it is diagnosed because of symptoms) could have 
contributed to the decreased mortality seen in the screened group. The follow up time 
for the screened population was 4-9 years, though, as compared with 2 years for the 
unscreened population. Likewise, it is unlikely that in the screened population, more 
indolent tumours with longer preclinical durations were detected (length bias sampling), 
as the distributions of the grades of cancers detected were similar in both groups. The 
worse outcomes in the unscreened population could be explained if they received less 
effective therapy than the screeners. The unscreened patient outcomes, however, 
paralleled those reported in contemporary series of optimum treatment for similar 
tumour stages and grades, so inferior therapy in the control population does not appear 
to have been involved. The control group was not randomised, and its subjects may 
have differed from the screeners in terms of their health consciousness or other risk 
factors. This screening method has other problems as well. Although the test's 
sensitivity approaches 100% for cystoscopically detectable tumours (Messing et al., 
1992; Messing et al., 1995; Messing et al., 1990), the specificity is only 8% and the 
PPV (positive predictive values) is also only 8% (although the PPV is 11% for all 
malignancies and 33% for serious disease). 
In summary, in the absence of a prospective randomized trial, the available information 
strongly suggests that screening shifts the diagnosis to an earlier noninvasive stage, with 
a resulting decrease in mortality. If other screening tests could be used to reduce the 
number of false-positive results (thereby reducing the number of negative workups), 
both cost effectiveness and public and physician acceptance would be enhanced even 
further. 
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1.1.7 The treatment of bladder cancer 
1.1. 7.1 Superficial disease (Ta; Tl; CJS) 
Although it is possible to remove Ta, TI tumours surgically, 50-70% of patients have a 
recurrence within 1-2 years (Van der Meijden, 1998). To prevent this, patients may be 
treated with adjuvantly intravesical drugs. These drugs are instilled in the bladder as a 
watery solution, kept in the bladder for 1-2 hours, and then simply voided. Cytostatic 
agents such as thiotepa, adriamycin, mitomycin C, and epirubicin have been used, and 
during the past decade BCG has been one of the most effective drugs given 
intravesically (Harris et al., 1 997). During the past two decades the European 
Organisation for Research and Treatment of Cancer Genito-Urinary (EORTC-GU) 
group and the British Medical Research Council's working party have performed a 
series of randomised phase Ill studies investigating the prophylactic treatment of stage 
Ta, TI bladder cancer after transurethral resection. Many studies have shown the 
advantage of adjuvant treatment after transurethral resection in decreasing the 
recurrence rate of bladder tumours or in prolonging the disease free interval of patients 
(Van der Meijden, 1998; Sternberg, 1 999). The studies failed, however, to show the 
superiority of one agent over another, probably with the exception of BCG. There is also 
no evidence that adjuvant prophylactic treatment is of long-term benefit compared with 
transurethral resection alone in progression to muscle invasive disease and duration of 
survival. 
BCG is the treatment of choice for CIS, producing complete response rate in 70% of 
cases. In one study, this complete response rate was increased to 87% with additional 
maintenance therapy. This consisted of 3 weekly treatments every 6 months for 3 years 
(Lamm, 1995). A recently published Southwest Oncology Group study examined 385 
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patients randomized to either maintenance therapy (weekly instillations for 3 weeks at 3 
and 6 months, and then every 6 months) or observation after an initial 6 weeks BCG 
induction course (Lamm, et al., 2000). The treated group showed greater freedom from 
recurrence (35% in the observation group compared with 76% in the maintenance 
group). 
Appropriate therapy for superficial disease is based on the risk of recurrence or 
recurrence with progression in each individual patient. Patients with an initial episode of 
solitary low-grade Ta disease will usually be successfully treated by resection alone. 
Patients with multiple Ta tumours, who are more likely to experience recurrence, may 
benefit from adjunctive intravesical chemotherapy. Those with T1 tumours, CIS alone 
or CIS in the presence of papillary disease may be at a substantially increased risk for 
recurrence with progression. They may benefit from BCG therapy, but also should be 
considered for more aggressive surgical intervention if they do not demonstrate a 
prompt and complete response to conservative measures (Hassen et al., 2000). 
1.1. 7.2 Muscle invasive disease (T2; TJ; T4) 
The therapies for muscle-infiltrating disease can be divided into those that are bladder 
sparing and those that are non-bladder-sparing (Table 3). The standard treatments with 
curative intent are surgical removal of the entire organ by radical cystectomy or external 
beam radiotherapy (EBRT). The latter can be given as a radical dose with curative 
intent or a smaller dose for palliation. 
In appropriately selected cases of T2 disease, an aggressive TUR may be adequate, 
although this is controversial (Solsona, et al., 1992). The key point is that neither 
approach is particularly successful as the very best 5 year survival rates that might be 
expected are 60-70% for T2 tumours, 50% for T3a tumours, 25% for T3b tumours and 
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only 5-10% for T4 tumours (Bloom et al., 1982; Esring et al., 1994). The most recent 
published data is from the University of Southern California. In this series the 5-year 
survival after cystectomy in 633 patients with pT2, pT3a, pT3b and pT4 disease was 
72%, 58%, 38% and 33% respectively (Stein et al., 2001). In 284 patients at the 
Memorial Sloan Kettering Cancer Center, 5-year survival with pT2 tumours was 59%, 
pT3 was 25%, and pT4 was 29% (Dalbagni et al., 2001). 
The exact value of radical radiotherapy is difficult to establish because changes in 
treatment techniques and selection of patients have biased the results. The 5-year 
survival rates are reported to be 35-71% in Tl tumours, 27-59% in T2 tumours, 10-38% 
in T3 tumours and 0-16% in T4 tumours (Sengeltv et al., 1999). 
Full dose external-beam irradiation is a common treatment scheme for T2 and T3 
tumours in Great Britain, with cystectomy reserved for salvage therapy. The largest 
radiotherapy series, with long-term follow up, is the Edinburgh series. 
With a minimum dose of SS Gy in 4 weeks, 25% of 5-year local control was achieved 
for Tl, T2 and T3 patients; in T4, the long-term local control was 16% (De Braud et al., 
2002). 
Cystectomy alone has not been tested against definitive radiotherapy in randomized 
trials (Dunst et al., 2001). However, four relatively small trials compared preoperative 
radiotherapy and planned cystectomy vs. definitive radiotherapy alone with selective 
salvage cystectomy (Table 4). 
The smallest study, from the M. D. Anderson Cancer Center, showed a benefit for 
radical cystectomy; however, the surgical patients in this study were pretreated with a 
potentially curative preoperative radiation regimen with SO Gy (Miller et al., 1977). The 
other studies demonstrated comparable results with preoperative radiotherapy and 
planned cystectomy vs. radical radiotherapy with salvage cystectomy (Harwich et al., 
1995; Sell et al., 1991). 
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Table 4. Randomized Trials of Preoperative Irradiation and 
Planned Cystectomy vs. Radical Radiotherapy Alone in Muscle- Invading Bladder 
Cancers 
Treatment No. Stage 5-year overall 
of 
patients survival 
M.D. Anderson Hospital (Miller et al., 1977) 
50 Gy + cystectomy 35 T3 46% 
60 Gy (+salvage cystectomy) 32 T3 22% 
U.K. Co-op Group (Harwich et al., 1995) 
40 Gy + radical cystectomy 98 T3 39% 
60 Gy (+salvage cystectomy) 91 T3 28% 
National Danish Trial (Sell et al.,l991) 
40 Gy + radical cystectomy 88 T3 29% 
60 Gy (+salvage cystectomy) 95 T3 23% 
National Bladder Cancer Group# 
40 Gy + radical cystectomy 37 T2-T4a 27% 
60 Gy (+salvage cystectomy) 35 T2-T4a 40% 
# S. D. Cutler, personal communication 1983. 
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In summary, a significant advantage of cystectomy has not yet been proven (Dunst et al., 
2001). 
Metastatic bladder cancer is usually incurable and the general approach is to help 
palliate symptoms. Although some patients with minimal metastatic disease may benefit 
from aggressive treatment, the vast majority of patients with metastatic disease should 
be managed with palliative intent. Individualized treatment plans are required, because 
each patient differs in his or her needs. Radiation can help alleviate many symptoms and 
chemotherapy may be offered as well. Radical surgery is not usually warranted in these 
cases (Metts et al., 2000). 
Randomized trials have demonstrated that M-VAC (methotrexate, vinblastine, 
doxorubicin and cisplatin) is the most effective chemotherapeutic regimen (Perry et al., 
1994; Scher, 1992). For the M-VAC regimen, various studies have shown response 
rates 30-50% (Loehrer et al., 1992; Sternberg et al., 1988). Unfortunately, M-VAC has 
substantial side effects and produces long-term survival in only, approximately I 5-20% 
of patients. 
The median survival duration is only 13 months and long-term survival is attained in, 
approximately I 5% of patients with metastases in visceral sites and 30% of those with 
nodal disease (Oosterlinck et al., 2002). Novel chemotherapeutic agents such as 
gemcitabine and the taxanes obtain similar overall survival, time to progressive disease, 
time to treatment failure, and response rate but gemcitabine + cisplatinum appears to 
have a reduced toxicity profile compared to M-VAC (Sternberg, 2000; von der Maase et 
al., 2000). 
The combination of gemcitabine and taxol has been shown to be highly effective in 
patients who have failed prior M-VAC (Sternberg et al., 2000). When cisplatin 
gemcitabine and taxol were given to untreated patients, high overall response rate were 
observed (Bellmunt et al., 2000). 
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The development of agents with activity m TCC has expanded the opportunity to 
combine them into synergistic and possibly more effective combinations. Recent 
clinical trials have placed an emphasis on defining the nature of response and toxicity to 
all possible combinations while recognizing that quality of life is an important endpoint 
in the treatment of patients with metastatic cancer (Table 5). 
Two key problems remain: firstly, the accurate prediction of prognosis for bladder 
tumours, and secondly, the need for more effective treatments for all stages of disease. 
The problem of accurately assigning a prognosis to a particular tumour has led to 
attempts to identify clinico-pathological correlates which predict invasive potential, and 
might thereby allow a much more systematic approach to treatment, with earlier 
aggressive treatment of selected superficial tumours which are deemed likely to 
progress. In addition, a better understanding of the biology, and mechanisms of 
recurrence and progression in bladder cancer will help the development of new 
generations of rational therapeutic targets. A third and equally important goal of 
assigning an accurate prognosis to particular tumours is that patients with a dismal 
prognosis might be spared flawed attempts at affecting a cure through heroic but 
ultimately ill-advised surgery. 
In 90% to 95% of cases, removal of the entire bladder is required to achieve local 
control. The exact indication may vary between institutions. Most physicians 
recommend cystectomy for (1) muscle-invading tumours (2) low-stage tumours 
unsuitable for conservative management, for example, because of multicentric and 
frequent recurrences resistant to intravesical instillation's, (3) high-grade tumours 
(TIG3) associated with Tis, or (4) bladder symptoms such as frequency or 
haemorrhage, rendering the patient a bladder "cripple". Survival distributions would be 
expected to vary for patients who undergo treatment for these indications. 
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Table 5. Combination regimens of new agents in metastatic TCC. 
Study Number Objective Complete Regimen 
of patients response rate response rate 
% % 
von der Maase et al 44 41 4 
(1997) 
Gemcitabine 
Stadler et al 47 59 11 + 
(1997) cisplatin 
Moore et al 17 71 23 
(1999) 
Murphy et al 20 65 20 
(1996) 
Paclitaxel + 
Burch et al 29 72 34 
(1999) cisplatin 
Vaughn et al 33 50 12 Paclitaxel 
(1998) + 
carboplatin 
Pycha et al 32 71 31 
(1999) 
Sengelov et al 25 60 28 
(1998) 
Docetaxel + 
Garcia del Muro et 19 53 21 cisplatin 
al (1999) 
Paclitaxel + 
Tu et al 25 40 0 cisplatin + 
(1995) methotrexate 
Cisplatin + 
Oh et al 24 67 7 5-tluorouracil 
( 1999) + 
Methotrexate 
Bajorin et al Cisplatin + 
(2000) 44 68 23 paclitaxel + 
and ifosfamide 
McCaffrey et al 
(1999) 
Gemcitabine 
Meluch et al 26 60 8 + 
(1999) paclitaxel 
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1.1.8 Chemotherapy 
Chemotherapy given before cystectomy or definitive radiotherapy is termed neoadjuvant 
chemotherapy whereas that given after radical treatment is termed adjuvant 
chemotherapy. Many chemotherapeutic regimens have been tried in attempts to improve 
the outlook but with limited success. The most successful regimens include cisplatinum, 
methotrexate, vinblastine, and adriamycin (MVCA) and encouraging results have been 
obtained (Sternberg et al., 1995). 
1.1.8.1 Neoadjuvant chemotherapy 
Neo-adjuvant chemotherapy is given before cystectomy or in some instances before 
radiation therapy. There are two principal reasons to use neo-adjuvant chemotherapy: to 
improve survival in patients with micrometastatic disease, and secondly to preserve the 
bladder (Sternberg et al., 2000; Sternberg et al., 1995). This approach has been useful in 
the treatment of several solid tumours. Although combination treatments with cisplatin, 
methotrexate, vinblastine, and adriamycin achieved complete remission in some 
patients, their impact on a large proportion of patients with bladder cancer remained 
unclear. Randomised prospective phase lii trials comprising 100-300 patients were not 
able to detect a difference between definitive treatment alone versus neoadjuvant 
chemotherapy followed by definitive treatment. This may lead to the conclusion that 
neoadjuvant chemotherapy does not improve the prognosis of patients or that the 
difference might be so small that it cannot be detected in a series with limited numbers 
of patients. On the basis of the expected proportion of response from previous studies, 
the EORTC-GU group and the British Medical Research Council working party 
embarked on an international phase Ill study of neoadjuvant cisplatin, methotrexate, and 
vinblastine, and definitive local treatment with radical cystectomy or radiotherapy (Hall, 
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1996). Other international oncology groups have also joined the study. A total of 
975 patients with muscle invasive bladder tumours and without detectable metastases 
were randomised. Patients received either three cycles of cisplatin, methotrexate, and 
vinblastine or no chemotherapy before radical cystectomy or full dose external beam 
radiotherapy. The study aimed to detect an absolute increase of three year survival of at 
least 10% in the chemotherapy arm. After a median follow up of22 months the overall 
survival for patients treated with the drug combination was 62%, and 60% for those not 
receiving such treatment (p=0.63). As the follow up period is too limited, no definitive 
conclusion can be made yet. Apparently, however, if there is a difference in survival 
between the two groups it will be small. The results of this largest international series 
indicate that it is necessary to organise large prospective randomised studies to detect 
small differences, if any, between different treatments. Collaboration between trial 
organisations is therefore essential. Small series will not provide reliable conclusions, 
and patients might be harmed and efforts and funds wasted. 
Table 6 displays the results of randomised neo-adjuvant chemotherapy trials in the 
literature. Many trials have a similar design; the differences between trials are due to the 
use of different types of chemotherapy. 
Some of the trials have used single agent cisplatin, and some have used combination 
therapy. Although the equivalence of radiotherapy, cystectomy or a combination ofboth 
has not been proved by a randomised trial, all of these are used as local definitive 
treatment for muscle-invasive bladder cancer in several countries. There is no reason to 
expect that a benefit from chemotherapy would differ greatly with different local 
treatments. It seems that most of these trials appear to show no difference, but they may 
not have enrolled sufficient numbers of patients to detect realistic differences in 
survival. 
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Table 6. Randomised phase m trials of neo-adjuvant chemotherapy: 
Study group Neo-adjuvant arm Standard arm Patients Results 
Aust!UK DDPIRT RT 255 No difference 
(Wall ace et al .. 1991) 
Spain (CUETO) DDP/Cyst Cyst 121 No difference 
(Martinez et al., 1995) 
Canada/NCI DDPIRT or preop RTor preop 99 No difference 
(Coppin et al., 1996) RT+Cyst RT+Cyst 
EORTCIMRC CMVIRTor Cyst RTorCyst 976 No difference 
( 1999) 
SWOG Intergroup M-VAC/Cyst Cyst 307 No difference 
(Natale et al., 200 I) 
Italy (GUONE) M-VAC/Cyst Cyst 206 No difference 
(Bassi et a., 1998) 
Italy (GISTV) M-VEC/Cyst Cyst 171 No difference 
(1996) 
Genoa DDP/5-FU/RT/Cyst Cyst 104 No difference 
(Orsatti et al., 1995) 
No difference, 
Nordic I ADM/DDPIRT RT/Cyst 311 15% benefit 
(Malmstrom et al., 1996) /Cyst with 
ADMIDDP in 
T3-T4a 
Nordic 2 MTXIDDP/Cyst Cyst 317 No difference 
(Malmstrom et al., 1999) 
Abol-Enein CarboMV/Cyst Cyst 194 Benefit with 
(1997) CarboMV 
DDP or C, cisplatin; MTX, methotrexate; ADM, doxorubicin; E, epirubicin; V, vinblastine; 
Carbo, carboplatin; Cyst, cystectomy; RT, radiation therapy; 5-FU, 5-.uorouracil; preop, 
preoperatively; M-VEC, methotrexate, vinblastine, epirubicin, cisplatin; M-VAC, methotrexate, 
vinblastine, doxorubicin, cisplatin; Aust/UK, Australia/United Kingdom; NCI, National Cancer 
Institute; EORTC/MRC, European Organization for Research and Treatment of Cancer/Medical 
Research Council; SWOG, South West Oncology Group. 
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I. I. B. 2 Adjuvant chemotherapy 
Adjuvant chemotherapy is given after cystectomy to patients at high risk of relapse 
(Sternberg et al., 2000; Sternberg et al., 1995). It is also widely used in patients with 
pT3-pT4a and/or pN+ MO disease in an effort to delay recurrence and prolong survival. 
This approach of giving chemotherapy after local treatment has led to increases in 
survival in patients with several solid tumours. However, the advantage of adjuvant 
chemotherapy after radical cystectomy or radiotherapy has not been proved (Sternberg 
et al., 1995). Studies have been hampered by small series of patients, patient selection, 
and high morbidity in elderly patients that have been exposed to extensive surgical 
procedures. In selected patients with minimal disease, adjuvant chemotherapy may 
improve survival (Skinner et al., 1991) but conclusive evidence and large series are 
lacking. 
The rationale for giving adjuvant (rather than neoadjuvant) chemotherapy is that the 
local definitive treatment is performed immediately. There is no delay in surgery and no 
time is wasted especially for those patients who do not respond to chemotherapy. 
Treatment decisions are based on pathological criteria, after careful examination of the 
cystectomy specimen. Micrometastases are treated when really at a low volume. 
Orthotopic bladder substitutions and the decreased morbidity of cystectomy are reasons 
to perform cystectomy and adjuvant chemotherapy (Sternberg, 2002). 
The major disadvantage of treatment with adjuvant chemotherapy is the delay in giving 
systemic therapy for occult metastases while treating the primary tumour. Response 
cannot be easily evaluated, and the only clinical endpoint that can be assessed is time to 
recurrence. An additional disadvantage may be that it is more difficult to administer 
chemotherapy following cystectomy (Sternberg, 2002). There have been very few 
randomised trials evaluating adjuvant chemotherapy (Table 7). 
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Table 7. Trials of adjuvant chemotherapy following cystectomy 
Investigator Chemo Chemo No Randomised Results 
Chemo 
Logothetis CISCA 62 71 No Benefit, but not 
(1988) randomised 
Skinner CAP 47 44 Yes Benefit, but too 
(1991) few patients 
received therapy 
Stoclde M-VAC/M- 23 26 Yes Benefit, small 
(1992) VEC patient numbers, 
premature 
closure, no 
treatment at 
relapse 
Stud er DDP 40 37 Yes No benefit, single 
(1994) agent therapy 
probably 
inadequate 
Bono CM 48 35 Yes No benefit for 
(1995) NOMO 
Freiha CMV 25 25 Yes Benefit in 
(1996) relapse-free 
survival 
Ono M-VEC 55 53 Yes No benefit 
(2001) 
Chemo, chemotherapy; M, methotrexate; C, cisplatin; V, vinblastine; DDP, cisplatin; 
M-VEC, methotrexate, vinblastine, epirubicin, cisplatin; M-VAC, methotrexate, 
vinblastine, doxorubicin, cisplatin. 
49 
New trials should be developed on the basis of current knowledge. Urologists, medical 
oncologists, and radiotherapists should collaborate in providing more extensive evidence 
rather than relying on the limited results of single studies. 
Treatment considerations should include a cost benefit analysis. In most countries, three 
to four cycles of chemotherapy cost (at 1998 prices) the equivalent of about £3000, 
radiotherapy costs about £1500, and radical cystectomy including hospital stay costs 
about £6000. Such economic considerations may play an increasingly important role in 
the future treatment of bladder cancer (Van der Meijden, 1998). 
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1.2 Angiogenesis 
The term angiogenesis was coined in 1935 to describe the formation of new blood 
vessels in the placenta (Hertig, 193 5). Angiogenesis is defined as the biological process 
by which new capillaries are formed from pre-existing vessels by sprouting i.e. cellular 
outgrowth (Battegay, 1995). It is different from vasculogenesis, which is the 
development of embryonic blood vessels (Risau, 1994). 
In the adult male, angiogenesis only occurs in abnormal conditions such as wound 
healing, fractures, and in muscles during athletic training, while in the adult female it 
occurs normally in the menstrual period, and placenta formation (Weiss, 1991; 
Klagsbrun and D'Amore, 1991). 
Although the molecular mechanism of the angiogenesis cascade is incompletely 
understood, the sequence of events leading to the formation of new vessels has been 
well documented. Studies of this process revealed that there are many steps involved 
including, degradation of the basement membrane (BM) of the pre-existing vessels by 
proteinases derived from activated microvascular endothelial cell (MVEC) (Gross et a/, 
1983; Stetler Stevenson, 1999), followed by the migration and proliferation of 
endothelial cells (ECs) from the degraded site towards the angiogenic stimulus 
(chemotactic factor) (Ausprunk: and Folkman, 1977; Klein et al., 1997). Then the lumen 
is formed (Folkman and Haudenschild, 1980), and individual sprouts join with each 
other to form loops, and lastly blood flow begins, pericytes appear and a new basement 
membrane is synthesized. Fig. 12 shows the process of angiogenesis. 
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Fig. 12. P rocess of angiogenesis: The process of angiogenesis occurs as an orderly series of events: 
1. Diseased or injured tissues produce and release 
angiogenic growth factors (proteins) that diffuse into 
the nearby tissues 
2. The angiogenic growth factors bind to specific 
3. 
5. 
6. 
receptors located on the endothelial cells (EC) of 
nearby preexisting blood vessels 
Once growth factors bind to their receptors, the 
endothelial cells become activated. Signals are sent 
from the cell's surface to the nucleus. The endothelial 
cell's machinery begins to produce new molecules 
including enzymes 
Enzymes dissolve tiny holes in the sheath-like covering 
(basement membrane) surrounding all existing blood 
vessels 
The endothelial cells begin to divide (proliferate), and 
they migrate out through the dissolved holes of the 
existing vessel towards the diseased tissue (tumor) 
Specialized molecules called adhesion molecules, or 
integrins (avb3, avb5) serve as grappling hooks to help 
pull the sprouting new blood vessel sprout forward 
7. Additional enzymes (matrix metalloproteinases, or 
(5) EC 
pro lifera.tian 
( 6) Directional 
Mgration 
(7) ECM re:mode ling 
( 10) V asc:ular stabili:za.tian 
MMP) are produced to dissolve the tissue in front of the sprouting vessel tip in order to accommodate it. As the vessel extends, the tissue is remolded around the 
vessel 
8. 
9. 
10. 
Sprouting endothelial cells roll up to form a blood vessel tube 
Individual blood vessel tubes connect to form blood vessel loops that can circulate blood 
Finally, newly formed blood vessel tubes are stabilized by specialized muscle cells (smooth muscle cells, pericytes) that provide structural support. Blood flow then 
begins 
Adapted from the Angiogenesis Foundation site (http://www.angio.org) 
The process of angiogenesis can be physiological or pathological (Table 8). 
1.2.1 Physiological angiogenesis: 
Physiological angiogenesis is an essential process to maintain a constant oxygen and 
nutrient supply to newly growing or recycling tissues (Thompson, 1989). This type of 
angiogenesis is a very tightly controlled process (Moses and Langer, 1991 ). It occurs 
normally in children particularly in osteogenesis in which the new blood vessels invade 
the previously avascular cartilage prior to the formation of bone (Weiss, 1991 ). It also 
occurs in wound healing, the process which cannot occur without angiogenesis. 
Angiogenesis plays more than a nutritive role, the endothelial cell is also an organizer 
and a regulator of healing (Arnold and West, 1991). 
Physiological angiogenesis occurs as a normal process m the female reproductive 
organs (ovary and uterus), and in placenta at the time of pregnancy (Reynolds et a/, 
1992). Rapid growth and regression of female reproductive tissues are accompanied by 
equally rapid changes in rates of blood flow (Reynolds, 1986). 
1.2.2 Pathological angiogenesis: 
Pathological angiogenesis occurs in what are known as angiogenic diseases, in which 
the normal actions of factors involved are perturbed in the environment of a disease to 
ultimately cause pathological neovascularisation (Schultz and Grant, 1991 ). In other 
words under normal homeostatic conditions, most tissues express relatively high levels 
of angioinhibitory substances, maintaining the vasculature in a quiescent state (Bouck et 
al., 1996). However, during disease states, such as neoplasia, the balance is shifted in 
favour of endothelial activation and induction of angiogenesis (Fig 13) (Hanahan et al., 
1996; Bouck et al., 1996). 
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Table 8. Physiological and pathological angiogenesis: 
Physiological Pathological 
Ovulation Neoplasia 
Development of the corpus luteum Solid and haematological tumours 
Embryogenesis Cardiovascular disorders 
Lactating breast Atherosclerosis Haemangiomatosis 
Immune response 
Wound repair Ocular disorders Diabetic retinopathy 
Neovascular glaucoma 
Retrolental fibroplasia 
Chronic inflammatory diseases 
Diabetes 
Psoriasis 
Pyogenic granuloma 
Rheumatoid arthritis 
Systemic sclerosis 
Fig. 13. Angiogenesis balance: 
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1.2.3 Angiogenic and anti-angiogenic factors 
Angiogenesis is a finely regulated process. Many substances are now known to 
modulate angiogenesis i.e. pro- and anti-angiogenic factors (Table 9&10}. Most of the 
ang10geruc factors are non-specific for the angiogenesis process (i.e. non-specific 
endothelial cell mitogens or chemotactic or both), or indirect (i.e. do not induce 
angiogenesis by themselves, but by recruiting cells which produce direct angiogenic 
factors). Humoral angiogenic factors include polypeptides and non-peptide low 
molecular weight compounds. In addition, many anti-angiogenic factors have been 
identified. 
In addition to the humoral angiogenic factors, many cells including endothelial cells, 
macrophages/monocytes (Polverini et al., 1977), mast cells (Azizkhan et al., 1980), 
pericytes (Orlidge and D'Amore, 1987), and tumour cells influence the formation of 
new blood vessels by secreting soluble angiogenic and antiangiogenic molecules. 
Pathological angiogenesis (angiogenic disease) is probably the consequence of an 
imbalance between factors stimulating and factors inhibiting angiogenesis, or an 
inadequate expression of constituents in their signalling pathway (Schweigerer and 
Fotsis, 1992). In order to prevent the development of angiogenic diseases, at least one of 
the main steps of angiogenesis process must be stopped (i.e. basement membrane 
degradation, endothelial cell migration, proliferation, lumen formation, etc). 
Complete inhibition of angiogenesis should be well tolerated in most adults since, under 
physiologic conditions, angiogenesis is required only for wound healing and 
reproduction. 
However, a better understanding of angiogenesis process cascade of events will 
facilitate the development of anti-angiogenic factors. 
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Table 9. Examples of proangiogenic factors 
Growth factors and Peptides Matrix-degrading enzymes Steroid Lipids Others 
cytokines hormones 
Basic and acidic fibroblast Substance P Urokinase and tissue-taype Estrogen Prostaglandins El Nitric oxide 
growth factors Angiotensin II plasminogen activator. and E2. Adenosine 
Vascular endothelial growth Matrix metalloproteinases. Platelet activating Histamine 
factor Hyaluronidase. factor. Copper 
Placental growth factor 
Angiopoietins 1 and 2 
Scatter factor 
Epidermal growth factor 
Transforming growth factor 
a and~-
Interleukin 8 
Granulocyte macrophage-
colony-stimulating factor. 
Tumor necrosis factor a 
Angiogenin 
Thymidine phosphorylase 
Midkine 
Pleiotrophin 
Proliferin 
*Adopted and modified from Campbell et al., 1998. 
Table 10. Examples of antiangiogenic substances 
Endogenous substance Encrypted Anticancer treatments Antibiotics Inhibitors of matrix Others 
molecules tumourover 
Interferon a, ~and r Angiostatin Bleomycin Linomide Synthetic inhibitors of Aspirin and cyclo-
Thrombospondin I and 2 Endostatin Methotrexate Minocycline matrix metalloprotein- oxygenase-2 inhbi-
Interleukins I, 4 and I2 Laminin Radiotherapy Suramin ases. tors. 
Interferon r-inducible Fibronectin Antiestrogens (tamoxifen) TNP-470 and other Inhibitors of collagen Captopril. 
protein IO Prolactin Hyperthermia fumagillin derivatives synthesis. Vitamin D3 anal-
Platelet factor 4. Retinoids ogues. 
Tissue inhibitor of matrix Antibodies to av~3 
metalloproteinase. and av~S integrins. 
*Adopted and modified from Camp bell et al., I998. 
In all types of angiogenesis, either under physiologic or pathologic conditions, 
endothelial cell activation is the first process to take place. Cytokines from various 
sources are released in response to hypoxia or ischaemia. It is suggested that vascular 
endothelial growth factor (VEGF) is a major player in angiogenesis initiation based on 
its ability to induce vasodilatation via endothelial nitric oxide (NO) production and its 
endothelial cell permeability increasing effect (Ziche et al., 1997). This allows plasma 
proteins to enter the tissue to form a fibrin-rich provisional network (Dvorak, 1986). 
The observation that VEGF production is under control of hypoxia inducible factor 
{HIF) strengthens the suggestion of an early involvement of VEGF in the angiogenic 
response. The level of HIF-1 a mRNA itself does not change in response to hypoxia, 
however HIF-1a's oxygen dependent degradation via the ubiquitin-proteasome pathway 
is inhibited (Wenger et al., 1997; Huang et al., 1998). This degradation is usually 
stimulated by the von Hippel-Lindau (VHL) gene product p(VHL), the loss of which 
has been demonstrated as a characteristic finding in clear cell carcinoma of the kidney, 
and is the key genetic variant in the pathogenesis of the VHL syndrome. The interaction 
between HIF-1a and pVHL is regulated through hydroxylation of a specific proline 
residue at position 564 (Jaakkola et al., 2001 ). Hypoxia causes a rise in HIF-1, and this 
is maximal at 0.5% oxygen tension in vitro (Jiang et al., 1996). It has previously been 
demonstrated in a mouse embryo model, that loss of HIF-1a leads to reduced 
expression of the proangiogenic vascular endothelial growth factor (VEGF) in response 
to hypoxia, leading to mouse foetal death (Ryan et al., 1998). Inhibition of HIF-1 via 
knockout of the HIF-1 P subunit leads to reduced in vitro and vivo xenograft tumour 
growth and angiogenesis, or alternatively in utero murine death (Maxwell et al., 1997; 
Maltepe et al., 1997). In vitro study of several bladder cancer cell lines has 
demonstrated increased levels ofHIF-la protein (not mRNA) in hypoxia, with matched 
rises in VEGF induction. This upregulation of VEGF was lost at confluence in some, 
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though not all superficial cell lines, but not in invasive phenotype cells, in keeping with 
their more solid morphology in vivo (Jones et al., 2001). Invasive cell lines also 
demonstrated increased levels of IDF-2a protein. Moreover, VEGF receptor (VEGFR) 
expressiOn is up-regulated under hypoxic or ischaemia conditions (Forsythe et al., 
1996). 
Besides the already mentioned proangiogenic factors, many others have now been 
identified in various settings of physiologic and pathologic angiogenesis. Among them 
are bFGF (Gospodarowicz, 1974), aFGF (Roberts et a/, 1986), TGF-a and TGF-~, 
granulocyte macrophage-colony-stimulating factor, epidermal growth factor, 
interleukin-1 (IL-l), scatter factor, platelet-activating factor, IL-8 (Koch et a/, 1992), 
and substance P (Bouck et al., 1996; Yoshida et al., 1997). Their effects can be either 
directly or indirectly on the endothelium via activation of surrounding cells to produce 
other factors with proangiogenic activity or modulation of receptors/receptor activities 
(Yoshida et al., 1997; Giraudo et al., 1998). 
Hypoxia is an important environmental factor that leads to neovascularization. In the 
case of tumour growth, however, cancer-causing genetic changes, possibly in 
conjunction with environmental influences, are able to induce angiogenesis as well (Rak 
et al., 1995; Okada et al., 1998). Many oncogenes, among which c-myb, sis, and src, 
have been shown to stimulate the expression of a wide variety of molecules that induce 
angiogenesis. Furthermore, mutant ras oncogenes strongly up-regulated the 
proangiogenic factors TGF-cx, TGF-~, and VEGF. Activated oncogenes can also 
indirectly contribute to the angiogenic phenotype by affecting the production and 
activation of BM and ECM -degrading enzymes (Bouck et al., 1996; Okada et al., 1998). 
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Tumour suppressor genes have now also been identified to play a role in angiogenic 
activities of cells. Inactivation of p53, for example, down-regulated the antiangiogenic 
ECM component thrombospondin (Dameron et al., 1994; Grossfeld et al., 1997). 
Besides the involvement of tumour cell-associated changes in p53, this tumour 
suppressor gene also plays a role in endothelial cell-mediated control of angiogenesis. 
Moreover, the multinucleated variant endothelial cells expressed a mutant p53 type, 
which may be indicative for loss of endothelial cell growth control (Satoh et al., 1998). 
As with tumour cells, it is most likely that in vivo a combination of mutations in various 
tumour suppressor genes and oncogenes leads to a proliferative proangiogenic character 
of the endothelial cells. 
1.2.4 Methods for studying angiogenesis: 
The development of simple, reliable, reproducible, quantitative in vivo and in vitro 
assay procedures is essential to enable the investigator to test both angiogenesis 
inducers and angiogenesis inhibitors. 
Several methods have been developed to test these agents. These methods have many 
drawbacks including that they are difficult to perform, extremely time consuming, 
expensive, only qualitative, require large amounts of expensive test material, and they 
give variable results (Table 11 ). 
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if able ll. 1Models of angiogenesis 
I !'In;vitro__ __ I' In vivo 
I Endothelial, ... cell . .cu~tu~e systeffill Comeali micropocket model. 
I (Citemotaxtsiand prohferat10n)! Chick embryo chori6ailantoic membrane. I i 
:Human' ;placenta! !bloqd 'Ves!)~ls · fragme11ts · assay. 
'in fibfin gel.. R<lt subcl!t!\neolls air sac. modeE 
' . . 
Rat aorta-explants. Angiogenesis in vivo using basement 
membrane extracts (Matrigel). 
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1.2. 5 Tumour angiogenesis 
The idea that solid tumour growth is dependent on the induction of neovascularization 
originated in the 1960s from experiments in which tumours were grown in isolated 
perfused organs (Folkman, et al., 1963. Folkman, et al., 1966). In 1971, Folkman and 
eo-workers showed that a soluble extract from solid tumours was able to induce 
microvascular growth in the absence of tumour itself (Folkman, et al., 1971). 
Subsequently, Folkman put forward the hypothesis that "Once tumour take has 
occurred, every further increase in tumour cell population must be preceded by an 
increase in new capillaries which converge upon the tumour." Many tumours in humans 
persist in situ for months to years without neovascularization but then become 
vascularized when a subgroup of cells in the tumour "switches" to an angiogenic 
phenotype. Tumours can accomplish the switch from an antiangiogenic to an 
angiogenic phenotype by either upregulating the expression of angiogenesis inducers or 
downregulating inhibitors, and in some instances, both mechanisms are operative 
(Hanahan et al., 1996; Volpert et al., 1997; Campbell et al., 1998). This switch is 
usually accompanied by rapid growth of the tumour. 
Stimuli, which may promote this angiogenic switch, include metabolic stresses, such as 
hypoxia, acidosis and hypoglycaemia, as well as mechanical strain due to tissue growth, 
and inflammatory or immune cell activation. Genetic mutation, causing dysregulation of 
factors involved in angiogenesis, may affect the balance of angiogenic factors directly. 
It is the switch to the angiogenic phenotype that may allow clinically dormant 
microscopic neoplastic disease to grow and become clinically apparent, and there is 
extensive experimental evidence to support the claim that tumours and metastases are 
angiogenesis dependent, (Folkman, 1990). Folkman first described the need for tumours 
to develop their own blood supply to grow beyond 2-3mm3 in 1971 (Folkman, 1971). 
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The onset of angiogenic activity enables rapid expansion of the tumour population and 
increases the risk of metastasis, and this can be stimulated by inflammation. 
The process of tumour angiogenesis begins with the enzymatic degradation of the 
basement membrane of a postcapillary venule and the breakdown of the interstitial 
matrix. This permits chemotaxis of endothelial cells towards the angiogenic stimulus 
and proliferation into the surrounding stroma of the existing endothelium. Three distinct 
zones of angiogenesis result in: a migratory zone, a proliferative zone and a zone of 
maturation, where functional vessels can be identified (Polverini, 1995). Capillary 
endothelial cells become organized into tubular structures and capillary sprouts form 
anastomoses between themselves and components of the host vasculature, following 
which initial blood flow can be seen (Baillie e/ at, 1995; Hayes, 1994; Ferrara, 1995). 
These new vessels migrate towards the tumour to form the basis of the tumour stroma, 
together with interstitial fluid, interstitial collagens, fibrin, fibronectin, vitronectin, 
glycosaminoglycans, proteoglycans, fibroblasts and some inflammatory cells (Senger, et 
al., 1995; Dvorak, et al., 1995a). 
There are many important differences between the structure of normal and tumour 
vasculature. Vessels which grow in response to a tumour stimulus are mainly composed 
of endothelial cells, whilst normal capillaries usually also contain vascular pericytes. 
The tumour vasculature appears as a disorganised network that consists of many 
abnormal blood vessels including sinusoidal vessels, giant capillaries and blood 
channels with a discontinuous endothelial lining. Although normal vessels may also be 
recruited from the host tissues (Blood & Zetter, 1990; Baillie et al., 1995). As the 
tumour vasculature lacks innervation and has low effective capillary density, this leads 
to hypoxia and acidosis within the tumour stroma. This is further aggravated by the 
fibrinous and later a collagenous matrix that separates tumour cells from blood vessels. 
Tumour vasculature also has leaky blood vessels and poor lymphatic drainage, which 
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causes raised interstitial hydrostatic pressure within the tumour core. This can lead to 
occlusion of the tumour interior blood vessels with consequent ischaemia and 
eventually necrosis within the tumour core. Failure of the tumour vasculature can be 
precipitated by hypotension, alterations in blood coagulability or viscosity, or by 
damage to endothelial cells resulting in coagulation and the blocking of nutrient vessels 
with white cells (Blood & Zetter, 1990; Battegay, 1995; Baillie, et a/, 1995; Dvorak, et 
al., 1986). 
As previously mentioned, in the prevascular phase, the tumour is rarely larger than 2 to 
3 mm3 and may contain a million or more cells (Folkman, 1995). Such asymptomatic 
lesions are sometimes directly visible on the skin or cervix or in the bladder, but usually 
they are clinically undetectable. Cells in prevascular tumours or dormant 
micrometastases may replicate as rapidly as those in expanding, vascularized tumours, 
but without the growth of new vessels the rate of proliferation of such cells reaches 
equilibrium with their rate of death (Idem, 1995; Holmgren, et al., 1995). A tumour 
consists of 2 interdependent compartments: the parenchyma (tumour cells) and the 
stroma (supporting cells and connective tissue). A blood vessel network is contained 
within the stroma, which provides nutrients, gas exchange and waste disposal, and 
allows the cancer cells to establish continuity with the normal vasculature (Dvorak, 
1986; Ferrara, 1995; Gasparini & Harris, 1995). In addition, the stroma may act as a 
barrier, blocking recognition of the tumour cells by inflammatory and immune cells 
(Dvorak, 1986; Blood & Zetter 1990. Folkman, 1995b). 
What actually causes the tumour angiogenic switch is currently under investigation, 
however it may occur due to the down-regulation of an inhibitor of angiogenesis under 
the control of a tumour suppressor gene such as p53, aided by the expression of 
angiogenic factors such as basic fibroblast growth factor (bFGF) or vascular endothelial 
growth factor (VEGF) (Samoto et al., 1993; Campbell et al., 1998) (Fig. 14). 
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Fig. 14. The angiogenesis-signaling cascade: 
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VEGF and bFGF are ftrst synthesized inside tumour cells and then secreted into the 
surrounding tissue. When they encounter EC, they bind to specific protein (receptors), 
sitting on the outer surface of the cells. The binding of either VEGF or bFGF to its 
appropriate receptor activates a series of relay proteins that transmits a signal into the 
nucleus of the EC. The nuclear s ignal ultimately prompts a group of genes to make 
products needed for new endothelial cell growth. 
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There is no doubt that tumour angiogenesis is the result of the concerted interplay of a 
multitude of different cytokines, growth factors and cell adhesion molecules. Some of 
these interact directly with the cells responsible for neovascularisation, such as 
endothelial cells and pericytes, and others stimulate cells such as macrophages, mast 
cells and fibroblasts to produce primary or secondary angiogenic factors (Hayes, 1994; 
Miles, 1999) (Fig. 15). 
Angiogenesis may not always appear as the initial step in tumour formation. In cervical 
neoplasia, angiogenesis typically occurs prior to the gross appearance of tumour: in 
breast and bladder, a marked increase in angiogenesis occurs coincidentally with tumour 
development; and in melanoma and ovarian carcinoma, angiogenesis occurs after 
tumour formation (Folkman, 1990). Experimental and clinical data indicate that most 
tumours occur without angiogenic activity, exist in the in situ stage without 
neovascularization for a long period of time, and then become vascularized when a 
subset of cells within the tumour switches to the angiogenic phenotype (Folkman, 
1995). 
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Fig. 15. Source of angiogenesis factors: Not only cancer cells but also 
inflammatory cells that infiltrate the tumour and the extracellular matrix can be a 
source of angiogenesis factors. 
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1.2.6 Angiogenesis and Metastasis 
Experimental and clinical evidence suggests that the process of metastasis is also 
angiogenesis dependent. For a tumour cell to metastasize successfully, it must breach 
several barriers and be able to respond to specific growth factors (Nicolson, 1988; 
Watanabe et al., 1991; Zetter, 1998). Thus, tumour cells must gain access to the 
vasculature in the primary tumour, survive the circulation, arrest in the microvasculature 
of the target organ exit from this vasculature, grow in the target organ, and induce 
angiogenesis (Weidner et al., 1991; Weinstat-Saslow et al., 1994). Therefore, 
angiogenesis appears to be necessary at the beginning as well as at the completion of the 
metastatic cascade. 
In experimental animals, tumour cells are rarely shed into the circulation before a 
primary tumour is vascularized, but they can appear in the circulation continuously after 
neovascularisation (Liotta, et al., 1980). The number of cells shed from the primary 
tumour correlates with the density of tumour blood vessels as well as with the number 
of lung metastases observed later. Tumour cells can enter the circulation by penetrating 
through proliferating capillaries that have fragmented basement membranes and are 
leaky (Dvorak et al., 1999). Further, angiogenic factors from tumours such as bFGF and 
VEGF induce increased production of plasminogen activator and collagenases in 
proliferating endothelial cells, thus further contributing to degradation of basement 
membranes. These degradative enzymes may facilitate the entry of tumour cells into the 
circulation. Tumour cells that have successfully metastasized may not immediately 
become neovascularized after reaching the target organ. Such a metastasis lacking 
angiogenic activity for any of a variety of reasons may remain as a microscopic tumour 
of 100 to 200 11m diameter indefinitely (Chambers, 1999; Folkman, 1995). It is 
generally assumed that in human dormant micrometastases (e.g., metastases appearing 
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5-10 years after removal of a breast cancer), tumour cells are not cycling or are in GO. 
Increasing experimental evidence, however, indicates that micrometastases can be held 
dormant by blocked angiogenesis that results in a balance of tumour cell proliferation 
and apoptosis (Holmgren et al., 1995; Folkman, 1995). Finally, experimental metastases 
are as susceptible as primary tumours to control by specific angiogenesis inhibitors 
(O'Reilly et al., 1996; Teicher et al., 1992). For these inhibitors, the microvascular 
endothelial cell is the only target; tumour cells are not directly affected in vitro. 
In many types of human cancer including bladder cancer, microvessel density in a 
histologic section of the tumour is an independent prognostic indicator of the risk of 
future metastases (Weidner et al., 1991; Camp bell et al., 1998). Since the report of 
Weidner and colleagues in 1991, there have been many different reports that in human 
breast cancer there is a positive association between tumour angiogenesis and metastatic 
risk (Folkman, 1998). 
Because of the clonal origin of metastases (Kerbel et al., 1988; Weinstat-Saslow et al., 
1994), a primary tumour containing a high proportion of angiogenic malignant cells is 
more likely to generate metastases that are already angiogenic when they arrive at the 
target tissue. In contrast, there are a number of reports of no association between tumour 
angiogenesis and metastatic risk (Folkman, 1998; Gasparini and Harris, 1999). 
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1. 2. 7 Angiogenesis in bladder cancer 
The initial observations demonstrating that bladder cancer is partly an angiogenic 
disease were provided by Chodak and colleagues, who showed that bladder tumour 
fragments could induce neovascularity when implanted in the cornea of rabbits, whereas 
normal bladder tissue could not (Chodak et al., 1980; Chodak et al., 1997). Subsequent 
studies demonstrated that urine from bladder cancer patients is also strongly angiogenic, 
suggesting secretion of angiogenic factors by these tumours (Chodak et al., 1988; 
Chodak et al., 1981). Chodak's group eventually isolated an angiogenic substance from 
the urine of mice with bladder cancer and showed that it was a heparin-binding growth 
factor with properties similar to those of the FGF family of molecules (Chodak et al., 
1988). A long list of agents involved now exist, and only those which have been 
described in particular reference to bladder cancer are listed in Table 12. 
Multiple lines of evidence have now converged to demonstrate that bladder tumours are 
dependent on angiogenesis for progression, growth, and metastasis. Fluorescein 
angiography reveals markedly increased uptake in papillary tumours and carcinoma in 
situ compared with normal urothelium, indicating that neovascularity is acquired 
relatively early during bladder tumourigenesis (Zimmern et al., 1995). 
Published studies describing the association between bladder cancer and angiogenesis 
are shown in Table 13. Data with regard to superficial bladder cancer remains 
controversial, possibly due to difficulties in quantification within a friable papillary 
tumour (Dinney et al., 1998; Ozer et al., 1999). Technical problems, such has 
unrepresentative sampling of microvessel hotspots, where other investigators quote 
mean MVD, and the differing nature of tissue, either transurethral resection versus 
cystectomy specimens may explain some inconsistencies between series. 
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Table 12. Pro- and anti-angiogenic factors described in bladder cancer. 
Pro-angiogenic factors Anti-angiogenic factors 
Basic fibroblast growth factor (bFGF) Cortisone 
(Gazzaniga et al., 1999). (Lee et al., 1990) 
Acidic fibroblast growth factor (aFGF) Thrombospondin I (TSP-1) 
(Chopin et al., 1993) (Grossfeld et al., 1997) 
Vascular endothelial growth factor (VEGF) Angiostatin 
(Crew et al., 1999) (Beecken et al., 200 I) 
Epidermal growth factor (EGF) Interferon-a 
(Perrotte et al., 1999) (Slaton et al., 1999) 
Thymidine phosphorylase (TP) 
(Arima et al., 2000) 
Scatter factor/hepatocyte growth factor (SF) 
(Tamatani et al., 1999) 
Midkine (MK) (O'Brien et al., 1996) 
Hyaluronic acid (HA) (Lokeshwar et al., 1997) 
Angiogenin (Miyake et al., 1999) 
Cyclooxygenase 2 (Cox 2) 
(Yoshimura et al., 200 I) 
Hypoxia inducible factors 1&2 (HIF-l!HIF-2) 
(Talks et al., 2000) 
EIF-4e (Crew et al., 2000) 
Matrix metalloproteinases. 
(Papathoma et al., 2000) 
Urokinase plasminogen activator 
(Hasui et al., 1996) 
Mutant p53 (Reiher et al., 2001) 
Interleukin-8 (Inoue et al., 2000) 
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The published literature regarding invasive tumours is more convincing (Streeter et al., 
2002). 
Quantitative immunohistochemistry analysis of endothelial antigens such as Factor 
Vlll-related antigen, CD31, and CD34 also supports the angiogenic dependence of 
bladder cancer. Microvessel density has been demonstrated to be a useful prognostic 
indicator in a variety of malignancies, including melanoma (Srivastava et al., 1988; 
Barnhill et al., 1992}, breast cancer (Weidner et al., 1992; Horak et al., 1992} and 
prostate cancer (Weidner et al., 1993; Brawer et al., 1994). In general, increased 
microvessel density counts have been associated with tumour progression and decreased 
overall survival (Srivastava et al., 1988; Barnhill et al., 1992; Weidner et al., 1992; 
Horak et al., 1992; Weidner et al., 1993; Brawer et al., 1994). The relationship between 
microvessel density count and tumour progression has been examined in patients with 
bladder cancer (Bochner et al., 1995; Jaeger et al., 1995; Dickinson et al., 1994; 
O'Brien et al., 1995; Campbell et al., 1997). Jaeger et al., demonstrated a significant 
correlation between tumour angiogenesis (as determined by microvessel density) and 
lymph node metastases in 41 patients with invasive bladder cancer (Jaeger et al., 1995). 
Dickinson et al., showed microvessel density to be an independent prognostic indicator 
of disease progression in 45 patients with invasive bladder cancer followed for a median 
of 37 months (Dickinson et al., 1994). The most comprehensive such study was by 
Bochner and colleagues, in which 164 patients with invasive disease managed with 
radical cystectomy were retrospectively divided into groups with low, intermediate, and 
high microvessel density. The 5-year recurrence-free rates for these three groups were 
81%,44%, and 32%, respectively, and the overall 5-year survival rates were 68%, 44%, 
and 34%, respectively (Bochner et al., 1995). 
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Table 13. Studies of microvessel density (M\'1)) and prognosis in bladder cancer: 
Study 
Dickinson 
(1994) 
Bochner 
(1995) 
Jaeger 
(1995) 
Philp 
(1996) 
Grossfeld 
(I 997) 
Bochner 
(1997) 
Dinney 
(1998) 
Hawke 
(1998) 
Chaudhary 
(1999) 
Ozer 
(1999) 
Inoue 
(2000) 
Sago I 
(2001) 
No Histology 
45 Invasive 
(TURBT) 
164 Invasive 
(Cystectomy) 
41 Invasive 
(Cystectomy) 
113 Superficial or 
invasive (TURBT) 
163 Invasive 
(Cystectomy) 
161 Invasive 
(Cystectomy) 
54 Tl (TURBT & 
Cystectomy) 
42 Invasive 
(Cystectomy) 
88 Invasive 
20 
51 
80 
(Cystectomy) 
G3Tl 
(TURBn 
Invasive 
(Cystectomy) 
Superficial 
(TURBT) 
Stained for 
CD3I 
CD34 
Factor VIII 
CD31 
CD34 
CD34 
Factor VIII 
Factor VIII 
CD31 
Factor VIII 
CD34 
CD31 
p-value 
(rec. free surv) 
NIA 
<0.0001 
NIA 
NIA 
NIA 
<0.001 
NIA 
NIA 
0.03 
0.002 
0.048 
NIA 
p-value 
(overall surv) 
0.026 
0.0007 
NIA 
0.01 
NIA 
0.003 
NIA 
0.04 
0.02 
0.01 
NIA 
NIA 
TURBT=transurethral resection of bladder tumour; Invas1ve=stage T2 or greater; N/A=data not avrulable. 
* Adopted from Streeter et al., 2002. 
Uni/ 
multivariate Comments 
Univariate MVD not associated with stage and grade, but 
high ---.MVD-2.5x !mortality. 
Multivariate 1 MVD correlates with stage at presentation, 
recurrence and survival 
NI A 1 MVD correlates with lymph node metastases at 
presentation 
Multivariate MVD correlated with stage at presentation 
NIA 1 MVD associated with !survival and low 
Thrombospondin-1 
Multivariate 1 MVD associated with progression, and loosely 
with!p53 
Univariate No association between MVD and recurrence or 
progression. 
Univariate MVD of no independent prognostic value. 
Univariate 1 MVD associated with nodal metastases at 
cystectomy, 1 recurrence, !survival. 
Univariate 1 MVD associated with 1 recurrence and 
!survival. 
Multivariate 1 MVD predicts recurrence in patients given 
neoadjuvant MV AC chemotherapy 
Univariate MVD did not differ from Ta to Tl, or predict 
recurrence. 1 MVD associated with 1 grade. 
On multivariate analysis, microvessel density proved to be an independent prognostic 
indicator when evaluated in the presence of histological grade, pathological stage, 
regional lymph node status, and p53 status (Bochner et al., 1995; Bochner et al., 1997). 
High microvessel density was also associated with a twofold to threefold higher risk of 
death from invasive bladder cancer in other recent studies (Hawke et al., 1998; 
Dickinson et al., 1994). However, Chopin and colleagues found no correlation between 
microvessel density and relapse-free survival in 49 patients with negative lymph nodes 
who had been treated with radical cystectomy (Chopin et al., 1996). Differences in 
patient populations, statistical power, and immunohistochemistry protocols could 
account for such disparate findings. 
A further recent series of 51 cystectomy cases using hot spot analysis showed high 
MVD predict recurrence in patients given neoadjuvant MV AC chemotherapy (Inoue et 
al., 2000). 
Assays for the expression of a variety of angiogenic factors may also have predictive 
power for bladder cancer. Increased expression of thymidine phosphorylase has 
correlated with tumour grade and stage (O'Brien et al., 1997; O'Brien et al., 1996} and 
midkine (a member of a family of heparin-binding growth factors) with poor outcomes 
in patients with invasive disease (O'Brien et al., 1996). Urinary levels of VEGF (Crew 
et al., 1997; Crew et al., 1998}, aFGF (acidic fibroblast growth factor) (Chopin et al., 
1993}, bFGF (basic fibroblast growth factor) (Nguyen et al., 1993; Bochner et al., 
1997}, and scatter factor (Rosen et al., 1997) have all correlated with disease status and, 
in many cases, with tumour grade and stage. Urinary bFGF levels have been evaluated 
most extensively. Bochner et al., in 1997 reported a correlation between urinary bFGF 
and microvessel density, again indicating a functional role for this growth factor in the 
induction of angiogenesis in this disease. In the study by Nguyen and colleagues, 
urinary levels of bFGF were found to have better predictive value than cytological 
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analysis for the diagnosis of recurrent bladder cancer (Nguyen et al., 1993). More recent 
investigation in a series of 185 resections showed no correlation between VEGF protein, 
recurrence or survival (Chow et al., 1999), with a separate report correlating VEGF with 
increasing grade oftumour, but not with MVD (Ogura et al., 1998). 
Bemardini et al., in 2001 showed in his study a significant difference in serum vascular 
endothelial growth factor in healthy controls and patients with bladder cancer. The 
serum level was significantly associated with tumour stage, grade, vascular invasion and 
carcinoma in situ. Patients with metastasis had significantly higher levels than those 
with localized diseases (Bemardini et al., 2001 ). 
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1.3. Radiotherapy 
Radiotherapy treatments aim to deliver a homogeneous dose of irradiation to an 
accurately localized tumour volume and to minimize the effect on the surrounding 
normal tissue. This requires the target volume to be defined as accurately as possible 
from clinical examination, radiological investigations, which frequently includes CT 
scans, and from knowledge of the natural history and patterns of spread of any 
particular type of malignancy. 
Radiation therapy is one of four approaches to the treatment of cancer. The other three 
are surgery, chemotherapy, and biological therapy. Since each type of cancer is unique, 
research has helped physicians determine which treatment or combination of treatments 
is appropriate for each type of cancer. Radiation therapy may be used alone or in 
combination with surgery, chemotherapy, and/or biological therapy. Radiation therapy 
may be used in an attempt to cure the cancer or to treat unpleasant symptoms the cancer 
is causing such as pain or bleeding. The most common types of cancer that radiation 
therapy is used for are brain tumours, head and neck cancers, lung cancer, breast cancer, 
prostate cancer, skin cancer, rectal cancer, cervix and uterine cancers, lymphoma, and 
sarcoma (Robert et al., 2000). 
Radiation therapy for the treatment of cancer may be given in two different ways. 
External beam irradiation is the most common method. The radiation is delivered to a 
specific area of the body using a large machine similar to an x-ray machine. The 
treatment is given each day, Monday through Friday, for I to 8 weeks depending on the 
type of cancer and the reason for the treatment. The treatment may be given once a day, 
twice a day, or as many as three times a day for certain cancers. 
The other method of delivering radiation treatment is called brachytherapy. In this 
method, a source of radiation in the shape of needles or seeds is implanted in the body. 
This treatment is often given before or after external beam irradiation as a way of 
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increasing the radiation dose to only the tumour. Brachytherapy is often used in cervix, 
uterine, and prostate cancers, some head and neck cancers, and sarcomas. Some of the 
implants stay in place permanently, whereas others are removed after 2 or 3 days. 
The role of radiotherapy for a particular tumour type is determined partly by the average 
radiosensitivity of the tumour relative to adjacent normal tissues and partly by the 
probability that the tumour is localized to the irradiation field. Irradiation with photons 
(x-rays or gamma rays), electrons or high energy particles such as neutrons interact 
indirectly or directly with tissue to produce short lived ion radicals (Dizdaroglu et al., 
1992; Ward, 1994). These damage nuclear DNA leading eventually to programmed cell 
death (apoptosis), also called interphase death (Bryant, 1997). Cells undergoing 
apoptosis as an immediate consequence of radiation damage usually die in interphase 
within a few hours of irradiation, irrespective of and without intervening mitosis. They 
share distinct morphologic changes, including loss of normal nuclear structure and 
degradation of DNA that can be demonstrated by a classical pattern of "laddering" on 
DNA blots (Lowe et al., 1993). Cells whose mitotic cycle time is short will show signs 
of radiation damage more quickly than those whose cycle time is long. However, it has 
been suggested by some authors that the level of DNA damage induced by radiation 
may be the primary determinant of radiosensitivity (Radford, 1986). 
The other mechanism for cell killing is radiation-induced reproductive failure. Radiation 
in sufficient doses can inhibit mitosis; that is, the cell's ability to divide and proliferate 
indefinitely. The inhibition of cellular proliferation is the mechanism by which radiation 
kills most cells (Robert et al., 2000). 
The extent of DNA damage following radiation exposure depends on several factors. 
One of which is the level cellular oxygen (Littbrand et al., 1969). Hypoxic cells are 
considered less radiosensitive compared to the well-oxygenated cells. In fact, anoxic 
cells require 2 to 3 times the radiation dose to produce an equivalent amount of cell kill, 
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as do oxygenated cells (Chapman et al., 1999). Earlier reports have shown that severely 
anaemic patients undergoing radiotherapy were associated with poorer outcome. This 
was in contrast to the improvements seen in the outcome of radiotherapy patients who 
had received hyberbaric oxygen (Henk, 1981 ). Oxygen is believed to prolong the 
lifetime ofthe short-lived free radicals produced by the interaction ofx-rays and cellular 
H20. 
Ionizing radiation is consequently less efficacious in tumours with significant areas of 
hypoxia and necrosis. In contrast, damage following exposure to ionizing radiation is 
independent of cellular oxygen levels (Boice et al., 1996). 
The extent of DNA damage following radiation exposure is also dependent on the phase 
of the cell cycle (Eikind, 1997). Radiosensitivity varies both between and within the 
various phases. In general, the most sensitive phases are G2- and M-phases; the least 
sensitive are G 1- and late S-phases (Bryant, 1997; Olive et al., 1997), depending on the 
cell line studied. Irradiation of an asynchronously dividing population of tumour cells 
results in killing of a greater proportion of cells in G2- and M-phases, while surviving 
G 1 a- and S-phase cells may progress to more sensitive phases, a phenomenon known as 
reassortment. In contrast to indirectly ionizing radiation, DNA damage following 
exposure to directly ionizing radiation is less dependent upon the phase of the cell cycle 
(Raju et al., 1978). Similarly, normal tissues show varying sensitivity both to the degree 
and timing of radiation damage. 
Total dose of irradiation on tumours as well as normal tissues could be dramatically 
modified by dividing it into smaller parts or fractions. Empirically fractionated 
treatment regimes were developed which allowed for higher total doses to be delivered 
obtaining better local tumour control but without a high incidence of normal tissue 
damage. Fractionated treatment spares normal tissue because sublethal damage is 
repaired between daily fractions of treatment and normal tissues are allowed to 
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repopulate if the overall treatment time is sufficiently long. Many tumours have a 
relatively poor blood supply and contain hypoxic regions, which are relatively resistant 
to radiotherapy. Increasing the treatment time using a fractionated regimen allows 
surviving hypoxic tumour cells to re-oxygenate and additionally cells are allowed to re-
assort into the more radiosensitive phases of the cell cycle (Abeloff et al., 2000). 
Generally acute reactions occur within 3 months of treatment, late reactions occur at 
more protracted intervals. Tissues having a high proliferative rate, such as skin and 
mucosal surfaces, express damage more rapidly (acute reacting), whereas slowly 
dividing tissue are late reacting. In particular it is possible that damage to vascular 
endothelial cells is responsible for many of the late radiation effects apparent clinically 
(Hopewell et al., 1989). 
1.3.1. Radiotherapy in bladder cancer 
In the United States, the standard treatment for muscle invading TCC is radical 
cystectomy, while in Europe; external beam irradiation is a more common treatment 
(Kanady et al., 1997). It is also recommended for patients deemed "unfit" for 
cystectomy, on the basis of either co morbid conditions or disease extent. 
The goal of treatment with radiotherapy is definitive local (or loco-regional) control as 
an absolute prerequisite for cure. The correlation between local control and metastasis 
indicates that better systemic treatments, although badly needed, must not be developed 
without care for local control because local failure can be the source of further 
metastasis in patients initially free of distant disease (Pollack et al., 1994). In a series of 
379 patients treated at the Netherland Cancer Institute, 136 experienced a local 
recurrence and 120 of those recurred locally before regional or distant metastasis were 
detected (Moonen et al., 1998). 
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Several authors, covering a large span of practices with various techniques and 
treatment schedules, have reported results of external radiotherapy. There are two 
fundamental approaches: the British-inspired schedule of 2.5Gy per fraction, five 
fractions per week for 4 weeks and the classical, continental schedule of 1. 8 to 2 Gy per 
fraction, five fractions per week for 6 to 7 weeks. Since these approaches have never 
been tested against each other in a randomized trial, it is difficult to recommended one 
as being superior to the other. Data from larger series, summarized in table 14, show 
variation in local control and survival among the various series. 
Overall, long-term local control and cure can be achieved in 60 to 80 per cent of clinical 
T1, 30 to SO per cent ofT2, and 20 to 40 per cent ofTJ tumours with doses in the range 
SO to 70 Gy (in 4 to 7 weeks). A dose-effect relationship has been shown to exist in 
transitional bladder cancer supporting the use of high-dose radiotherapy, either from 
radical radiotherapy series or from preoperative series suggesting a better down-staging 
with higher radiation doses (Moonen et al., 1998; Nasslund et al., 1994). 
The patient presenting with a transitional cell bladder cancer is usually elderly. This 
important fact has often resulted in a recruitment selection between younger patients, 
who are frequently treated by radical surgery and older patients, in poorer general 
condition, who are more often referred to the radiation oncologist. Experience indicates 
that the success of radiotherapy may be favourably influenced by certain prognostic 
factors such as the absence of ureteral obstruction, the achievement of a complete 
transurethral resection before irradiation, the presence of papillary rather than a sessile 
tumour, and the clinical stage (Shipley et al., 1985; Petrovich et al., 2001). 
It is of interest to note the importance ofureteral obstruction on survival in patients with 
T2 and TJ tumours. The S-year survival of radiotherapy treated patients without ureteral 
obstruction was 54% versus 22% for those with ureteral obstruction (p=0.02) (Shipley 
et al., 1985). 
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Table 14. Five-year local control and overall survival in selected larger series after 
definitive radiotherapy for bladder cancer. 
Local control Overall survival 
Author Stage N Dose (%at 5 years) (% at 5 years) 
Blandy et al T2-T3 352 50-55 Gy/20 - 34 
(1980) fx 
Goodman et al T2-T3 470 50 Gy/20 fx 56 38 
_i1981) 
Yu et a1 Tl-T4 356 60-66 Gy/30- 20 38 
(1985) 35 fx 
Jenkins et al T2-T3 182 50-55 Gy/20 - 40 
(1988) fx 
Davidson et a1 TI-T4 709 50-64 Gy/ 20- - 25 
_il990) 30 fx 
Jahnson et a1 TI-T4 319 54-77 Gy/22- 51 18 
( 1991) 45 fx 
Pollack et al T2-T4 135 60-70 Gy/30- 32 27 
(1994) 35 fx 
Sengelov et al Tl-T4 94 58-63 Gy - 7 
(1997) 
Moonen et al T2-T3 379 50-75 Gy/ 25- 40.3 22.2 
(1998) 37 fx 
Hayter et al T2-T4 1,372 60Gy - 28 
(1999) 
Fx = fractions, N = number of patients. 
81 
A study of 347 T3 (TCC) patients was reported from Western General Hospital of 
Edinburgh, Scotland. Patients were scheduled to receive SS Gy in 20 fractions over a 
period of 18 days. Local tumour regression was assessed cystoscopically 6 months 
following completion of radiotherapy in 272 (82%) patients. Of these 272 patients, 112 
(41%) showed complete tumour regression. The incidence of tumour regression was 
similar for those with ulcerative and solid tumours (about 52%), while it was 27% for 
papillary and 31% for mixed lesions, (p=0.024). Tumour grade and size (<5 cm vs. >5 
cm) were also important factors influencing tumour regression (p=0.003). Grade I 
tumours had a regression rate of 17%, grade li of 31%, and grade Ill of 56% (p < 
0.0001). The 5-year incidence of local tumour control was 10% for grade I, 14% for 
grade 11, and 35% for grade m patients. 
In multivariate analysis only patients age (p=0.06) and haemoglobin level (p=0.025) 
were important prognostic factors. Local tumour regression following radiotherapy was 
an important factor predicting survival. The 5- and 10-year survival of patients with 
complete tumour regression was 45% and 25%, respectively, as compared with 21% 
and 15%, respectively, for those with partial tumour regression (Quilty et al., 1986). 
In patients with muscle invasive bladder cancer it is difficult to compare the outcomes 
of definitive radiotherapy and surgical treatments. This is primarily due to the obvious 
selection bias-favouring patients who are to undergo radical cystectomy (Petrovich et 
al., 2001). A review of 10 selected studies with a total of 4,368 patients treated with 
radiotherapy alone and using various treatment techniques, shows 5-year survival rates 
ranging from low of 7% to a high of 40% (Table 14). 
In most series, despite negative selection, results are inferior to those observed with 
radical surgery. This is partly a result of the difficulty of rendering the bladder tumour 
free by external beam radiation alone, and the continued risk for developing new 
tumours in the organ left in situ. In most cases, treatments are delivered in five daily 
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fractions a week, ranging from 2.0 to 2.5 Gy to a total treatment dose of 55 to 65 Gy, 
with no interruptions. In designing the radiation fields to treat a patient with bladder 
cancer, the target is best defined by information from the planning cystogram, the er 
scan, the cystoscopic examination, the bimanual examination, and having the bladder 
empty to assist set-up reproducibility and adequate coverage of the tumour at each 
treatment (Turner, et al., 1994; Marks, et al., 1992; Sur, et al., 1993). 
The bladder has a good tolerance to radiation; a diseased bladder may be more liable to 
side effects, either acute (frequent micturition) or late (haematuria, contracted bladder). 
Therefore, care must be taken to protect nontumoural areas of the bladder during the 
boost to 66 Gy. The rectosigmoid, small bowel, pelvic bones, and femoral heads are 
also critical tissues, which must not be injured by radiotherapy. The dose to the anterior 
rectal wall should be limited to less than 45 Gy. However, those dose limits are only 
guidelines and must be adapted according to each individual clinical situation. The 
planned schedule of 2 Gy per fraction, five fractions per week, must be accurately 
followed, in particular without gaps in the treatment, which could lengthen the total 
irradiation time. Indeed, tumours repopulate during radiotherapy and 6-7 weeks of 
irradiation represents a delicate trade-off between tumour sterilization and normal tissue 
sparing. Any gap in the treatment will break the equilibrium in favour of tumour 
repopulation. For example, in the radiotherapy series of Symonds et al., 1990, a 2-3 
week split in the treatment significantly decreased the 5 year survival from 35 to 22 per 
cent. Judgements as to the most appropriate treatment for an individual require a 
detailed clinical and radiological assessment of each patient and their tumour so as to be 
able to accurately define the extent and stage of disease as well as the suitability of an 
individual patient for a particular treatment approach. 
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1.3.2. Morbidity of radical radiotherapy 
The reported rate of morbidity is dependent on registration, classification and grading, 
and most studies have limited information on this subject. Adverse effects can be 
difficult to distinguish from symptoms due to residual tumour, and may be influenced 
by irradiated volume, field arrangement, beam quality, fraction size, total dose, previous 
operative procedures in the area and the general condition of the patient (Abrahamsen et 
al., 1990). Treatment related deaths are reported to be 2-3% (Goodman et al.. 1981; 
Hopkins et al., 1987; Jahnson et al., 1991). The side effects arise from damage caused 
to bladder and bowel included in the radiation field. The rate of any acute side effects is 
24-70% for bowel symptoms (diarrhea, pain, and incontinence) and 53% for urinary 
symptoms (dysuria, frequency, pain, cramps) (Goffinet et al., 1975). The actuarial rate 
of non-severe intestinal side effects according to RTOG scoring system is about 12% at 
5 years. Severe or major events are usually defined as complications requiring surgery 
or at least 30 days of hospitalization. The rate of severe acute bowel complications is 2-
17% (Duncan et al., 1986; Goffinet et al., 1915; Hopkins et al., 1987; Sengelov et al., 
1997). Late effects occur after 3 or more months, with a median time of 18-26 months 
after completion of radiotherapy (Duncan et al., 1986; Jahnson et al., 1991 ). The crude 
rate of patients with major events such as ileus, peritonitis and fistula after radiotherapy 
is about 3.5-8% (Greven et al., 1990; Salminen et al., 1990; Shipley et al., 1987). 
However, when using actuarial methods taking into consideration the number of 
patients at risk, the complication rates are as high as 11-79% (Bretheau et al., 1996; 
Fossa et al., 1993; Jahnson et al., 1991; Pollack et al., 1994; Sengelov et al., 1997). 
Surgery performed for complication of late radiation effects can have a postoperative 
mortality as high as 33% (Jahnson et al., 1991). The actuarial incidence of severe 
urinary radiation side effects, such as uraemia or contracted bladder is 8-12% at 5 years 
(Jahnson et al., 1991; Sell et al., 1991 ). In a prospective study by Lynch et al., 1992, 
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symptoms and quality of life in 72 patients achieving complete response after 
radiotherapy was compared with a matched healthy non-irradiated control group. No 
significant difference in quality of life or treatment related symptoms except from 
haematuria was encountered. Information on late effects on sexual function is sparse. 
One study has found that 41% could practice normal coitus 18 months after 
radiotherapy (Sell et al., 1991 ). Retrospectively, the frequency of morbidity has been 
similar for total doses in the range of 60-72 Gy and 50- 57.5 Gy (Quilty et al., 1986). 
However, one study has found a reduced morbidity when the radiation dose was 
reduced from 55.0 to 52.5 Gy, but dose per fraction was also decreased (Whillis et al., 
1992}. Data from several studies have shown that the morbidity increases with 
increasing field size (Davidson et al., 1990} and increasing dose per fractionation 
(Abratt et al., 1983; Fossa et al., 1993; Jahnson et al., 1991 ). The complication rate was 
higher with rotational Cobalt-60 irradiation than with two opposed fields (Shipley et al., 
1998) or with the four-field technique in retrospective comparisons (Jahnson et al., 
l991;Pollacketa/., 1994). 
1.4 Prognostic markers 
The search for biological parameters that could select patients who will respond to 
radiation treatment has become essential (Rode! et al., 2000}. The ultimate aim is to find 
individual markers related to stage and grade, sex, survival, recurrence and response to 
treatments. Such findings could be useful in routine clinical practice to determine which 
patients with muscle invasive bladder cancer should receive aggressive therapy, and in 
which patients the effectiveness of radiotherapy can be predicted. 
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1.4.1 Monoclonal mouse anti-human endothelial cell, CD 31 & CD34 
Platelet/endothelial adhesion molecule (PECAM-1) or CD3 I belong to the 
immunoglobulin superfamily with adhesive properties. It is a single chain membrane 
glycoprotein with a molecular mass of 130 kDa (Yan et al., 1995; Parums et al., 1990). 
CD31 is strongly expressed by all endothelial cells and more weakly on several types of 
leucocytes (Parums et al., 1990). Functionally CD31 is an adhesion molecule with both 
homophilic and heterophilic binding. The homotypic binding involves interaction as an 
important step in leucocyte transendothelial migration (diapedesis) and passage into the 
extracellular matrix (Liao et al., 1995). The heterotypic ligands have been reported to 
include integrin a.v~3 (Buckley et al., 1996) and glycosaminoglycans (DeLisser et al., 
1993). Staining of vessels with antibody to CD31 has been shown to be appropriate for 
the assessment of angiogenesis in several types of tumours such as breast cancer (Horak 
et al., 1992; Charpin et al., 1995; Fox et al., 1997), colorectal cancer (Takebayashi et 
al., 1996; Engel et al., 1996) and lung cancer (Giatromanolaki et al., 1996). 
The CD34 antigen is found on blood vessel endothelium, where it shows some variation 
in expression; most noticeably it appears to be absent from large veins and arteries and 
from sinuses in the placenta and spleen (Fina et al., 1990; Kuzu et al., 1992). On a 
subcellular level, CD34 is expressed on the luminal side and especially on membrane 
processes that interdigitate between endothelial cells (Fina et al., 1990). On growing 
vascular sprouts, such as those seen on vessels in tumours, the location of CD34 is 
altered and is found on the luminal microprocesses of these vessels (Schlingemann et 
al., 1990). Because the MY10 and QBEND10 antibodies react with oligosaccharide side 
chains (Sutherland et al., 1992), it was important to show whether this resulted from 
expression of the CD34 gene in endothelial cells or simply reflected recognition of an 
oligosaccharide determinant present on an unrelated protein backbone molecule. Fina 
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and eo-workers showed clearly that the CD34 gene is in fact expressed in endothelial 
cells (Fina et al., 1990). 
1.4.2 Monoclonal antibody Ki-67 antigen (MJB-1) 
In recent years the study of the proliferative activity of bladder carcinoma has attracted 
the interest of numerous researchers involved in the search for an indicator of biological 
aggressiveness that might be more reliable than the classical prognostic factors, grading 
and staging. Markers used to assess cellular proliferation have included mitotic count, 
silver stained nucleolar organizer regions, Ki-67 and proliferating cell nuclear antigen. 
The 2 most promising immunohistochemical markers of cellular proliferation are Ki-67 
and proliferating cell nuclear antigen. Ki-67 monoclonal antibody is currently used in 
evaluating the cellular turnover rate of malignant tumours (Brown et al., 1990; Gerdes, 
1990). It reacts with a non-histone nuclear protein of 395 kD and 345 kD expressed 
during G1, S-G2 and M phases, but not in GO phases of the cell cycle (Gerdes et al., 
1983; Gerdes et al., 1984). The fi-action of proliferating cells as determined by Ki-67 
immunoreactivity is an important prognostic feature of many malignancies. Increased 
expression of these antigens indicates a higher level of proliferative activity in tumour 
cells, and is associated with tumours of more aggressive biological potential with an 
increased propensity for tumour progression and metastasis (Fradet et al., 1993). Since 
this antibody was discovered in 1983 it has been extensively evaluated in a variety of 
human malignancies (Brown et al., 1990). Okamura et al., 1990, reported a correlation 
between increased expression of Ki-67 in bladder cancer and tumour grade and stage. 
Several other studies have not only confirmed this relationship but also have shown a 
significantly higher recurrence rate in surgically managed bladder tumours with a high 
proliferative index (Tsujihashi et al., 1991; Bush et al., 1991). The role of Ki-67 in 
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predicting local control after radiation is controversial. Lara et al., 1998, found better 
local control after radical RT in bladder cancer patients with very low proliferating 
tumours, indicating that rapid tumour repopulation during fractionated radiotherapy 
might reduce the probability of tumour control. Conversely, in a study of Ogura et al., 
1995, a high proliferative index predicted radio-responsiveness in 60 patients treated 
with preoperative RT followed by radical cystectomy for invasive bladder cancer. Rodel 
et al., 2000, also reported that the AI (apoptotic index) and the proliferation index (Ki-
67) helped to identify patients whose invasive bladder tumour responded completely to 
a regimen of combined RCT (radiochemotherapy) following initial TUR-B. Five-year 
local control with bladder preservation was significantly better for tumours with a high 
AI and a high cell proliferation. In an exploratory multivariate analysis, these markers 
and especially their combination had a higher predictive value for initial CR and local 
control with preserved bladder than the T -stage, and the grading. Rode I et al., 2000, 
concluded that patients with a high spontaneous AI and a high pretreatment Ki-67 index 
should be considered preferentially for treatment with RCT, whereas those with low 
proliferation and low levels of apoptosis are less likely to respond to RCT. Other studies 
also showed higher local control rates after definitive RT for head and neck cancer 
(Raybaud-Diogene et al., 1997) and cervical carcinoma (Nakano et al., 1997) with high 
Ki-67 labeling indices. These results are consistent with the clinical experience whereby 
rapidly proliferating tumours are more sensitive to irradiation than those growing 
slowly. 
1.4.3 Monoclonal mouse anti-human P53 protein 
The tumour suppressor gene product p53 is present in a wide variety of cells. In the 
normal cell the concentration of wild type p53 protein is generally below the detection 
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level of immunohistochemical methods because of its short half life (Vojtesek et al., 
1992). The p53 gene is located at 17p 13 .I (I so be et al., 1986) and codes for a 53 kDa 
(393 amino acid) transcription factor with a critical role in the regulation of DNA repair 
and apoptosis (Marx, 1993). It is not essential for life, but if both copies of the gene are 
knocked out in mice, there is a vastly increased risk of developing malignancy 
(Donehower et al., 1992). Wild type (i.e. normal) p53 migrates to the nucleus in the S-
phase of the cell cycle and switches on the transcription ofWAF1 (p21), which bind 
and inhibits cyclin-dependent kinase 2 (CDK2) (Marx, 1993). CDK2 normally drives 
the cell into the next phase of the cycle and its inhibition allows time for DNA repair or 
orchestration of apoptosis. The p53 gene is a tumour suppressor gene (TSG). It can be 
inactivated by loss of both copies, by loss of one copy with mutation of the other, or by 
mutant copy acting in hemizygous state (Marshall, 1991 ). Mutated p53 protein has a 
much longer half-life than wild type, allowing its detection by immunocytochemical 
methods. The mutant form forms complexes with the wild type, prohibiting its function. 
Allelic losses at 17p are reported in many bladder cancers (Dalbagni et al., 1993), and it 
has been shown that molecular defects at the DNA level correspond well with 
expression of mutant p53 (Esrig et al., 1993). About half of bladder tumours show loss 
of p53 function and this has been shown to be strongly associated with higher tumour 
stage and grade (Reznikoff et al., 1996). In superficial disease, although less frequent, 
mutant p53 expression is often associated with poor outcome (Tetu et al., 1996). Also, 
Sarkis et al., 1995, concluded that p53 has a role in predicting progression in superficial 
disease. Many p53 studies have been carried out in recent years and there have been 
conflicting reports. Not surprisingly, p53 has been investigated in all these fields. There 
seems no doubt that altered p53 expression is associated with higher stage, grade and 
poorer prognosis (Fujimoto et a/1992; Miyamoto et al., 1996; Watanabe et al., 1994). It 
is also suggested that p53 is a predictor of decreased survival, as Esrig et al., 1994, 
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found that altered p53 expression was associated with a doubling in the risk of death, 
and other studies concur with this. Tsuji et al., 1997, examined 31 primary TCCs, 
removed at radical cystectomy, for Ki-67 and p53 indices, they found that patients with 
tumours that had both a low Ki-67 index(< 32% of cells staining for the proliferative 
marker (Ki-67) and a low p53 index(< 20 % staining positive for p53) had no evidence 
of recurrence and none had died from bladder cancer at 66 months of follow-up, despite 
having muscle invasive disease. It was hoped that p53 might be of some use in 
preventing unnecessary radical cystectomy in patients who already had undetectable 
micrometastases. However, work by Glick et al., 1996, showed that although altered 
p53 expression was very common in muscle invasive disease, it gave no predictive 
indication of which patients would eventually suffer recurrence or die after cystectomy. 
Again, there is controversy about the role of p53 in predicting recurrence, as work by 
two groups suggest p53 expression is associated with recurrence in superficial disease 
(Kuczyk et al., 1995; Moch et al., 1994), whereas a study of86 tumours by Underwood 
et al., 1996, showed no predictive relationship. The evidence is mounting that p53 has a 
significant role in progression and its frequent association with carcinoma in situ, and 
its obvious poorer outlook further substantiates this. This also supports the argument 
that p53 has a role in the path to progression from an early stage (Sarkis et al., 1994; 
Schmitz-Drager et al., 1994). A role exists for p53 in predicting poor response to 
chemotherapy and the possible avoidance of this form of therapy in favour of more 
aggressive inteJVention in patients with p53 positive tumours (Hudson et al., 1995). 
Cote et al., 1997, contradicted this when they found that tumours that were p53 positive 
responded three times more effectively to adjuvant chemotherapy, after radical 
cystectomy, than those that were negative. In a response to this article, Lowe and Jacks 
1997 explained that these findings are not in keeping with most studies, and pointed out 
some factors that had caused such inconsistencies in the p53 studies, i.e. that 
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immunoreactivity does not necessarily reflect a tumour's p53 state, and that large studies 
looking at alterations at the DNA level might resolve the discrepancies. An interesting 
study by Raitanen et al., 1997, provided evidence that DNA aneuploidy precedes altered 
p53 expression and that some tumours change from negative to positive expression at 
recurrence. This type of longitudinal study provides valuable information about tumour 
progression over time, and it is clear that there are many other pathways to progression 
that do not rely on p53. p53 is the most important discovery in tumour molecular 
biology to date, but disappointingly, despite a decade of work, no effective targeting 
therapy has been discovered. 
1.4.4 Monoclonal mouse anti-human Bc/-2 Oncoprotein 
Recent advances in molecular genetic analysis have shown that the genetic alterations in 
oncogenes and suppressor genes, bcl-2, p53 and c-myc, appear to influence the 
susceptibility of cells to apoptosis. This might influence the sensitivity of cancer cells to 
radiation and chemotherapy (Hale et al., 1996). It has been estimated that more than 
half of the world's cancer burden is composed of malignancies with an alteration in the 
tumour suppressor gene locus or in proto-oncogenes or both (Cohen and Ellwein 1991 ). 
All of these changes may confer a growth advantage to the tumour cells by stimulating 
cell proliferation. However, tumour growth (i.e. the rate of cell accumulation) is 
dependent not only on cell proliferation but also on the rate of physiologically occurring 
cell death. Thus, it is conceivable that neoplastic growth also may be caused or 
promoted by factors inhibiting cell death (Kerr et al., 1994; Reed 1994). A new class of 
proto-oncogenes has been defined that contribute to malignancy by inhibiting 
programmed cell death or apoptosis (Williams, 1991). The prototype of proteins that is 
encoded by these oncogenes and involved in such a regulatory pathway is the bcl-2 
protein (Tsujimoto et al., 1985). The bcl-2 gene was initially cloned from the t( 14; 18) 
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translocation in a follicular B-cell lymphoma (Tsujimoto et al., 1985). It IS over 
expressed in various human cancers, indicating a close association with tumour 
development and progression (Fontanini et al., 1995; Bhargava et al., 1994; 
Kapucuoglu et al., 1997). This gene protects against apoptosis induced by numerous 
apoptotic stimuli including growth factor withdrawal, irradiation, glucorticoids and 
multiple chemotherapeutic agents, to prolong cell survival (Nunez et al., 1990; Chen et 
al., 1995; Alnemri et al., 1992; Miyashita et al., 1993; Chiou et al., 1994). Although its 
biochemical mechanism is incompletely understood, bcl-2 protein appears to control a 
distal step that may be a final common pathway involved in apoptosis. Because of its 
anti-apoptotic effects, bcl-2 protein is thought to be an important multidrug resistance 
molecule. Overexpression of bcl-2 protein has been shown to provide protection against 
a wide variety of apoptotic insults, including radiation and nearly all chemotherapeutic 
drugs (an issue that relates to the tumour cell metastatic propensity) (Ruoslaht and 
Reed, 1994; Reed, 1995). It has also been reported that cells that coexpress bcl-2 can 
override the apoptotic death triggered by wild-type p53 by excluding the p53 protein 
from the nucleus, thus being allowed to proliferate (Ryan et al., 1994). 
Bcl-2 is a member of a family of bcl-2 homologues that regulate apoptosis differently. 
In this multigene family some members (such as bcl-2, bcl-XL and bag-1) block cell 
death (Reed, 1994; Boise et al., 1993; Walton et al., 1993; Takyama et al., 1995), 
whereas others promote apoptosis. The latter include bax, bad, bak and bci-XS (Reed, 
1994; Oltvai et al., 1993; Farrow et al., 1995; Yang et al., 1995). The bax gene has ex-
tensive amino acid homology with bcl-2, and it may form heterodimers with bcl-2 that 
oppose bcl-2 function and contribute to cell death. It has been proposed that the ratio of 
bcl-2/bax and other anti-apoptotic members of the bcl-2 family govern the relative 
sensitivity response of cells to apoptotic stimuli (Oltvai et al., 1993; Korsmeyer et al., 
1993). The tumour suppressor gene p53 that is frequently mutated in human cancers 
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also regulates cell death. Cells with mutated p53 are more resistant to chemotherapy 
because of a lesser ability to undergo apoptosis. Clinical studies show that p53 mutated 
tumours are more resistant to chemotherapy than p53 wild-type tumours. Miyashita et 
al., 1994 reported that wild-type p53 protein directly contributes to the negative 
regulation of bcl-2 and positive regulation of bax gene expression (Miyashita et al., 
1994). The bcl-2 gene may block p53 induced apoptosis, suggesting that bcl-2 and p53 
may participate in a common pathway to regulate cell life and death (Wang et al., 
1993). Gazzaniga et al., 1996, evaluated the expression of bcl-2 and bax in low grade 
bladder cancer and found that bcl-2/bax messenger RNA expression may be a marker 
for disease, early relapse and progression. The increased expression of bcl-2 has been 
found to alter tumour sensitivity to chemotherapy and radiation (Dole et al., 1994; 
Pollack et al., 1997). Pollack et al., 1997, reported that bcl-2 overexpression was 
associated with impaired radiation response in patients with bladder cancer treated with 
a regimen of preoperative radiotherapy. The significance of this anti-apoptotic protein, 
as well as the role of proliferation as measured by the Ki-67-labeling index in predicting 
local control in bladder cancer treated by a combination of radio- and chemotherapy, 
remains to be established. Correlating the expression of several molecular markers and 
clinicopathological factors and elucidating their interrelationships may finally help to 
identify subgroups of patients that will most probably benefit from bladder preservation 
by combined modality treatment. 
1. 4. 5 Monoclonal mouse anti-human macrophage, CD 68 
Macrophages belong to the mononuclear phagocyte system. They form a heterogeneous 
cell population because of different developmental and functional stages (Rutherford et 
al., 1993). Macrophages share a common progenitor cell with granulocytes in the bone 
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marrow. Commitment to the macrophage lineage gives rise to the macrophage colony-
forming cells, which are succeeded by monoblasts, the first characteristic phagocytic 
cells. They further differentiate into promonocytes and bone marrow monocytes 
(Rutherford et al., 1993; Furth et al., 1992). Monocytes then enter the blood stream and 
migrate into tissues, where they undergo final differentiation to tissue macrophages, 
often assuming tissue-specific properties as histiocytes, alveolar macrophages, Kupffer 
cells, osteoclasts, peritoneal macrophages, synovia type A cells, or microglia. 
Developmental stages and differentiation steps of macrophages have been defined 
according to the intracellular localization pattern of peroxidase activity (Furth et al., 
1992) or the expression of distinct antigens. (Sorg et al., 1992) Subsequently, it was 
shown that inflammatory infiltrates contain several differentiation stages of 
macrophages (Rutherford et al., 1993; Furth et al., 1992; Sorg et al., 1992}. 
Macrophages are thus present ubiquitously in all tissues and in case of inflammation 
certain subtypes are recruited from the b 1 ood-bome monocytes. A multitude of 
functions can be performed by the mononuclear phagocyte system, such as endocytosis, 
cytotoxicity, and secretion of more than I 00 cell products (Adams et al., 1992; Nathan, 
1987). However, macrophages do not carry out all these functions at the same time. 
Their activities are rather dependent on the pathophysiological situation (Rutherford et 
al., 1993; Adams et al., 1992). In order to become angiogenic, the versatile secretory 
potential of macrophages needs to be activated. Tumour angiogenesis was initially 
believed to be induced only by tumour cells themselves (Folkman, 1985; Blood et al., 
1990). However, macrophages also appeared to be involved in vascularization and 
growth of tumours. Mice depleted of monocytes showed a strong reduction of tumour 
vascularization in implanted syngeneic fibrosarcomas (Evans, 1977). Similarly, tumour 
growth in nude mice showed association with the monocytic infiltrate of tumours 
(Stenzinger et al., 1983). Neoplastic tissues exhibited angiogenic activity in vivo and in 
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vitro only when macrophages were present (Mostafa et al., 1980; Polverini et a/1984). 
Polverini and Leibovich, 1984, showed that macrophages isolated from tumours were 
indeed able to induce neovascularization in the cornea assay. Thus, vascularization of 
tumours appears to be either induced or modulated by macrophages. Their appearance 
at sites of neoplastic growth is part of the inflammatory reaction usually provoked by 
tumours (Pugh-Humphreys 1992). Macrophages are set into different functional states 
by a process called activation. This term was originally introduced to describe increased 
phagocytic or microbicidal activities of macrophages induced by a given stimulus such 
as lipopolysaccharide (LPS) (Adams et al., 1992). Later, activation of macro phages was 
also thought to entail alterations of their chemotactic response and their secretory 
activity (Adams et al., 1992). However, activation does not lead to simultaneous 
enhancement of all macrophage activities. When activated macrophages increase 
performance of particular functions, they down-regulate others. For example, certain 
macrophages can be either tumouricidal or bactericidal, but not both at the same time 
(Rutherford et al., 1993 ). Thus, the activation process appears to be based on complex 
regulation with different stimuli involved. Activation of macrophages proceeds in 
sequential steps (Rutherford et al., 1993; Adams et al., 1992). In order to present 
antigens, for example, macrophages first have to express class IT major 
histocompatibility complex (MHC) molecules followed by expression of interleukin-1 
(IL-l) or other cytokines (Steinmann 1988). Activation sequences for other macrophage 
functions such as the induction of angiogenesis have not yet been elaborated. 
Several studies have confirmed that macrophages need to be activated to exert 
angiogenic activity (Steinmann, 1988). Human and murine monocytes did not promote 
neovascularization unless treated with concanavalin A, endotoxin, or other activators 
(Koch et al., 1986; Kaminski et al., 1987; Meyer et al., 1989). Activation of 
macrophages in angiogenesis has biological relevance. The proliferation rate of 
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endothelial cells in normal tissues is very low (Hobson et al., 1984). In growth and 
repair processes neovascularization is up regulated for brief periods and then completely 
inhibited or even down regulated. Persistent neovascularization, on the other hand, is a 
characteristic feature of malignant tumours and chronic diseases, such as rheumatoid 
arthritis. Thus, in healthy organisms angiogenesis is under tight control. Cells able to 
induce neovascularization should be expected to remain inactive unless activated. Many 
of the macrophage derived angiogenic factors are indeed synthesized or released only 
by activated macrophages. Among the potential activators of macrophages, the bacterial 
product LPS is known to induce angiogenic activity (Koch et al., 1986; Polverini et al., 
1977) but does not appear to be a general stimulus of angiogenesis. More specific 
activation signals could be provided by the particular metabolic conditions found in 
wounds. Macrophages became angiogenic when exposed to low oxygen tensions 
(Knighton et al., 1983) or to woundlike concentrations of lactate, pyruvate, or hydrogen 
ions (Jensen et al., 1986). Macrophages can also be activated by cytokines such as 
interferon-y (IFN-y), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
platelet-activating factor (P AF), or monocyte chemotactic protein (Adams et al., 1992). 
These activating cytokines are released by a number of cells, among them activated 
endothelial cells (Goerdt et al., 1993). An attractive model for the controlled activation 
of macrophages at sites of inflammation would therefore be the activation by local 
endothelial cells. Macrophages recruited to sites of inflammation by endothelial 
adhesion molecules (Goerdt et al., 1993) thus become simultaneously activated by 
endothelial cytokines such as GM-CSF, PAF, and monocyte chemotactic protein. 
In invasive breast carcinoma, the neoplastic cell population is often outnumbered by 
such stromal cells as tumour associated macrophages (TAMs), which can comprise 
more than 50% of the total tumour mass (O'Sullivan et al., 1994). It is thought that 
monocytes in the peripheral circulation are recruited to the tumour site by the release of 
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the chemotactic cytokines, monocyte chemotactic protein-! (MCP-1) (Graves et al., 
1991), CSF-1 (Scholl et al., 1994), granulocyte macrophage CSF (Fu et al., 1992), and 
VEGF (Clauss et al., 1990) by such tumours. Once recruited, monocytes differentiate to 
become T AMs and are modified in the tumour microenvironment to secrete several 
growth factors, such as EGF (O'Sullivan et al., 1993), TNF-oc (Pusztai et al., 1994), 
VEGF and bFGF (Lewis et al., 1995). Focal macrophage infiltration also appears to be 
an important prognostic factor in invasive carcinoma of the breast, being predictive of a 
worsened outcome and of reduced relapse-free and overall survival when MI 
(macrophage index) is high. Leek et al., 1996, also reported that MI is a more powerful 
predictor of survival than nodal status, and suggested that macrophages may have a 
direct role in disease progression. Other studies have found associations between higher 
levels of macrophage infiltration and markers of poor prognosis such as Ki-67 
(Hildenbrand et al., 1995), and Pupa et al., 1996, have described a positive correlation 
between macrophage infiltration and c-erbB2 as well as high grade in invasive breast 
carcinoma. Herrmann et al., 1994, also demonstrated a significant correlation between 
CD68-positive cell infiltration and vascularization in thyroid carcinoma, enumerating 
the infiltrating cells as the possible source of angiogenic factors. In a more recent study, 
Hanada et al., 2000, reported on series of 63 patients with bladder cancer, including 40 
superficial bladder cancers and 23 invasive bladder cancers. The T AM count in invasive 
bladder cancers was significantly higher than in superficial bladder cancers. The 
microvessel count (MVC) in invasive bladder cancers was also significantly higher than 
in superficial bladder cancers. There was a positive correlation between T AM count and 
MVC. Patients with a high T AM count (~67) showed significantly higher rates of 
cystectomy, distant metastasis and vascular invasion than those with a lower T AM 
count (<67). The 5-year survival rate was significantly lower in patients with a high 
T AM count than those with a low T AM count. 
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The best macrophage reagents produced to date are those recognising the CD68 antigen 
(Knapp, 1989). This 110 kD antigen belongs to a family of acidic, highly glycosylated 
lysosomal glycoproteins that include the lamp-1 and lamp-2 molecules (Fukuda, 1991 ). 
CD68 is the human homologue of the murine macrosialin antigen (Holness et al.; 1993) 
and is present in the cytoplasmic granules of monocytes, macrophages, neutrophils, 
basophils and large lymphocytes (Pulford et al., 1990). This antigen is also expressed to 
some degree in the cytoplasm of some non-hemopoietic tissue. The function of the 
molecule is currently unknown. The murine PG-Ml monoclonal antibody (lgG3, k) was 
raised against spleen cells of Gauchers disease (Falini et al., 1993). Reactivity with cells 
transfected with a human cDNA encoding for the CD68 antigen confirms PG-M! as a 
member of the CD68 cluster. In bone marrow paraffin sections, PG-M I strongly stains 
macrophages but not granulocytes and myeloid precursor. PG-M! also shows 
immunopositivity with mast cells and synovial cells. 
98 
1.5 Aims of the study 
1. 5.1 General objective 
The purpose of this study was to investigate the role of several biologic markers that 
may predict response to radiotherapy in muscle invasive bladder transitional cell 
carcinoma. This study examines the relationship of clinical data and histopathological 
parameters in cases of muscle invasive bladder TCC with response to radiotherapy. It 
involves clinical audit and utilises histological skills including tumour recognition and 
grading, immunohistochemistry and the use of a Chalkley eyepiece graticule, as well as 
statistics to determine treatment and outcome. This study may indicate predictive 
factors that would alter patient's treatment and management. 
1.5.2. Specific objectives 
To retrospectively determine the relationship between the following: 
a) Patient's age, sex, and haemoglobin level and the response to radiotherapy. 
b) Tumour stage, grade and the response to radiotherapy. 
c) Tumour angiogenesis (CD3l&CD34) in bladder TCC and the response to 
radiotherapy. 
d) Intratumour macrophage (CD68) concentration and the response to radiotherapy. 
e) Tumour proliferation as measured by Ki-67 (MIB 1) and the response to 
radiotherapy. 
f) p53 expression and apoptosis (bcl-2) of tumour cells and the response to 
radiotherapy. 
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MATERIALS 
& 
METHODS 
MATERIALS & METHODS 
2.1. Patients 
Muscle invasive transitional cell carcinomas from 101 patients were identified from the 
archives of Derriford Hospital, Plymouth and Royal Devon & Exeter Hospital, Exeter 
between 1984-1996. 
The initial material was reviewed, and this consisted of either bladder biopsies or 
specimens from transurethral resections of the bladder tumour (TURBT) taken before 
any treatment had been started. All cases were reviewed. Either, the original 
haematoxylin and eosin (H&E) sections were examined if possible or, alternatively, 4 
J..lm thick H+E stained recuts were examined. Muscle invasive transitional cell 
carcinoma was confirmed only when there was unequivocal invasion through bundles of 
muscularis propria by tumour (Fig. 2.1 ). All equivocal cases were excluded. Similarly, 
cases of non transitional cell carcinoma, including adenocarcinoma, squamous cell 
carcinoma, or small-cell carcinoma were also excluded. 
Each tumour was graded according to the World Health Organization (WHO 1982) 
grading system and staged according to the International Union Against cancer (1997) 
TNM classification. All cases were treated by one regime of radiotherapy with no 
adjuvant or concomitant chemotherapy. 
After completion of the radiotherapy course, all the patients were followed up closely 
by cystoscopy and other complementary examinations as clinically indicated. The 
follow-up regime required at least cystoscopy to be performed every 3 months for the 
first 2 years, every 6 months from the third to the fifth year, and yearly from then on. 
All the patients' records were examined for the recorded post-radiotherapy tumour 
response. 
lOO 
Fig. 2.1. Muscle invasive TCC: 
Muscle bundles 
Muscle bundles 
b) High power H&E (X40): 
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The patients were classified into two groups, in two different ways, according to the 
response; the first group includes (I) those free of disease (no tumour detected in the 
bladder at the 3-month cystoscopy), (2) those with residual disease (tumour present in 
the bladder at 3-months cystoscopy). The second classification includes (I) those with 
persistent or recurrent cancer in the bladder (tumour recurred after an initial 3 months 
negative check cystoscopy together with patients with residual disease at 3 months), (2) 
those free of disease in the bladder at all subsequent cystoscopies. 
From the clinical records, data relating to the position of the primary tumour in the 
bladder, age, stage, grade and radiotherapy dose including number of fractions and 
number of days over which the course of radiotherapy was given. Patient survival was 
recorded for analysis. 
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2.2 Immunohistochemistry 
2. 2.1 Reagents 
For each case, one representative formalin-fixed, paraffin wax-embedded block was 
chosen from between 1 and 3 different block sections. Serial slices, each 4J..lm thick 
were taken from each chosen block and were immunostained using the antibodies 
previously described. In brief, the antibodies used were CD31 (Monoclonal Mouse 
Anti-Human Endothelial cell CD31, Clone JC/70A, Code No. M 0823, DAKO, 
Denmark.), CD34 (Anti-Endothelial cell Marker, QBEndlO-Mouse Monoclonal 
immunoglobulin G, sub-class I, code No. M 87030, Bionostics, UK.), MIB1-KI67 
(Monoclonal antibody Ki-67 Antigen, Clone MIB-1, lmmunotech, France), bcl-2 
(Monoclonal Mouse Anti-Human BCL2 Oncoprotein, Clone 124, code No. M 0887, 
DAKO, Denmark), CD68 macrophage (Monoclonal Mouse Anti-Human Macrophage, 
CD68, Clone PG-M1, Code No. M 0876, DAKO, Denmark), and p53 (Monoclonal 
Mouse Anti-Human p53 Protein, Clone D0-7, Code No. M 7001, DAKO, Denmark). 
2. 2. 2 Immunohistochemistry procedure 
Below outlines the immunohistochemical technique used for all the antibodies, with 
indication of specific techniques required for certain antibodies. To maximize 
homogeneity of staining for each antibody, immunostaining for individual antibodies 
was performed in batches with positive and negative control slides included in every 
batch. The positive control tissue was human tonsil. The negative control was bladder 
tissue, which was treated with Tris/Tween buffer only in the absence of primary 
antibody. 
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1. Paraffin sections for immunoperoxidase, were cut at 4 microns thick, onto APES 
(3-aminopropyltriethoxysilane, Sigma code A3648) coated slides and placed in a 
37 o C incubator and left overnight. The following morning, the slides were 
transferred to a 60 o C incubator for one hour to complete the drying process. 
2. Slides were de-waxed in : 
3. Xylene removed in : 
Xylene 1 minute 
Xylene 1 minute 
Xylene 1 minute 
Alcohol 1 minute 
Alcohol 1 minute 
Alcohol 1 minute 
4. Endogenous peroxidase was quenched with (3%) hydrogen peroxide solution in 
methanol for 10 minutes (9 mls 30% hydrogen peroxide to 300 mls of 
methanol). 
5. Sections were washed with running tap water for 5 minutes. 
6. The antigen retrieval method used depended on the antibody, and this included 
microwave oven and pressure cooking. 
Sections for CD31, bcl-2 and p53 immunostaining were placed into 800ml of 
citrate buffer (pH 6.0), and microwaved at full power in a 950W microwave 
oven, for 30 minutes. 
Sections for MIB 1 staining were pressure cooked for 1 Y2 minute at full pressure 
in citrate buffer (pH 6.0). 
Following these treatments, the hot buffer was gradually replaced by cold 
running tap water to cool the sections. 
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Sections for CD68 immunostaining were treated with 0.1% calcium chloride 
solution at 37 a C for 10 minutes, followed by washing in cold running tap water 
for 5 minutes. 
7. The sections were ringed with a PAP pen. This acts as a hydrophobic barrier to 
prevent the antibody solutions from spreading over the entire slide. Slides were 
then placed in a bath of Tris (Hydroxy methyl methylamine, BDH Laboratory 
supplies) and Tween 20 (polyoxyethylene (20) sorbitan monolaurate BDH) 
buffer (pH 7.6) for 5 minutes. Tween 20 is a detergent added at 0.05% to 
decrease background staining. 
8. The excess buffer was drained off and Normal Horse Serum (NHS) diluted 
1:100 in Tris/Tween buffer was pipetted onto the sections and incubated for 20 
minutes at room temperature. This reduced non-specific binding of the antibody 
to the tissue. 
9. The excess NHS was drained off and the diluted pnmary antibody, at the 
dilution given below was applied to the sections. 
The optimum dilutions for each primary antibody had been carefully titrated for 
this immunohistochemistry regime. Incubation was for 30 minutes at room 
temperature. 
Dilution for antibodies 
Primary Dilution for CD31: I :40 
Primary Dilution for CD34: I :40 
Primary Dilution for CD68: I :40 
Primary Dilution for MIB I: I :40 
Primary Dilution for bcl-2 : 1 :20 
Primary Dilution for p53: 1 :300 
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10 The excess antibody was then drained from the sections, which were then 
placed in a Tris/Tween buffer bath for 5 minutes. Two further changes of buffer 
were performed to wash off excess unreacted antibody. 
11 The buffer was drained off and the secondary antibody applied. The secondary 
antibody was a biotinylated universal horse antibody, which reacts either with 
mouse or rabbit primary antibodies. This was diluted 1:50 in 1: 100 Normal 
Horse Serum. Incubation was for 30 minutes at room temperature. 
12 The sections were washed as in step 10. 
13 The buffer was drained off and the tertiary antibody applied. The tertiary 
antibody was a streptavidin-biotin complex (Vectastain Universal Elite ABC 
Kit, Cat. No. PK-6200, Vector Laboratories, USA) prepared by mixing solution 
A (Streptavidin) with an equal amount of solution B (Biotinylated horseradish 
peroxidase) in Tris/Tween buffer to give a 1:50 dilution. Incubation was for 30 
minutes at room temperature. 
14 The working DAB (3,3-diaminobenzidine tetrahydrochloride) solution was 
prepared 10 minutes before the end of the incubation of the tertiary antibody, 
using Sigma tablets (Sigma Fast, D4293). One tablet of DAB and one tablet of 
urea hydrogen peroxide were added to 15 ml of distilled water and allowed to 
dissolve. 
15 The sections were washed as in step 10. 
16 The filtered DAB solution was applied to sections for 10 minutes. 
17 The excess DAB was tipped into a bleach container to deactivate excess DAB 
and slides were placed in a slide rack. 
18 Slides were washed in running water for 1 minute. 
19 Slides were placed in DAB enhancing solution for 2 minutes; DAB enhancing 
solution contains Copper Sulphate and Sodium Chloride Salt and makes the 
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DAB appear darker brown. 
20 Slides were washed in tap water and placed in haematoxylin for 2 minutes. 
2I Slides were washed in tap water then differentiated haematoxylin in acid 
alcohol (0.7% concentration). 
22 Slides were washed in tap water. 
23 Slides were then "blued" in Scotts tap water substitute for 1 0 seconds. 
24 Slides were washed in tap water. 
25 Slides were dehydrated in serial alcohol (industrial methylated spirit), 
Alcohol I min 
Alcohol I min 
Alcohol 1 min 
26 Slides were bathed in serial xylenes 
Xylene Imin 
Xylene 1min 
Xylene Imin 
27 All sections were hand mounted using DPX mounting medium (RA lamb) and 
glass coverslips. 
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All immunostained slides were analysed and scored in a blind fashion without 
knowledge of outcome, grade, stage or survival data by one observer (Dr. Z. Saki) for 
consistency 
2.2.3 Vessel density determinations 
Antibodies CD31 and CD34 were used to detect the endothelial cells of the 
microvasculature. This includes capillaries and small venules. Both these antibodies are 
well known vascular markers and anti CD34 antibodies have been found to recognize 
small-calibre vessels that are associated with neovascularisation in bladder cancer more 
effectively than factor VIII antibodies (Bochner et al., 1997). The techniques described 
by Weidner et al., 1991 and Fox et al., 1995, outlined the assessment of microvessel 
density. 
Examination of immunostaining by CD31 (Fig. 2.2) and CD34 (Fig. 2.3), the 
microvessel density was assessed in areas with a solid tumour morphology away from 
any distorting artefact (Fox et al., 1995a). 
In brief, the vessel counting was performed in areas of maximal neovascularization; 
these so-called "hotspots" were areas where the highest numbers of discrete 
microvessels were stained and were identified after scanning the entire section at low 
power (XlO) by light microscopy (Leitz, Laborlux 12, Germany). Significant 
heterogeneity of vessel density was noted in virtually all cases. Areas associated with 
ulceration or granulation tissue were excluded. 
Any brown-staining endothelial cell or endothelial cell cluster, clearly separated from an 
adjacent microvessel, was regarded as a single, countable microvessel. Vessel counts 
were then estimated using a 25-point Chalkley eyepiece graticule (Chalkley, 1943) at 
X40 magnification. The graticule (Graticules, Tonbridge, UK) was rotated in the 
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·eyeptece to· where the maximum number of graticule dots' overlay 
immunohistochemically identified vessels or their I lumens. The mean of the three: 
Cliaikiey count was,u·sedl for the individual tumour. This method' ofvascular.assessrnent 
has:bee!l 1 prev.iot~sly shown to cqrrelltte repr:od_1.1dbly:·with field counts;in:invasive!breast 
. . . 
carcinomast~ox et al.', il995a)! 
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Fig. 2.2. Staining endothelium cells for CD31: 
a) Low power: CD31 positive irnmunostaining outlining the microvasculature in 
tumour tissue. 
b) High power (X40): Arrows show CD31 positively stained microvessels. 
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Fig. 2.3. Staining endothelium cells for CD34: 
b) Low power: Numerous CD34 positive immunostaining microvessels are visible in 
the tumour tissue. 
b) High power (X40): Arrows show CD34 positively stained microvessels. 
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2.2.4 Immunohistochemical analysis of bcl-2, p53, MIB-1 and CD68. 
The expression of bcl-2 was determined to be positive when there was strong or weak 
(focal or diffuse) cytoplasmic staining. On the contrary, when there was no cytoplasmic 
staining, bcl-2 was scored as negative. Figure 2.4 shows positive expression of bcl-2 in 
muscle invasive bladder transitional cell carcinoma. 
The sections for p53 (Fig. 2.5) and MIB-1 (Fig. 2.6) were scanned for areas with the 
highest density of positively stained nuclei (strong brown nuclear staining). In many of 
the sections there were varying degrees of nuclear staining. However, every cell that 
showed intense and weak nuclear staining was considered positive. MIB-1 proliferation 
and p53 protein staining were not classified as positive or negative. Rather, their degree 
of staining was recorded as a labelling index (Ll). A similar method was applied for 
assessing the concentration of tumour macrophages, stained by CD68 (Fig. 2. 7 a & Fig. 
2.7 b). Tumor regions were examined by scanning at low magnification (XIO) (Leitz 
microscope), and counts (of approximately 1000 cells) were then estimated using a 
1 Ox I 0 square grid eyepiece graticule (Jencons-PLS, Cherrycourt way, Stanbridge Rd, 
Leighton Buzzard, LU7 8UA, UK) (Fig. 2.8a) at X40 magnification. The counting was 
repeated 2 times for each slide. The labelling index was determined as the percentage of 
positive nuclei out of the total number of nuclei examined. The average score was taken 
for each case. 
An alternative method of assessing p53 immunostaining was also applied. Tumour was 
graded positive if there was > 30% positive immunostaining of nuclei and were graded 
negative if there was <30% positive immunostaining nuclei (Jahnson et al., 1995). 
There was no significantly difference between this and the counting system used above 
(see appendix page 193 & 199). 
112 
Fig. 2.4. Bcl-2 positive staining: 
b) Low power: This shows positive cytoplasmic staining for bcl-2. 
a) High power (X40): This shows positive cytoplasmic staining for bcl-2. 
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Fig. 2.5. p53 positive staining: 
a) Low power: area with the highest density of positively stained nuclei for p53. 
b) High power (X40): arrows show positive nuclear staining for p53 . 
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Fig. 2.6. MIB-1 positive staining: 
a) Low power: area with the highest density of positively stained nuclei for MIB-1. 
b) High power (X40): arrows show positive nuclear staining for MIB-1. 
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Fig. 2. 7. CD68 positive cells: 
a) Low power: 'Jhis s!loWs llll' are!l of high, (leQ~ity of immimopositivity for the 
macrophage marker CD68. 
1,>) High power (X40): ,arrows show positive immunostaining for the macrophage 
- · marker CID68. 
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2.3 Counting technique 
Counting cell within stained sections is as follows: 
(1) An eyeptece graticule (10x10 square) (Jencons-PLS, Cherrycourt way, 
Stanbridge Rd, Leighton Buzzard, LU7 SUA, UK) was used to aid counting; the 
method employed is indicated in (Fig. 2.8 a). 
(2) The immunostained section was initially scanned to determine the area of high 
staining density at low magnification (X I 0). 
(3) A minimum of I 000 cells nuclei were counted (stained nuclei cells + non-stained 
tumour cells); the number of stained nuclei within this sample was noted at high 
magnification (X40) (as further discussed). 
(4) When calculating the number of cells within the graticule only those with nuclei 
positioned on the outer lines to the right and the superior lines were counted and 
those on the inferior and outer left lines were ignored (Fig. 2.8 b,c). 
(5) The percentage oflabelled nuclei was determined as indicated: 
a = total number of nuclei counted (number of p53 or MIB-1 positive tumour cells + 
number of negative tumour cells) 
b =number oflabelled immunopositive cells (number ofp53 or MIB-l positive tumour 
cells) 
Counting for macrophages (CD68): 
a= total number of cells counted (number of macrophages +number of tumour cells) 
b = number of labelled immunopositive cells (number of CD68 positive macrophages 
cells) 
Labelling Index = .!! x I 00 
[LI %] a 1 
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Fig. 2.8i €ounting cells within stained sections: 
a) 
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2.4. Statistical methods 
The SPSS 10 package was used to perfonn the statistical analysis of the data obtained. 
Univariate analysis 
Categorical variables 
The association between two categorical variables was assessed using the chi-squared 
test. 
Quantitative variables 
Nonnality of quantitative variables was checked using the Kolmogorov-Smirnov test. 
Variance was checked by Levine's test. 
Where normality and equal variance were confirmed a t-test was used to compare 
means of 2 groups. Where more than 2 group means were compared Analysis of 
Variance (ANOV A) was used. 
Where data was not nonnally distributed a non-parametric test was used. In such cases 
the Mann-Whitney test was used to compare 2 groups and the Kruskal-Wallis where 
there were more than 2 groups of data. 
Pearson (for normally distributed data) and Spearman (for non-normally distributed 
data) correlation coefficients were used for correlation analysis between variables. 
Regression analysis 
Multiple regression analysis was used to identify variables with a significant effect on 
outcome. This was performed using a stepwise modal selection procedure, which 
eliminates insignificant variables one at a time 
Survival analysis 
Survival analysis was performed using the Kaplan-Meier method (Kaplan and Meier 
1958). 
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RESULTS 
RESULTS 
101 patients received radical external beam radiotherapy (EBRT) (range 50-60 Gy; 
fraction median=20) over an 8-year period. There were 85 males (84. 1 %) and 16 female 
patients (15.9%). The mean ages were 69.5 years for men and 68.6 years for women and 
the median ages were 71 years and 73 years respectively (Table 3.1). 
Table 3.1: Mean and median age by gender: 
Male Female 
Number 85 16 
Median age (year) 71 73 
Mean age (year) 69.5 68.6 
Figure 3.1 shows the distribution of selected patients by age at diagnosis. The highest 
incidence is in the 70-79 year age range. 
Figure 3.1. The distribution of studied bladder cancer patients by age at diagnosis: 
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3.1 Section one 
In the first analysis 2 outcomes are considered: 
Complete response to EBRT - Patients' who were found to have no tumour in the 
bladder at the 3-month cystoscopy. 
No response to EBRT - Patients with residual tumour in the bladder at the 3-month 
cystoscopy. 
3-months after completion of radiotherapy treatment 46 patients (45.5%) had no clinical 
response to radiotherapy whilst 55 (54.4%) had responded. 67 patients (66.3%) were 
alive and 34 (33.7%) had died during the follow up period (Table 3.1.1). 
Table 3.1.1. Patient's response to EBRT and crude survival during the follow up 
period: 
Dead Alive 
No response to ll 35 
EBRT 
Complete response to 23 32 
EBRT 
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3.1.1. The effects individually of age, sex, haemoglobin level and duration of 
treatment on the response to radiotherapy: 
Figure 3.1.1, shows the age distribution of patients who responded to EBRT compared 
to those who did not. Patients in the age group 60-69 years appear to respond better to 
radiotherapy than do other age groups. 
Figure 3.1.1. Distribution of Age by response to radiotherapy: 
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When patient' s age is considered as a quantitative variable there was no significant 
difference between the mean ages of those patients who responded and those who did 
not (t-test p=0.959) (Table 3.1.2). 
Table 3.1.2. Mean age (SD) by response to radiotherapy: 
Mean age (SD) p-value 
No response 69.41 (9.483) 
Complete response 69.31 (10.553) 0.959 
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Females, whilst representing only a small fraction ofthe total (16 out of 101) showed an 
inferior response to radiotherapy when compared to that of male patients, and this is 
confirmed by Chi-Square test (p=0.048) (Table 3.1.3). 
Table 3.1.3. Gender of patients by response to EBRT. 
No response Complete response p-value 
Male 35 50 
Female I I 5 0.048 
Haemoglobin level 
There was a significant difference in the median haemoglobin levels for patients who 
responded to EBRT and those who did not respond, higher median for response group 
(Mann-Whitney test, p=0.031) (Table 3. 1.4). 
Table 3.1.4. Patients haemoglobin level by response to radiotherapy: 
No response Complete response p-value 
Median haemoglobin g/dl 12.75 13.3 0.031 
(IQR) (2.32) ( 1.80) 
* IQR- Interquartile Range 
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3.1.2. The effects individually of tumour stage, tumour grade and site in the 
bladder on the response to EBRT: 
Tumour stage 
48 (47.5%) of the tumour were stage 2 and 53 (52.4%) were stage 3. There was no 
significant difference in the response to EBRT between the two stages (chi-squared test 
p=0.586) (Table 3.1.6). 
Table 3.1.6. Stage of tumour by response to EBRT: 
No response Complete response p-value 
Stage 2 20 28 
Stage3 26 27 0.586 
Tumour grade 
11 tumours (I 0.8%) were grade 2 and 90 (89.1 %) were grade 3. There was no 
significant difference between the two grades and their response to EBRT (chi-squared 
test p=0.753) (Table 3.1.7). 
Table 3.1. 7. Grade of tumour by response to EBRT: 
No response Complete response p-value 
Grade 2 6 5 
Grade 3 40 50 0.753 
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11\lmO.lirs:·were dt:flnea .ils oc<;iming :(>ni the right wall !(25), the 1left wall :{30) •or "other" 
sites.(46). 'No. significant association was fouiltl.betweeri·the siterofithe .tUmour a_rid the 
'Fable 3~L8::Site oftumour 1by response>to'EBRT: 
Nor response: 
I 
Complete :respoiise .P'"~alue 
' 
Right :Wall 11 14 
-
--
. l;eft :wall 16 ' 14 0!579 
' 
"other" J9 2:7' 
126 
3.1.3. Tumour angiogenesis, lntratumour macrophage infiltration, p53, M.IB-1, 
bcl-2 and the response to EBRT 
Angiogenesis 
46 patients did not respond to radiotherapy. The median MVD for these patients using 
CD31 was 4.3 (IQR 2.00) and using CD34 was 4.6 (IQR 1.47). 55 patients did respond 
to radiotherapy and their MVD's were 4.3 (IQR 1.70) and 4.6 (LQR 2.30) respectively. 
No statistically significant association was found between MVD and the response to 
EBRT for either method of quantifying angiogenesis using Mann-Whitney test [p=0.777 
(CD31) and p= 0.686 (CD34)] (Table 3.1.9). 
Table 3.1.9. Median (IQR) of tumour angiogenesis by response to radiotherapy: 
Median MVD(IQR) p-value 
No response 4. 3 (2.00) 
MVD(CD31) Complete response 4. 3(1.70) 0.777 
No response 4. 6 (1.47) 
MVD(CD34) Complete response 4. 6 (2.30) 0.686 
l11tratumour macropllages 
Macrophage infiltration (CD68) was detected in all the specimens. The CD68 labelling 
index (LI) ranged from 23.8% to 67.2% (mean 41.29%, SD 10.38) for none responders 
and 20% to 65.4% (mean 43.38, SO 11.00) for patients who did respond to EBRT. The 
mean CD68 labelling index showed no significant difference between patients who did 
not respond to EBRT and those who did respond to EBRT (t-test p= 0.331) (Table 
3.1.10). 
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Table 3.1.10. Mean CSD) ofCD68 (LI) infiltrations by response to radiotherapy: 
No response 
Complete response 
p53 expression 
Mean CD68 (SD) 
41.29 (10.38) 
43.38 (11.00) 
p-value 
0.331 
Nuclear p53 protein was detected in 90 tumours. 11 of the tumours stained negative for 
p53. The p53 labelling index (p53 Ll) ranged from 0% to 99% (median 64.0, IQR 
29.07) for the no response group of patients and from 0% to 99% (median 61.8, IQR 
45.80) for tumours in the response group. The median p53 Ll showed no significant 
difference between tumours that responded to EBRT and those, which did not. Using a 
Mann-Whitney test (p=0.230) (Table 3.1.11). 
Table 3.1.11. Median (IQR) of p53 (LI) infiltrations by response to radiotherapy: 
EBRT 
No response 
Complete response 
M/B-1 
Median p53 Ll (IQR) 
64.0 (29.07) 
61.8 (45.80) 
p-value 
0.230 
The MIB-1 LI of tumours ranged from 32.7% to 98.6% (mean 67.13, SD 16.17) for 
tumours, which did not respond, to radiotherapy and from 33.8% to 96% (mean 67.34, 
SD 15.41) for tumours, which did respond. There was no significant difference in the 
MIB-1 LI between the two groups (t-test p=0.945) (Table 3.1.12). 
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Table 3.1.12. Mean (SD) of MIB-1 (LO by response to radiotherapy: 
EBRT Mean MIB-1 LI (SD) p-value 
No response 67.13 (16.17) 
0.945 
Complete response 67.34 (15.41) 
Bcl-2 
48 (47.5%) of the tumours showed bcl-2 expression and 53 (52.5%) no bcl-2 
expression. The response of the two groups to EBRT is shown in the following table. 
No significant association was found for bcl-2 scoring and the response to EBRT (chi-
squared test p=0.291) (Table 3.1.13). 
Table 3.1.13. Response to radiotherapy by bcl-2: 
No response Complete response p-value 
Bcl-2 +ve 25 23 
0.291 
Bcl-2 -ve 21 32 
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3.1.4 Association between MVD, haemoglobin, macrophage infiltration, MIB-1, 
bcl-2, o53 and tumour characteristics: 
MVD and stage 
MVD quantified by CD31 showed no significant association with tumour stage (Mann-
Whitney test p=0.469). When MVD was quantified using CD34 a significant difference 
was observed; MVD being lower in higher stage tumours (Mann-Whitney test p=O.OSO) 
(Table 3.1.14). 
Table 3.1.14. Median (IQR) of MVD by stage of bladder TCC: 
Tumour stage Median MVD (IQR) P value 
2 4.3 (2.22) 
CD31 
3 4.3 (2.00) 0.469 
2 4.8 (2.00) 
CD34 
3 4.3 (1.40) 0.050 
MVD and grade 
There were 11 grade 2 tumours and 90 grade 3 tumours. The median MVD for grade 2 
tumours was 4.00 (IQR 2.00) "for grade tumours" using CD31 and 3.60 (IQR 2.70) 
using CD34. The respective values for grade 3 tumours were 4.3 (IQR 2.00) and 4.60 
(IQR I. 78). There was no significant difference in the MVD for grade 2 (Mann-
Whitney test, p=0.525) and grade 3 tumours (Mann-Whitney test, p=0.252) when 
stained by either antibody (Table 3.1.15). 
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Table 3.1.15. Median (IQR) of MVD by grade of bladder TCC: 
Tumour grade Median MVD (IQR) p value 
2 4.00 (2.00) 
CD31 
3 4.3 (2.00) 0.525 
2 3.60 (2.70) 
CD34 
3 4.60 (1.78) 0.252 
MVD and tumour site 
25 tumours were on the right wall of the bladder. The median MVD for these tumours 
was 4.3 (IQR 2.30) using CD31 and 5.00 (IQR 1.95) using CD34. 30 tumours were on 
the left wall and the median MVD of these was 4.3 (IQR I. 78) using CD31 and 4.6 
(IQR 1.78) using CD34. The remaining 46 tumours were found at "other" sites in the 
bladder and the median MVD of these was 4.15 (IQR 2.00) using CD31 and 4.3 (IQR 
1.78) using CD34. There was no significant association between MVD (when quantified 
by either CD31 or CD34) and the site of the tumour (Kruskall-Wallis, p=0.398 and 
p=0.410) (Table 3.1.16). 
Table 3.1.16. Median (IQR) of MVD by site of bladder TCC: 
Site Median MVD (IQR) p value 
Right wall 4.3 (2.30) 
CD31 Left wall 4.3 (1.78) 0.398 
"Other" 4.15 (2.00) 
Right wall 5.0 (1.95) 
CD34 Left wall 4.6 ( 1.78) 0.410 
"Other" 4.3 (1.78) 
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Haemoglobin and stage 
ference between haemoglobin level in the different tumour There was no significant dif 
stages (Mann-Whitney test, p =0.388) (Table 3.1.17). 
Table 3. 1.17. Haemoglobin and stage of TCC: 
Median HB (IQR) p-value 
Stage 2 13.1 (2.30) 
Stage 3 12.8 (2.20) 0.388 
Haemoglobin and grade 
erence between haemoglobin levels in the different tumour There was no significant diffi 
grades (Mann-Whitney test, p=0.905) (Table 3.1.18). 
Table 3.1 .18. Haemoglobin and grade of TCC: 
Median HB (IQR) p-value 
Grade 2 12.70 (3.00) 
Grade 3 13.00 (2.10) 0.905 
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Haemoglobin and tumour site 
There was no significant association between haemoglobin level and site of the tumour 
(Kruskali-Wallis, p=0.966) (Table 3.1.19). 
Table 3.1.19. Haemoglobin and site of TCC: 
Median BB (IQR) p-value 
Right wall 13.00 (2.90) 
Left wall 12.95 (1.86) 
0.966 
"Other" 13.05 (2.38) 
CD 68 LT and stage 
There was no significant difference between macrophage infiltrations in the different 
tumour stages (t-test p=0.23) (Table 3.1.20). 
Table 3.1.20. CD68 and stage ofTCC: 
Mean CD 68 L1 (SD) p-value 
Stage 2 43.78 (10.44) 
Stage 3 41.20 (10.91) 0.23 
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CD 68 Ll and tumour grade 
There was no significant difference between macrophage infiltrations in the different 
tumour grades (t-test p=0.75) (Table 3.1.21). 
Table 3.1.21. CD68 and grade ofTCC: 
Mean CD 68 L1 (SD) p-value 
Grade 2 43.41 (11.36) 
Grade 3 42.31 (10.70) 0.75 
CD 68 Ll and tumour site 
There was no significant association between macrophage infiltration and site of the 
tumour (A VOVA p=0.93) (Table 3.1.22). 
Table 3.1.22. CD68 and site ofTCC: 
Mean CD68 LI (SO) p-value 
Right wall 41.88 (11.03) 
Left wall 42.24 (1 0.86) 
0.93 
"Other" 42.84 (1 0.67) 
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Bcl-2 and tumour stage 
26 of the 48 stage 2 tumours expressed bcl-2 and 22 of the 53 stage 3 tumours showed 
bcl-2 expression. No significant association was found between bcl-2 expression and 
tumour stage (chi-square test p= 0.203) (Table 3.1.23). 
Table 3.1.23. Association between bcl-2 and stage of bladder TCC 
bcl-2 +ve bcl-2 -ve P value 
Stage 2 26 22 
Stage 3 22 31 0.203 
Bc/-2 and tumour grade 
11 tumours were grade 2 and of these 8 showed expression of bcl-2. 90 turn ours were 
grade 3 and of these 40 showed expression of bcl-2. No significant associ ation was 
found between bcl-2 expression and tumour grade (Chi-square test p=0.07 6) (Table 
3.1.24). 
Table 3.1.24. Association between bcl-2 and grade of bladder TCC 
bcl-2 +ve bcl-2 -ve P value 
Grade 2 8 3 
Grade 3 40 50 0.076 
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Bcl-2 a11d tumour site 
12 out of 25 tumours on the right wall; 14 out of 30 tumours on the left wall and 22 
tumours found at "other" sites in the bladder showed bcl-2 expression. There was no 
significant association between bcl-2 expression and tumour site in the bladder (chi-
square test p=0.994) (Table 3.1.25). 
Table 3.1.25. Association between bcl-2 and site of bladder TCC: 
bcl-2 +ve bcl-2 -ve P value 
Right wall 12 13 
Left wall 14 16 0.994 
"other site" 22 24 
M/B-1 a11d tumour stage 
The mean MIB-1 Ll of the 48 stage 2 tumours was 67.99 (SD 14.86) and that for the 53 
grade 3 tumours was 66.57 (SD 16.50). There was no significant difference between the 
two groups (t-test p=0.653) (Table 3.1.26). 
Table 3.1.26. Association between Mm-J (L I) and stage of bladder TCC: 
Mean MIB-1 LI (SD) P value 
Stage 2 67.99 (14.86) 
Stage 3 66.57 (16.50) 0.653 
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MIB-1 and tumour grade 
The mean MIB-1 LI for the 11 grade 2 tumours was 65.80 (SD 21.83) and the mean 
MIB-1 LI for the 90 grade 3 tumours was 67.42 (SD 14.92). There was no si~:,'llificant 
association between MlB-1 and tumour grade (t-test p=0.748) (Table 3.1.27). 
Table 3.1.27. Association between MIB-1 and grade of bladder TCC: 
Mean MIB-1 Ll (SD) P value 
Grade 2 65.80 (21.83) 
Grade 3 67.42 (14.92) 0.748 
M/B-1 and tunwur site 
The mean MIB-1 LI for tumours on the right wall was 62.96 (SD 14.73), for those on 
the left wall 69.26 (SO 15.39) and for those at "other" sites 68.26 (SO 16.25). No 
significant association was found between MIB-1 LJ and tumour site (ANOVA p=0.28) 
(Table 3.1.28). 
Table 3.1.28. Association between MIB-1 and site of bladder TCC: 
Mean MIB-1 Ll (SD) p-value 
Right wall 62.96 (14.73) 
Left wall 69.26 ( 15.39) 0.28 
"other" site 68.26 ( 16.25) 
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o53 and tumour stage 
The median p53 LI of stage 2 tumours was 64.4 {IQR 41.15) and that for stage 3 
tumours was 59.4 (IQR 42.55). There was no significant difference between the two 
groups (Mann-Whitney test, p= 0.522) (Table 3.1.29). 
Table 3.1.29. Association between p53 (LD and stage of bladder TCC: 
Median p53 LI (IQR) p-value 
Stage 2 64.4 (41.15) 
Stage 3 59.4 ( 42.55) 0.522 
p53 a11d tumour grade 
The median p53 LI for grade 2 tumours was 70.00 (IQR 53.70) and that for grade 3 
tumours was 63.40 (lQR 39. 18). There was no significant difference in the p53 staining 
for grade 2 and grade 3 tumours (Mann-Whitney test, p=0.616) (Table 3.1.30). 
Table 3.1.30. Association between p53 (LI) and grade of bladder TCC: 
Median p53 LI (IQR) p-value 
Grade 2 70.00 (53.70) 
Grade 3 63.40 (39.18) 0.616 
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3.1.5 Association between other variables: 
p53 and MVD (CD31, CD34) 
p53 is not correlated (Spearrnan correlation) with CD31 (r=0.187, p=0.062) and CD34 
(r=O.l67, p=0.096) (Table 3.1.32, figure 3.1.2). 
Table 3.1.32. Correlation between p53 (Lll and MVD in bladder TCC: 
Tumour Tumour 
. . 
angwgenes IS angiogenesis 
CD31 CD34 
p53 (LI) expression Correlation coefficient 0.1 87 0.167 
in bladder TCC% Sig. (2-tailed) 0.0 62 0.096 
N I 01 101 
Figure 3.1.2. Scatter plot of p53 Vs MVD (CD34): 
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Scatter plot of p53 Vs MVD (CD31) see appendix (page 203). 
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MIB-1 and MVD (CD31, CD34) 
MIB-1 is not correlated (Spearrnan correlation) with CD31 (r=Ool34, p=Ool53) and 
CD34 (r=Oo l14, p=Oo254) (Table 3.1.33, figure 3.1.3). 
Table 3.1.33. Correlation between MIB-1 (LD and MVD in bladder TCC: 
Tumour Tumour 0 0 0 0 
angiogenesis angiogenesis 
CD31 CD34 
Proliferation of Correlation coefficient 00134 00114 
tumour cells Sigo (2-tailed) 00153 00254 
(MIBI )% N 101 101 
Figure 3.1.3. Scatter plot ofMffi-1 Vs MVD (CD31): 
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p53 and MIB-1 
There was a significant Spearman correlation (positive) between p53 Ll expression and 
MIB- 1 LI (r-0.332, p=O.OOI) (Table 3.1.34, figure 3.1.4). 
Table 3.1 .34. Correlation between p53 (LD and MIB-1 in bladder TCC: 
Proliferation of 
tumour cells 
MIB1 % 
p53 (LI) expression Correlation coefficient 0.332 
in bladder TCC % Sig. (2-tailed) 0.001 
N 101 
F igure 3.1.4. Scatter plot of p53 Vs Mffi-1: 
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p53 andCD68 
There was no significant positive Spearrnan correlation between p53 and CD68 
(r=0.036, p=0.719) (Table 3.1.35, figure 3.1.5). 
Table 3.1.35. Correlation between p53 and CD68 (LI) in bladder TCC: 
Tumour 
macrophage 
CD68 
p53 (LI) expression Correlation coefficient 0.036 
in bladder TCC % Sig. (2-tailed) 0.719 
N 101 
Figure 3.1.5. Scatter plot of p53 Vs CD68: 
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CD31 and CD34 
A significant positive Spearman correlation is found between CD31 and CD34 
(r=0.589, p<O.OOl) {Table 3.1.36, figure 3.1.6). 
Table 3.1.36. Correlation between CD31 and CD34 in bladder TCC: 
Tumour 
. . 
ang10genests 
CD34 
Tumour Correlation coefficient 0.589 
angiogenesis CD31 Sig. (2-tailed) 0.000 
N 101 
Figure 3.1.6. Scatter plot of CD31 Vs CD34: 
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CD31 and CD68 
There was no significant positive Spearman correlation between CD31 and CD68 
(r=O.l92, p=0.054) (Table 3.1.37, figure 3.1.7). 
Table 3.1.37. Correlation between CD68 (LD and MVD in bladder TCC: 
Tumour 
macrophage 
CD68 
Tumour Correlation coefficient 0.192 
angiogenesis CD31 Sig. (2-tailed) 0.054 
N 101 
Figure 3.1.7. Scatter plot of CD68 Vs MVD (CD31): 
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CD34 and CD68 
There was no significant Spearman correlation between CD34 and CD68 (r=0.078, 
p=0.436) (Table 3.1.38, figure 3.1.8). 
Table 3.1.38. Correlation between CD68 (Ll) and MVD in bladder TCC: 
Tumour 
. . 
angiOgenesis 
CD34 
Tumour Correlation coefficient 0.078 
macrophage CD68 Sig. (2-tailed) 0.436 
N 101 
Figure 3.1.8. Scatter plot of CD68 Vs MVD (CD34): 
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MIB-1 and CD68 
There was no significant Pearson correlation between MIB-1 and CD68 (r=0.072, 
p=0.475) (Table 3.1.39, figure 3.1.9). 
Table 3.1.39. Correlation between MIB-1 and CD68 (LD in bladder TCC: 
Tumour 
macrophage 
CD68 
Proliferation of Correlation coefficient 0.072 
tumour cells Sig. (2-tailed) 0.475 
MIBl % N 101 
Figure 3.1.9. Scatter plot of CD68 Vs MIB-1: 
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Haemoglobin and MVD (CD31 &CD34) 
Haemoglobin level is not correlated (Spearman correlation) with CD31 (r=0.020, 
p=0.845) and CD34 (r= -0.132, p=O.l87) (Table 3.1.40, figure 3.1.10). 
Table 3.1.40. Correlation between haemoglobin level and MVD in bladder TCC: 
Tumour Tumour 
. . . . 
angtogenesis angiogenesis 
CDJI CD34 
Haemoglobin Correlation coefficient 0.020 -0.132 
level Sig. (2-tailed) 0.845 0.187 
N 101 101 
Figure 3.1.10. Scatter plot of haemoglobin level Vs MVD (CD34): 
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Scatter plot of haemoglobin level Vs MVD (CD31) see appendix. 
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Haemoglobin and CD68 
There was no significant Spearman correlation between haemoglobin level and CD68 
(r=0.051 , p=0.612) (Table 3.1.41, figure 3.1.11). 
Table 3.1.41. Correlation between haemoglobin and CD68 (LD in bladder TCC: 
Tumour 
macrophage 
CD68 
Haemoglobin Correlation coefficient 0.051 
level Sig. (2-tailed) 0.612 
N 101 
Figure 3.1.11. Scatter plot of haemoglobin level Vs CD68: 
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Haemoglobin and p53 
Haemoglobin level is not correlated (Spearrnan correlation) with p53 (r= -0.108, 
p=0.281) (Table 3.1.42, figure 3.1.12). 
Table 3.1.42. Correlation between haemoglobin and p53 (LI) in bladder TCC: 
p53 (LI) 
expressiOn m 
bladder TCC % 
Haemoglobin Correlation coefficient -0.108 
level Sig. (2-tailed) 0.281 
N 101 
Figure 3.1.12. Scatter plot of haemoglobin level Vs p53: 
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Haemoglobin and MIB-1 
There was no significant Spearman correlation between haemoglobin level and MIB-1 
(r= -0.011, p=0.913) (Table 3.1.43, figure 3.1.13). 
Table 3.1.43. Correlation between haemoglobin and MIB-1 (LD in bladder TCC: 
Proliferation of 
tumour cells 
MIBl% 
Haemoglobin Correlation coefficient -0.011 
level Sig. (2-tailed) 0.913 
N 101 
Figure 3.1.13. Scatter plot of haemoglobin level Vs MIB-1: 
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Bcl-2 and MVD (CD31) 
There was no significant Spearrnan correlation between bcl-2 and CD31 (r=0.039, 
p=0.697) (Table 3.1.44). 
Table 3.1.44. Correlation between Bcl-2 and MVD (CD31) in bladder TCC: 
Tumour 
. . 
angiogenesis 
CD31 
Correlation coefficient 0.039 
Bcl-2 Sig. (2-tailed) 0.697 
N 101 
Bcl-2 and MVD (CD34) 
There was no significant Spearrnan correlation between bcl-2 and CD34 (r= -0.056, 
p=0.580) (Table 3.1.45) 
Table 3.1.45. Correlation between Bcl-2 and MVD (CD34) in bladder TCC: 
Tumour 
. . 
angwgenes1s 
CD34 
Correlation coefficient -0.056 
Bcl-2 Sig. (2-tailed) 0.580 
N 101 
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Bcl-2 and CD68 
There was no significant Spearrnan correlation between bcl-2 and CD68 (r= 0.027, 
p=0.792) (Table 3.1.46) 
Table 3.1.46. Correlation between Bcl-2 and CD68 in bladder TCC: 
lntratumour 
macrophage 
CD68 
Correlation coefficient 0.027 
Bcl-2 Sig. (2-tailed) 0.792 
N I 0 I 
Bcl-2 and p53 
There was no significant Spearrnan correlation between bcl-2 and p53 (r= -0.129, 
p=O.I99) (Table 3.1.47) 
Table 3.1.47. Correlation between Bcl-2 and p53 in bladder TCC: 
p53 expression 
in bladder TCC 
% 
Correlation coefficient -0.129 
Bcl-2 Sig. (2-tailed) 0.199 
N 101 
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Bcl-2 and MIB-1 
There was no significant Spearman correlation between bcl-2 and MIB-1 (r= -0.066, 
p=0.514) (Table 3.1.48) 
Table 3.1.48. Correlation between Bcl-2 and Mffi-1 in bladder TCC: 
Proliferation of 
tumour cells 
MIB-1 
Correlation coefficient -0.066 
Bcl-2 Sig. (2-tailed) 0.514 
N 101 
Bcl-2 and haemoglobin level 
There was a marginally significant Spearman correlation between bcl-2 and 
haemoglobin level (r= 0.197, p=0.049) (Table 3.1.49) 
Table 3.1.49. Correlation between Bcl-2 and haemoglobin level in bladder TCC: 
Haemoglobin 
level 
Correlation coefficient 0.197 
Bcl-2 Sig. (2-tailed) 0.049 
N 101 
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3.1.6 Multivariate analysis of the effects of the variables with respect to the 
response to radiotherapy: 
A multivariate logistic regression was fitted to the data with response to radiotherapy as 
the dependant variable and the other variables as independent. Because of the 
correlation between predictors, CD34 and MIBI were not used in the logistic regression 
model to avoid multicollinearity. 
The backward stepwise logistic re6rression shows that only sex seemed to be marginally 
significant, for instance the odds of response for a male patient is 3 times the odds of 
response for female adjusting for other variables. (Table 3.1.50). 
Table 3.1.50. Predictors for response to radiotherapy: 
95.0% C.I. for OR 
B Si g. Odds ratio Lower Upper 
a HB 0.259 0.060 1.296 0.989 1.699 
Sex -1.177 0.051 0.308 0.095 1.006 
p53 -0.013 0.091 0.987 0.972 1.002 
Constant -1.00 I 0.611 0.368 
8 Variable(s) entered on step 1: Age, Grade, HB, Site, Stage, CD31, CD68, Days, Sex, 
Radioth. Dose, Bcl-2 and p53. 
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3.2 Section two 
In this second analysis the two outcomes are as follows: -
Enduring complete response to EBRT- patients in whom bladder tumour was not 
found at any follow up cystoscopy. 
Failed treatment - patients who at any follow up cystoscopy were found to have 
bladder tumour. 
The two outcomes were used to analyse the data as above. 
In 42 ( 41.6%) patients there was a complete response to EBRT whilst 59 (58.4%) were 
considered treatment failures. During the 8-year follow up period 67 patients (66.3%) 
were alive and 34 (33.7%) had died (Table 3.2.1). 
Table 3.2.1. Patient's response to EBRT: 
EBRT Dead Alive 
Failed treatment 16 43 
Enduring complete 18 24 
response to 
156 
3.2.1. The effects individually of age, sex, haemoglobin level and duration of 
treatment on the response to radiotherapy: 
Figure 3.2.1, shows the age distribution of patients who responded to EBRT compared 
to those who did not. Patients in the age group 60-69 years appear to respond better to 
radiotherapy than do other age groups. 
Figure 3.2.1. Age distribution by response to EBRT: 
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When patient's age is considered as a quantitative variable there was no significant 
difference between the mean ages of those patients who responded and those who did 
not (t-test p=0.477) (Table 3.2.2). 
Table 3.2.2. Mean age (SD) by response to radiotherapy: 
EBRT Mean age (SD) p-value 
Failed treatment 69.12 (10.41) 
0.477 
Enduring corn plete response 69.69 (9.58) 
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In this study the ratio male to female is about 5:1. Females ( 15.8%), whilst representing 
only a small fraction of the total ( 16 out of 101) showed an inferior response (12.5%) to 
radiotherapy when compared to that of male patients (47.1 %), and this is confirmed by 
Chi-Square test (p=0.022) (Table 3.2.3). 
Table 3.2.3. Gender of patients by response to EBRT: 
SEX Failed Enduring p-value treatment complete response 
Male 45 40 
Female 14 2 0.022 
Haemoglobin level 
There was no significant difference in the mean haemoglobin levels for patients who 
responded to EBRT and those who did not respond (Mann-Whitney test, p=0.107) 
(Table 3.2.4). 
Table 3.2.4. Patients haemoglobin level by response to radiotherapy: 
Failed treatment Enduring complete p-value 
response 
Median haemoglobin 12.80 13.20 0.107 
g/dl (IQR) (2.40) ( 1.55) 
158 
Duration o(treatment 
Duration of treatment shows no significant difference between responders and none 
responders (chi-squared test p=O.l03) {Table 3.2.5). 
Table 3.2.5. Number of days by response to radiotherapy: 
Failed treatment Enduring complete p-value 
response 
Du ration =< 33 days 40 33 
0.103 
Duration > 33 days 19 9 
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3.2.2. The effect of tumour stage, tumour grade and site in the bladder on the 
response to EBRT: 
Tumour stage 
48 (47.5%) of the tumour were stage 2 and 53 (52.4%) were stage 3. There was no 
significant difference in the response to EBRT between the two stages (chi-squared test 
p=0.827) (Table 3.2.6). 
Table 3.2.6. Stage of tumour by response to EBRT: 
Failed treatment Enduring complete p-value 
response 
Stage 2 27 21 
0.827 
Stage 3 32 21 
Tumour grade 
l I tumours ( I 0. 9%) were grade 2 and 90 (89 .1%) were grade 3. There was no 
signjficant difference between the two grades and their response to EBRT (chi-squared 
test p=0.486) (Table 3.2.7). 
Table 3.2.7. Grade of tumour by response to EBRT: 
Failed treatment Enduring complete p-value 
response 
Grade 2 8 3 
0.486 
Grade3 51 39 
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Site of the tumour 
Tumours were defined as occurring on the right wall (25), the left wall (30) or "other" 
sites ( 46). No significant association was found between the site of the tumour and the 
response to radiotherapy (chi-squared test p=0.293) (Table 3.2.8). 
Table 3.2.8. Site of tumour by response to EBRT: 
Failed treatment Enduring complete p-value 
response 
Right wall 14 11 
Left wall 2 "1 9 0.293 
"other" 24 22 
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3.2.3. Tumour angiogenesis, Intratumour macroohage infiltration,p53, MJB-1, 
bcl-2 and the response to EBRT 
Angiogenesis 
59 patients did not respond to radiotherapy. The median MVD for these patients using 
CD3 1 was 4.30 (IQR 2.00) and using CD34 was 4.60 (IQR 1.40). 42 patients did 
respond to radiotherapy and their median MVDs ' were 4.30 (IQR 1.78) and 5.00 (lQR 
2.30) respectively. No statistically significant association was found between MVD 
count and the response to EBRT for either method of quantifying angiogenesis usi ng 
Mann-Whitney test [(p=0.635 (CD3 1) and p= 0.438 (CD34)) (Table 3.2.9). 
Table 3.2.9. Median (IQR) of tumour angiogenesis by response to radiotherapy: 
EBRT Median MVD p-value 
(lQR) 
Failed treatment 4.30 
MVD (CD31) (2.00) 
Enduring complete 4.30 0.635 
response (L78) 
Failed treatment 4.60 
MVD (CD34) (1.40) 
Enduring complete 5.00 0.438 
response (2.30) 
Jntratumour macrophages 
Macrophage infi ltration (CD68) was detected in all the specimens. T he CD68 labelling 
index (LI) ranged from 23.8% to 67.2% (mean 41.43%, SD I 0.20) for none responders 
and 20% to 65.4% (mean 43.8 1, SO 1 1.38) for patients who d id respond to EBRT. The 
mean CD68 labelling index showed no significant d ifference between patients who did 
not respond to EBRT and those who did (t-test p= 0.273) (Table 3.2.10). 
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Table 3.2.10. Mean (SD) of CD 68 (Lfl infiltrations by response to radiotherapy: 
EBRT Mean CD68 (SD) p-value 
Failed treatment 41.43 (10.20) 
Enduring complete response 43.81 (11.38) 0.273 
p53 expression 
Nuclear p53 protein was detected in 90 twnours. 11 of the tumours stained negative for 
p53. The p53 labelling index (p53 Ll) ranged from 0% to 99% (median 63.50, IQR 
36.00) for the no response group of patients and from 0% to 99% (median 61.45, IQR 
47.70) for tumours in the response group. The median p53 Ll showed no significant 
difference between tumours that responded to EBRT and those, which did not. Using a 
Mann-Whitney test (p=0.206) (Table 3.2.11). 
Table 3.2.11. Median (IQR) of p53 (LO infiltrations by response to radiotherapy: 
EBRT Median p53 LI (IQR) p-value 
Failed treatment 63.50 (36.00) 
0.206 
Enduring complete response 61.45 (47.70) 
M/B-1 
The MJB-1 LI of tumours ranged from 32.7% to 98.6% (mean 68.25, SO 15.35) for 
tumours, which did not respond, to radiotherapy and from 33.8% to 96% (mean 65.82, 
SO 16.20) for tumours, which did respond. There was no signjficant difference in the 
MJB-1 LI between the two groups (t-test p=0.446) (Table 3.2. 12). 
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Table 3.2.12. Mean (SD) ofMIB-1 (LD by response to radiotherapy: 
EBRT Mean MIB-1 LI (SD) p-value 
Failed treatment 68.25 (15.35) 
0.945 
Enduring complete 65.82 (16.20) 
response 
48 (47.5%) of the tumours showed bcl-2 expression and 53 (52.5%) no expression of 
bcl-2. The response of the two groups to EBRT is shown in the following table. No 
significant association was found for bcl-2 scoring and the response to EBRT (cbi-
squared test p=0.320) (Table 3.2.13). 
Table 3.2.13. Response to radiotherapy by bcl-2: 
No response Enduring corn plete p-value 
response 
Bcl-2 +ve 31 17 
0.320 
Bcl-2 -ve 28 25 
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3.2.4 Multivariate analysis of the effects of the variables with respect to the 
response to radiotherapy: 
A multivariate logistic regression was fitted to the data with response to radiotherapy as 
the dependant variable and the other variables as independent. 
The table below shows an output of the backward stepwise logistic regression. Sex and 
p53 are the only variables selected (Table 3.2.14). 
Table 3.2.14. Predictors for response to EBRT: 
Odds 95.0% C.I. for 
B Si g. ratio OR 
Lower Upper 
a Sex -1.906 0.017 0.149 0.03 1 0.707 
p53 -0.014 0.073 0.986 0.972 1.00 I 
Constant 2.574 0.011 13. 123 
a Variable(s) entered on step 1: Age, Grade, HB, Site, Stage, CD3 1, CD68, Days, Sex, 
Radioth. Dose, Bcl-2 and p53. 
165 
4. Survival 
Survival analysis describes the analysis of data that correspond to the time from a well-
defined time origin until the occurrence of some particular event or end-point. If the 
end-point is the death of a patient, the variable of interest will be survival times. 
Because the cause of death is not recorded in these data, only the crude survival time of 
patients is considered. The 5-year survival in this study was 32%. 
Kaplan-Meier survival plots (K-M plots) and log rank test were used to show difference 
between survivals for different factors. 
The table (4. 1) and figure (4.1) show a description of the variable, number of days of 
treatment. The mean value is 33.21 days with 95% confidence interval (3 1.83 to 34.59). 
33 days can be used as a cut-off point as it falls within the confidence interval. 
The Kaplan-Meier survival analysis shows that the survival time is significantly higher 
for those who were exposed longer to radiotherapy (> 33 days) (Log Rank, p=0.0246) 
(Fig. 4.2). The analysis showed significance for cut-off points between 30 and 40 days 
but not below or above these limits. This can be explained by the fact that few cases 
are observed on both tails of the distribution of days, which makes the size of one of the 
groups very small, and therefore reduce the power of the test (log rank), which is based 
on the chi-square test. 
The same procedures for cut-off points have been used for the remaining variables 
(table 4.1). 
CD68 shows a significantly higher survival time for those who have CD68 higher than 
42.4 (log rank, p=0.036) (fig. 4.3). 
The rest of the K-M plots (Figure 4.4 - Figure. 4.12) show no difference in survival 
times. 
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Table 4.1. Cut-off points of tbe variables: 
Cut-off point* 
Duration of treatment Mean* 33.2 
(days) 95% Confidence Lower bound 31.8 
interval for mean Upper bound 34.6 
Tumour Mean* 4.4 
Angiogenesis 95% Confidence Lower bound 4.2 CD31 interval for mean Upper bound 4.6 
Tumour Mean* 4.6 
Angiogenesis 95% Confidence Lower bound 4.3 CD34 interval for mean Upper bound 4.8 
Mean* 42.4 
CD68 95% Confidence Lower bound 40.3 interval for mean Upper bound 44.5 
Haemoglobin level Mean* 12.8 
95% Confidence Lower bound 12.5 
interval for mean Upper bound 13.1 
MrB-1 Mean* 67.2 
95% Confidence Lower bound 64.1 
interval for mean Upper bound 70.3 
p53 Mean* 57.37 
95% Confidence Lower bound 51.75 
interval for mean Upper bound 63.00 
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Figure 4.1. Mean (SD) for length of treatment: 
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Figure 4.2. Survival by length of treatment: 
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Figure 4.3. Survival times for CD68 (macrophage): 
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Figure 4.4. Survival times for stage of tumour: 
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Figure 4.5. Survival times for grade of tumour: 
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Figure 4.6. Survival times for Haemoglobin level: 
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Figure 4.7. Survival times for CD31: 
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Figure 4.8. Survival times for CD34: 
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Figure 4.9. Survival times for gender: 
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Figure 4.10. Survival time by tumour proliferation (MIB-1}: 
Survival Functions 
1.2 .,....-------------------., 
MIBI 
0 >65 
~ .2 
·~ 
0.0 m 
+ >65-censored 
0 <=65 
§ 
u -.2 + <=65-censored 
0 1000 2000 3000 4000 
Survival time in days (log rank p=0. 18) 
172 
Figure 4.11. Survival time by bcl-2: 
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Figure 4.12. Survival time by p53: 
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GENERAL DISCUSSION 
& 
CONCLUSION 
DISCUSSION 
4.1 General discussion 
The expansion of knowledge in cancer biology has transformed our understanding of 
neoplasia. It is well recognized that solid tumour carcinogenesis is dependent upon 
both increased cellular proliferation as well as reduced cellular death. The recognition 
of this interplay of various factors has potentially both prognostic and therapeutic 
implications. 
In this extensive study of 101 patients with muscle invasive transitional cell carcinoma 
treated by EBRT, several biological parameters associated with either cell proliferation 
or cell death were examined as potential prognostic indicators. Various physiological 
factors including age, sex, clinical staging, grading, site of tumour, haemoglobin level, 
radiotherapy total dose and duration of treatment, were also examined. Regulators of 
the apoptotic pathway, bcl-2 and p53 are recognized to be prognostic markers in several 
tumours and our study evaluated bcl-2 and p53 express10n (as indicated by 
immunohistochemistry) as potential prognostic markers for evaluating bladder tumour 
response to radiotherapy. In all 101 cases pre-treatment bladder tumour tissue was 
analysed by a blinded, stringent histological scoring system for each antibody. 
The most important aim of this study was to try and identify markers, whjch would 
predict the response of muscle invasive TCC of the bladder to EBRT. In this study, 
none of the molecular cell markers examined were found to be predictors of response in 
either univariate or multivariate analysis. Furthermore the response did not appear to be 
associated with age, and duration of treatment, stage and grade of the tumour or the site 
of the tumour in the muscle invasive bladder TCC. In all the statistical analysis females 
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were found to respond less well than males and haemoglobin level found to be higher 
for response group. 
The data obtained have been carefully analysed and several interesting observations 
made. 
In 89% of tumours (90 out of 101), nuclear p53 was detected by lliC. Statistical 
analysis of the median p53 labelling index failed to show a significant difference 
between those tumours that responded to EBRT and those, which did not. Also there 
was no statistical correlation between the p53 nuclear labelling index and tumour grade 
and stage in this study. 
The immunohistochemical determination of p53 status has a number of limitations. 
One of the difficulties in interpreting the results of p53 staining is the general lack of 
consistency in the technical aspects of performing the assay; another difficulty is in the 
interpretation of the results, since threshold values for altered p53 expression vary 
among studies. These technical considerations are the subject of a multicenter National 
Cancer Institute-sponsored trial evaluating the reproducibility of the interpretation of 
p53 staining between different laboratories that routinely performs the assay (McShane 
et al. , 2000). Although the overall interlaboratory reproducibility for the interpretation 
of p53 staining was good for specimens with no or minimal staining or for specimens 
with a high number of stained tumour cells, the reproducibility was not good for 
specimens with an intermediate range of staining. Such findings again indicate the need 
for caution when comparing results from different laboratories. 
In theory, the inactivation of p53 may be seen in either chromosomal loss of 17p 13 : 1 
and/or preferential mutations. The relationships between p53 protein over-expression as 
detected by immunostaining and p53 mutation have been seen in many solid tumours 
175 
including urothelial carcinoma. However, increased p53 immunoexpression may also 
be caused by p53 protein stabilization, for example by its binding to other proteins such 
as mdm2 (Haupt et al. , 1997). The mdm2 protein inhibits G 1 arrest and the apoptotic 
functions of p53 protein by stabilizing and inactivating wild type p53 protein (Chen et 
al., 1996). 
In cases of nonsense splicing variants and stop-codon mutations (Bodner et al. , 1992) 
p53 may be mutated without being detected by IHC. As sequence analysis was not 
performed in this study, we cannot exclude the possibility that normal expression did 
not hide a mutation, not picked up by IHC. Conversely, p53 positive staining may have 
been caused by the over expression of abnormally abundant, but normally functioning 
protein (Kociakowski et al., 1995). Also, the fixation of the archival material and the 
choice of antibodies may also affect the results (Fischer et al. , 1994). 
We chose antibody D07 as this is a widely used antibody, so that our study would be 
comparable to others in the literature. 
However, ignoring potential technical limitations of p53 immunostaining this studies 
results raises several interesting points. 
Kim et al. , in 1997 recently provided evidence in support of alternative pathways for 
radiation-induced the apoptosis. It has been well known that p53-independent apoptosis 
pathways exist in different cell types. For example pathways for p53-dependent 
(radiation-induced) and p53-independent (steroid induced) apoptosis have been 
identified in T -lymphocytes and thymocytes. Nevertheless, multiple pathways for 
radiation-induced apoptosis have not yet been characterised with most studies 
documenting the need for functional p53 in that pathway. However, recently, studies 
have shown that platelet-derived growth factor (PDGF) may mediate a p53-independent 
pathway by which radiation mediates apoptosis (Kim et al., 1997). This finding may, 
therefore, explain why there was no correlation between tumour response to 
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radiotherapy and p53 immunostaining. Secondly, p53 mutation alone might not be 
enough to influence treatment outcome, as carcinogenesis is a multistep process and 
many more oncogenes are involved, each ofthem with a possible influence on treatment 
outcome. Wu et al. , I996; Osen et al., I998; Qureshi et al. , 200 I also found no 
significant relationship observed between p53 detected by rnc and radiation response 
in patients with muscle invasive bladder cancer. However, Moonen et al., 200 I , in a 
more recent study established a significant relation between mutant p53 positivity and 
poor local control. In fact, conflicting results regarding the significance of many 
biological markers including p53 in relation to progress of the disease and response to 
treatment were established in many studies (Ong et al., 2001 ; Rodel et al., 2000; 
Krupski et al., 2000; Pfister et al. , I998; Popov et al. , 1997; Jahnson et al. , 1995). 
p53 tumour suppressor gene mutation has been described as occurring frequently in 
invasive and in-situ bladder tumours. High grade and high stage tumours were often 
found to be positive for p53 (Nakopoulou et al. , 1998). However, others have failed to 
show this correlation (Cooke et al., 2000, Wunderlich et al. , 2000). 
In this study only 11 tumours (I1 %) were grade 2 whilst (90) 89% were grade 3. The 
fai lure to detect a significant difference between the p53 immunostaining for these 2 
grades may have been caused by the small number of grade 2 tumours examined. 48 
tumours (47%) of tumours were stage 2 and 53 (53%) were stage 3, and by definition, 
these are high grade aggressive tumours, therefore, a significant p53 variation would be 
unlikely. 
Finally, the picture is complicated by the fact that immunohistochemical detection of 
oncoproteins not always reflects the functional status of the gene. For instance, it has 
been demonstrated that p53 stabilization is not necessarily a result of mutation-altered 
conformational changes but might as well be related to the tumour environment (Lane, 
1994). Furthermore, missense mutations often cause p53 protein overexpression, but 
177 
immunohistochemistry is unable to detect other mutations that prevent protein 
expression. Greenblatt et al., has pooled data from 84 studies that reported 
immunohistochemistry and DNA sequencing, and found that the sensitivity of detecting 
mutations by immunohistochemistry was only 75% and that the positive predicting 
value was only 63%. Future studies should be, therefore, preferentially performed with 
full knowledge of both protein and gene status (Greenblatt et al. , 1994). 
Bcl-2 
Apoptosis IS a complex pathway involving the interaction of numerous biologically 
active proteins and peptides. The protein encoded by the bcl-2 proto-oncogene is one 
such entity and this has been implicated in prolonging cell survival by blocking 
apoptosis. Cytoplasmic bcl-2 is thought to antagonise radiation-induced apoptotic 
pathways by inhibiting the release of cytochrome C from the mitochondria (Hockenbery 
et al., 1991 ). Increased expression of bcl-2 has been shown to alter tumour sensitivity 
to both chemotherapy and radiotherapy regimes (Lotem et al., 1993). However, in 
contrast, Rode) et al., 2000 found the expression of bcl-2 had no important influence on 
response to a combination of platin-based chemotherapy and radiation. A study carried 
out by Kong et al., concluded that bcl-2 expression correlated with a poorer response to 
radiation treatment, which indicates that a poorer prognosis for patients with bcl-2 
expression in invasive tumour could be partly due to the resistant response of cancer to 
radiation treatment (Kong et al. , 1998). This is consistent with the hypothesis that bcl-2 
protein could contribute to the resistance of epithelial cancer to clinical treatment, which 
has been observed in prostate carcinoma. Bcl-2 expression in prostate cancer is 
associated with tumour progression after hormonal therapy, suggesting that bcl-2 may 
increase resistance to androgen ablation treatment (McDonnell et al., 1992). Pollack et 
al., also reported that bcl-2 overexpression was associated with impaired radiation 
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response m patients with bladder cancer treated with a regtmen of preoperative 
radiotherapy (Pollack et al., 1997). 
However, whilst bcl-2 over-expression in certain types of malignancies such as high 
grade lymphomas, leukemia, neuroblastoma and prostatic cancer is a poor prognostic 
factor, lung and breast cancer patients with bcl-2 expression have a better chance of 
survival (Lu et al. , 1996). It has been argued that these differences could be due to 
multiple factors including tumour heterogeneity, tissue specificity, the evaluation 
method used in assessing bcl-2 expression, or most importantly the actual cause of the 
bcl-2 over expression In many tumours there is the classic t( 14: 18) translocation, but 
this has not been detected in bladder carcinoma, and suggestions of complex post 
transcriptional regulation may play a significant role in controlling the expression of 
bcl-2 (Yin et al. , 1994). Bcl-2 overexpression in bladder cancers is most commonly 
seen in early low grade and low stage tumours, whilst loss of bcl-2 expression Is 
significantly correlated with high TCC stage, particularly in invasive TCC. This IS 
thought to be due to the presence of overexpressed bcl-2 prolonging cell survival by 
inhibiting apoptosis and therefore leading to neoplastic growth at a slower rate. 
In this study a surprising 48 tumours (48%) showed bcl-2 expression whilst 53 tumours 
(52%) did not. Eight out of 11 positive tumours (73%) were grade 2 TCC whilst 40 bcl-
2 positive tumours out of 90 (44%) were grade 3 TCC. Statistically no significant 
difference between bcl-2 positivity and tumour grade has been found but there does 
seem to be a trend that fewer higher grade tumours, are bcl-2 positive as was found by 
Nakopoulous et al. , 1998. 
Forty six out of 101 tumours (45 .5%) did not respond to radiotherapy and this included 
25 out of 48 tumours (54%) of bcl-2 positive tumours. Of the 55 out of 101 tumours 
that did respond this included 23 out of 48 tumours (48%) of bcl-2 positive tumours. 
Whilst we found no statistical significant evidence that bcl-2 expression is a useful 
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prognostic indicator to assess response to radiotherapy, the results do suggest a trend 
that bcl-2 positive tumours are less likely to respond to radiotherapy. There may be 
many reasons why so many high stage and high grade TCCs in this study are bcl-2 
positive and have responded to radiotherapy either in the short or long term. There may 
be other factors affecting the response of tumour to radiotherapy, we have already 
discussed the role of p53 and there are numerous complex interactions required for the 
inhibition of apoptosis, not touched on by this study such as the subsequent 
heterodimerisation ofbcl-2 with Bax, that requires the BHl and BH2 domains of bcl-2. 
Reported data on the relationship of bcl-2 expression with standard clinicopathological 
parameters in urothelial carcinomas have so far been conflicting. Most studies, 
including the present one, have failed to establish an association between the presence 
of bcl-2 expression and grade or stage (Korkolopoulou et al. , 2002; Wu et al., 2000; 
Kirsch et al., 1998; Tzai et al. , 1998). There are also studies documenting an inverse or 
a positive association of bcl-2 expression with grade and/or stage (Nakopoulou et al., 
1998; Okamura et al. , 1998; Li et al. , 1998; King et al. , 1996 & Bilim et al. , 1996). 
The data showed no association between bcl-2 and p53 expression, which supported the 
finding of Cooke et al., 2000 and Ong et al. , 200 I. They found no relationship between 
expression ofthe two proteins on the tumours of patients with muscle invasive TCC. 
No significant correlation between bcl-2 and MIB-1 was found in these data. Rode! et 
al. , 2000, reported similar results. Although, Rode! et al. , in his work patients were 
treated for invasive bladder cancer by a combined treatment protocol, including 
transurethral resection (TUR-B) and radjochemotherapy (RCT). 
No correlation was found between bcl-2 and tumour angiogenesis and macrophages 
infiltration in this study. 
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M/B-1 
Ki-67, a DNA binding protein is associated with cell proliferation and is expressed in all 
active phases of the cell cycle (Schwarting et al., 1993) and Ki-67 labelled cells are 
recognised as a measure of the growth fraction. Characterisation of the protein 
recognised by Ki-67 antibody has led to the development of new monoclonal antibodies 
such as MIB-1 , which advantageously can be used in formalin-fixed paraffin embedded 
tissue. Immunohistochemical determination of proliferative activity using MIB-1 
equates with Ki-67 staining and has been demonstrated to be related to tumour biology, 
including tumour recurrence, tumour stage and grade in a given cell population. 
This study evaluated the MIB-1 LI as a potential prognostic indicator for muscle-
invasive TCC treated by EBRT. No statistical significance was found between the 
mean MIB-1 LI and those tumours that did and did not respond to radiotherapy. The 
range of values for a tumour that did not respond lies between 32.7%-98.6%, whilst the 
range for those that did respond is 33 .8%-96%. This result is somewhat surprising as it 
would be expected that tumours with a high proliferative index (i.e. high growth 
fraction) would be more vulnerable to radiotherapy treatment. However, the index for 
the tumours that respond and those that do not is quite high and so other factors such as 
size of tumour, hence penetration of radiotherapy, blood supply etc. should also be 
considered. Another factor that must play a role in the interpretation of MIB-1 
immunostaining is that proliferation in a neoplasm is a function of the proportion of 
cells replicating, as estimated by Ki-67 and of the time taken for completion of the cell 
cycle, a factor not measured by Ki-67. Therefore, a neoplasm with a slow cell cycle 
could have many cells in cycle, but still have a relatively low proliferation rate whereas 
a tumour with a short cell cycle could be highly proliferative with fewer cells actively 
cycling at any given moment (Kubota et al., 1992). 
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The fact that MlB-1 immunostaining cannot measure the time spent in the cell cycle 
may explain the incomplete correlation between MlB-1 and the clinical course of 
muscle invasive bladder cancer. 
A study conducted by Lara et al., 1998 exhibited better local control after radical EBRT 
in bladder cancer patients with very low proliferating tumours indicating that rapid 
tumour repopulation during fractionated radiotherapy might reduce the probability of 
tumour control. However, Ogura et al., 1995 showed that a high proliferative index 
predicted radioresponsiveness in 60 patients treated with pre-operative radiotherapy 
followed by radical cystectomy for invasive bladder cancer. 
Moreover, Rode! et al., 2000 also reported that the spontaneous Al and the proliferation 
index (Ki-67) helped to identify patients whose invasive bladder tumour responded 
completely to a regime of combined radiochemotherapy (RCT} following initial 
TURBT. In the data presented here a significant correlation between p53 LI expression 
and MlB-1 was observed. This is in agreement with the findings of Tsuji et al., 1997 
and Osen et al., 1998. Conversely, Moch et al., 1994 reported no significant differences 
between Ki-67 and p53 positive or negative tumour in muscle invasive bladder tumour. 
No significance between MlB-1 immunostaining and grade and stage of tumour was 
observed in this study. Possibly, as discussed before, all the tumours in this study are of 
high grade and stage and therefore little significant information could be gleaned from 
examining these parameters. Other studies examining a wider range of TCC tumour 
grades and stages have reported discernible differences (Okamura et al., 1990; Fontana 
et al. , 1992; Cohen et al., 1993; Kruger et al., 1995; Tsuji et al. , 1997 and Oosterhuis et 
al., 2000). 
Another factor that may influence the results and hence interpretation of the MlB-1 LI 
in this study, is the controversy regarding MlB-1 staining indices. Nakasu et al., 200 1 
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when examining meningiomas describes different results when using indices related 
either to randomly selected immunostained fields or to the area of highest labelling. 
There is no consensus on the better method to evaluate MIB-1 immunostaining though 
there is a commonly held believe that the degree of histological malignancy of tumours 
is determined by the area with the highest number of positive cells is commonly 
accepted. 
CD31, CD34 and CD68 
Tumour angiogenesis is essential for growth and metastases in human neoplasia. It is 
important for nutrient supply and production and delivery of various growth factors. 
Angiogenesis is usually determined by lHC staining of tumour tissue specific for 
endothelial cells. The degree of tumour angiogenesis is defined by the intratumoural 
microvessel density (IMD). This is known to be of prognostic value in many human 
malignancies, this circumstance being mainly attributable to the involvement of 
angiogenesis in the development of distant metastases. A considerable body of evidence 
points toward the existence of an interaction between tumour angiogenesis and radiation 
effect, either in terms of tumour oxygenation (Horsman and Overgaard, 1997), or of the 
vasculotoxic effects of X-rays (Baker and Krochak, 1989) or of the anti-apoptotic 
properties of angiogenic factors (Katoh et al., 1995; Haimovitz-Friedman et al. , 1994; 
Fan et al. , 1998). Nonetheless, few clinical reports have assessed angiogenic activity as 
a predictive factor in radiation therapy and those that have are contradictory (Revesz et 
al. , 1989; Hall et al. , 1994; Gasparini et al., 1995; Zatterstrom et al., 1995; 
Giatromanolaki et al. , 1999). The predictive power of IMD for radiocurability may be 
explained in several ways. Hypoxia is a major cause of resistance to radiation (Horsman 
and Overgaard, 1997), and because oxygen delivery depends upon blood flow, 
measurement of tumoural vascularity has been deemed to represent a direct means of 
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assessing the tissue's oxygenation state (Revesz et al., 1989; Awwad et al., 1986). 
However, since hypoxia is a key trigger for the induction of angiogenesis (Dachs and 
Chaplin 1998), the number of microvessels could theoretically reflect the degree of 
tumour hypoxia. This view takes into account the circumstance that tumour vasculature 
is often dysfunctional, being characterized by sluggish blood flow or shunting (Jain, 
1994). Moreover, high-resolution intravital measurements have revealed the absence of 
correlation between blood flow and perivascular p02 (Helmlinger et al. , 1997). Hence, 
the relationship between vascularity and the degree of oxygenation in clinical tumour 
samples remains to be clarified. Apart from the link between angiogenesis and hypoxia, 
angiogenic factors per se may interfere with radiosensitivity by inhibiting X-ray-
induced apoptosis: VEGF is known to suppress rray-induced apoptosis in both CMK86 
cells and normal haematopoietic stem cells (Katoh et al. , 1995). Furthermore, basic 
fibroblast growth factor has been shown to protect endothelial cells from radiation-
induced apoptosis via a protein kinase C mediated mechanism (Haimovitz-Friedman et 
al., 1994), and hepatocyte growth factor/scatter factor protects breast cancer cells from 
radiation-induced apoptosis by targeting the anti-apoptotic mitochondrial membrane 
protein Bci-XL (Fan et al. , 1998). Angiogenesis is closely regulated by a broad range of 
stimulators and inhibitors (Pepper et al., 1996). p53, which is essentially involved in 
cell cycle control, DNA repair and the regulation of apoptosis (Agarwal et al., 1998), 
also contributes to the regulation of angiogenesis: Loss of functional p53 leads to 
reduced expression of thrombospondin-1 (TSP-1) (Dameron et al., 1994), a key 
inhibitor of angiogenesis (Tuszynski and Nicosia 1996). Mutant p53 has been shown to 
upregulate the expression of vascular endothelial growth factor (VEGF) (Kieser et al. , 
1994), which has a pivotal role in triggering angiogenesis (Ferrara and Keyt, 1997). 
Two antibodies to endothelial cells were chosen. CD31 is recognized to be the most 
sensitive and specific endothelial cell marker (Miettinen et al., 1994). With the notable 
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exception of macrophages and platelets, CD31 expression is not seen in any other non-
endothelial tissue. Care was taken to distinguish between true endothelial CD31 
immunostaining and that of macrophages. This is because the staining of macrophages 
is distinctly granular whilst the staining of endothelial cells is intensely cytoplasmic 
with linear membranous staining. The function of CD34, a transmembrane glycoprotein 
is unknown, however, it is recognised to stain non-endothelial cells including 
macrophages, haemopoietic stem cells and dendritic cells seen around blood vessels, 
nerve sheath and within the dermis (van de Rijn and Rouse, 1994). 
This study showed that, the degree of angiogenesis and macrophages infiltration 
exhibited no marked difference in the average count of CD31 , CD34, and CD68 in 
patients responded and those who did not respond to radiotherapy. 
Both markers for angiogenesis (CD31 &CD34) were expressed in all slides in this study. 
The median for CD31 count was 4.3 for responded patients and 4.3 for non-responded 
patients. Whilst the median for CD34 counts was 4.6 for responded patients and 4.6 for 
non-responded patients. 
This study showed a strong positive Spearman correlation between MVD quantified by 
both CD31 and CD34, suggesting that both are reliable methods of quantifying 
angiogenesis in muscle invasive bladder TCC. 
Staining with CD31 showed no association between MVD and stage, grade or site of the 
tumour. In the case of CD34 a statistically difference was found in MVD for tumour 
stage but not grade. Sagol et al., 2001 reported increased MVD association with high 
grade of tumour. On the contrary, Krupski et al. , 2000 demonstrated that MVD did not 
significantly correlate with clinical stage while tumour grade did. 
The data showed no association between MVD and p53 expression, which contradicts 
the finding of Bochner et al. , 1997. They found a significant association between p53 
status and MVD in 161 cystectomy specimens. 
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No significant correlation between MVD and macrophage infiltration was found in 
these data. This is in contrast to the finding of Hanada et al., 2000. These authors 
reported a positive correlation between T AM count and MVD. However, out of their 
total of 63 bladder cancer only 23 were muscle invasive tumours whilst the data 
presented here is from I 01 muscle invasive tumours. 
Increased MVD counts have been associated with tumour progression and decreased 
overall survival in many studies (Srivastava et al. , 1988; Barnhill et al. , 1992; Weidner 
et al. , 1992; Horak et al. , 1992; Weidner et al., 1993; Brawer et al., 1994; Bochner et 
al., 1995; Jaeger et al., 1995; Dickinson et al. , 1994; O 'Brien et al. , 1995; Campbell et 
al., 1997). 
The data presented here do not support these finding as MVD did not predict either 
response to radiotherapy or overall survival. However, in this series it was only possible 
to analyse crude survival and not disease specific survival owing to incomplete clinical 
records. 
There are important methodological considerations related to staining technique, which 
must be taken into account when using MVD in tnis way. Firstly, the method of antigen 
retrieval can markedly affect the visualisation of blood vessels in tissue sections. 
Secondly, the choice of primary anti-endothelial antibody (e.g. CD31 , CD34 or vWF) 
can profoundly influence intensity of staining and thus blood vessel counts in tissue 
sections. In the past majority of investigators have used anti-vWF antibody, a pan 
endothelial marker, to quantify tumour MVD. It is now apparent that although this is 
excellent in visualising blood vessels in normal tissues, it may not stain some 
microvessels within and in the immediate vicinity of a tumour mass, which can be 
demonstrated by other endothelial markers (Wang et al. , 1994). Endothelial cells are 
highly heterogenous among normal vascular beds in their structure, function, growth 
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rate, antigenicity and pharmacology (Thorin et al. , 1997; Clarke et al., 1997). These 
differences are even more pronounced between normal and tumour associated 
endothelial cells. This may be why anti-CD31 , and not anti-CD34 or anti-vWF, proved 
a better reagent for staining blood vessels in bladder tumours. This is in contrast with 
observation made in colorectal tumours where it has been found that anti-CD34 
antibody produced stronger and more localised staining compared with anti-CD3 1 
antibody (Abdalla et al. , unpublished data). In other studies results of a panel of 5 anti-
endothelial antibodies (CD31 , CD34, CD 105, vWF and PALE) have been compared to 
quantify MVD in breast carcinomas (Wang et al. , 1994). Anti-CD 105 antibody was by 
far the best antibody in the visualisation of microvessels. If similar observation is made 
in other tumour types, it will have important practical implications, in that a single 
antibody may not be suitable reagent to visualise blood vessels in all types of tumours. 
For future studies we suggest that, prior to examining MVD in tumour, a panel of anti-
endothelial antibodies should be screened to identify the one, which will reliably stain 
blood vessel in and around the tumour. 
Angiogenesis was initially thought to be induced only by tumour cells themselves. 
However, it is likely that certain stromal components are also involved in the regulation 
of tumour behaviour. Among these, macrophages have been previously shown to play 
an important role in tumour angiogenesis as well as inflammatory reactions 
(Sunderkotter et al., 1994; Leek et al. , 1994). It has been shown that TAM secrete a 
wide range of cytokines, many of which have direct growth promoting properties on 
tumour cells (Leek et al., 1994; O'Sullivan et al. , 1993). Tumour associated 
macrophages also produce several ang10gemc factors, such as VEGF and bFGF, 
suggesting that these cells may be involved in tumour vascularization and/or 
invasiveness via these cytokines (Lewis et al., 1995; Scannel et al. , 1993). 
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CD68 expression was detected in all our slides and the CD68 labelling index (LT) 
ranged from 23 .8% to 67.2% (mean 41.29%, SD 10.38) for none responders and 20% to 
65.4% (mean 43 .38, SD 11.00) for patients who did respond to EBRT. CD68 labelling 
index showed no statistically significant differences between patients responded and 
those who did not respond to radiotherapy. 
The T AM count (CD68) did not predict stage or grade of the tumour or the response to 
EBRT in this study. We also found no positive correlation between T AM count and 
microvessel density count (CD3l&CD34). These results do not support finding by 
Hanada et al., 2000 and Leek et al. , 1996. They observed a positive correlation between 
T AM count and microvessel density count. 
The T AM count did however significantly predict crude survival, patients with higher 
counts(> 42) having a longer survival (Kaplain-Meir, p=0.036). Our results suggest that 
determination ofT AM count in muscle invasive bladder cancer tissues is of value to 
predict the survival in patients with bladder cancer. This is the opposite of the findings 
of Hanada et al., 2000. These authors found that the 5 year survival rate was 
significantly worse in patients with higher T AM counts. 
Treatment duration 
Reducing overall treatment time is another approach founded in the radiobiological 
results of tumour repopulation during the course of treatment (Hopkins and Looney 
1987). Split course in other tumour sites has been abandoned because longer treatment 
time has resulted in decreased tumour control (Overgaard et al. , 1988). This was not 
found in a randomised trial by Marcial et al. , 1985 and Salminen, 1989. They found no 
difference in response, long-term local control or survival. Decreased tumour control 
has been found in one retrospective study, where the 5 year survival of patients treated 
continuously were 35% in comparison to 22% when a split of 2-3 weeks were allowed 
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(Davidson et al., 1990). This was approved in another study in which data suggested 
that increased overall treatment time allowing accelerated tumour repopulation may 
decrease tumour control in transitional bladder cancer (Maciejewski et al., 1991 ; 
Plataniotis et al., 1994). 
The data presented in this study show that survival time was significantly better in 
patients whose treatment was fractionated over a longer period(> 33 days). 
Haemoglobin 
Radiobiologic studies suggest that anemia may cause or contribute to resistance to 
radiation therapy by increasing the hypoxic tumour fraction (Gray et al., 1953; Rubin 
and Casarett, 1968; Hirst, 1986). However, dose escalation to overcome the relative 
radioresistance of hypoxic cells is limited by the resultant risk of increased toxicity to 
the adjacent normal tissues. Measures aimed at overcoming tumour hypoxia that have 
been investigated include the use of hypoxic cell sensitizers (Dische, 1985; Overgaard 
et al., 1989; Overgaard and Horsman, 1996; Grigsby et al., 1999), hyperbaric oxygen 
(Dische and Anderson 1983), perfluorochemicals, and carbogen breathing (Song et al. , 
1985), hypoxic cell toxins (Brown, 1993) or blood transfusions (Vigario et al., 1973; 
Bush, 1984; Girinsky et al. , 1989; Fyles et al., 1995; Pedersen et al., 1995; Grogan et 
al., 1999) and more recently, by treating with recombinant human erythropoietin 
(Vijayakumar et al., 1993; Dusenbery et al., 1994). Although blood transfusions have 
proven effective in raising haemoglobin levels and relieving clinical symptoms of 
anemia, their effect on prognosis is still unclear and controversial. 
In some studies, the level of serum haemoglobin before therapy is considered as an 
indicator that should reflect the patient' s general condition better than the performance 
status itself (Dunst et al. , 1994; Pollack et al., 1994; Gospodarowicz et al. , 1989). 
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Pollack et al., 1994 managed to prove the independent prognostic value of haemoglobin 
level for the overall survival as well as for the local control of disease in patients treated 
by cystectomy after previous radiotherapy, while the prognostic value of haemoglobin 
level in patients treated by radiotherapy alone was not clearly confirmed, considering 
the controversy of those reports (Pollack et al., 1994; Gospodarowicz et al. , 1989). A 
group of investigators from Erlangen (Dunst et al., 1994) has confirmed the prognostic 
value of haemoglobin in patients treated by conservative approach. In a study carried 
out by Matos et al., 2000 that serum haemoglobin level failed to be associated with 
statistically significant differences in the disease specific survival. 
In our study, serum haemoglobin level found to be hjgher in patients responded to 
EBRT. On the other hand, serum haemoglobin level had no significant effect on 
survival in our patients. 
Gender 
A surprise finding was that female responded less well to EBRT than male. Although 
appearing to be statistically significant, out of 101 patients in total only 11 were female 
and this finding should be interpreted with caution. Comparable results from Sumiyoshi 
et al., 1994 that found the frequency of complete response was significantly different 
according to the sex (males 64%, females 29%; p=0.0239). Even though appearing to be 
statistically significant, patients were treated with a combination of intra-arterial 
chemotherapy and low dose radiotherapy. 
There was an insignificant trend to longer overall survival in males, compared to 
females in this study. It would be interesting to look at a large numbers to see if this 
finding is of significance. Similar findings found in a study carried out by Scrimger et 
al., 200 1 and Harada et al., 2000. 
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4.2 Conclusion 
Although, muscle invasive transitional cell carcinoma of the bladder was intensively 
investigated in this study, none of the selected markers was proven to be a prognostic 
value in determining patients most suitable for radiotherapy as primary treatment with 
curative intent for their bladder cancer. Moreover, standardization and reproducibility 
are still major difficulties that hinder the clinical application of these biomarkers. 
However, their potential applicability cannot be ignored and should be investigated 
further. Whether these biological markers can be used as predictors of radiosensitivity 
in muscle invasive bladder TCC remain to be proven in larger and preferentially 
prospective studies. 
The finding of a poorer response in females is also worthy of detailed study since, 
hormonal and anatomical influences may be important. 
191 
APPENDIX 
RESULTS 
Data was tested for nonnality using Kolmogorv-Smimov test. Data with p value of >0.05 
are normally distributed. The table below shows that only CD68 and MIB1 are normally 
distributed. 
Test of Normality 
Kolmogorov-Smimov 
p-value 
CD31 0.001 
CD34 0.007 
CD68% 0.200 
p53 expression% 0.020 
MIB-1% 0.166 
Haemoglobin level 0.031 
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Section one 
The chi-square tests show no evidence of association between p53 positive or negative and 
response to EBRT (Tab. 1a&b). 
Tab. la. p53 and response to radiotherapy 
Response to Radiotherapy Total 
No response Complete 
response 
Negative Count 2 9 11 18.2% 81.8% 100.0% p53 44 46 90 
Positive Count 48.9% 51.1% 100.0% 
Total Count 
46 55 101 
45.5% 54.5% 100.0% 
Tab. lb. Chi-Sguare Tests 
Value df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) (1-sided) 
Pearson Chi-Square 3.727 I 0.054 
Continuity Correction 2.591 1 0.107 
:uikelihood Ratio 4.060 l 0.044 
!Fisher's Exact Test .062 .05 1 
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p53 and stage o(tumour 
There was no significant association between p53 (positive-negative) and tumour stage by 
means ofchi-square (p=0.862) (Tab. 2a&b). 
Tab. 2a. p53 by stage of tumour 
Stage of Tumour Total 
Stage II Stage Ill 
Negative 6 5 11 
p53 
Positive 42 48 90 
Total 48 53 lOI 
Tab. 2b. Chi-Square Tests 
Value Df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) (I-sided) 
IPearson Chi-Square 
.244 1 .62 1 
~ontinuity Correction 
.030 I 0.862 
!Likelihood Ratio 
.244 I .622 
!Fisher's Exact Test .753 .430 
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p53 and Grade o{tumour 
There was no significant association between p53 (positive-negative) and tumour grade by 
means of chi-square (p=0.757) (Tab.3a&b). 
Tab. Ja. p53 by Grade of tumour 
Grade of tumour Total 
Grade II Grade Ill 
p53 Negative 2 9 11 
Positive 9 81 90 
Total 11 90 101 
Tab. Jb. Chi-Sguare Tests 
Value df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) (1-sided) 
!Pearson Chi-Square .676 1 .411 
~ontinuity Correction 0.096 1 0.757 
[Likelihood Ratio .589 1 .443 
!Fisher's Exact Test .342 .342 
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p53 (positive-negative ) and angiogenesis 
p53 (positive-negative) is not correlated (Spearman correlation) with CD31 (r=0.136, 
p=0.174) and CD34 (r=0.087, p=0.387) (Tab. 4a). 
Tab. 4. Correlation between p53 (positive-negative) and MVD in bladder TCC: 
Tumour Tumour 
. . . . 
angwgenes1s angiOgenesis 
CD31 CD34 
p53 (positive-negative) Correlation coefficient 0.136 0.087 
expression in bladder Sig. (2-tailed) 0.174 0.387 
TCC N 101 101 
p53 (positive-negative) and MIB-1 
There was no significant Spearman correlation between p53 (positive-negative) and MIB-1 
LI (r= -0.029, p=0.774) (Tab. 5). 
Tab. 5. Correlation between p53 (positive-negative) and MIB-1 in bladder TCC: 
Proliferation of 
tumour cells 
MIBl % 
p53 (positive-negative) Correlation coefficient -0.029 
expression in bladder Sig. (2-tailed) 0.774 
TCC N 101 
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p53 (positive-negative ) and haemoglobin 
p53 is not correlated (Speannan correlation) with haemoglobin level (r= -0.070, p=0.488) 
(Tab. 6). 
Tab. 6. Correlation between p53 (positive-negative) and haemoglobin level in bladder 
TCC: 
haemoglobin 
level 
p53 (positive-negative) Correlation coefficient -0.070 
expression in bladder Sig. (2-tailed) 0.488 
TCC N 101 
p53 (oositive-negative) and CD68 
There was no significant positive Speannan correlation between p53 and CD68 (r= -0.006, 
p=0.951)(Tab. 7). 
Tab. 7. Correlation between p53 and CD68 (LD in bladder TCC: 
Tumour 
macrophage 
CD68 
p53 (positive-negative) Correlation coefficient -0.006 
expression in bladder Sig. (2-tailed) 0.951 
TCC N 101 
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p53 and Bcl-2 
No significant association was found between p53 (positive-negative) and Bcl-2 using Chi-
Square tests (p= 0.862) (Tab. 8a&b). 
Tab. Sa. p53(positive-negative) by Bcl-2. 
p53 Total 
Negative Positive 
Positive 6 42 48 
Bcl-2 
Negative 5 48 53 
Total 11 90 101 
Tab. 8b. Chi-Sguare Tests. 
Value df Asymp. Sig. Exact Sig. Exact Sig. 
(2-sided) (2-sided) (1-sided) 
IPearson Chi-Square .244 1 .621 
!Continuity Correction .030 1 0.862 
fLikelihood Ratio .244 1 .622 
!Fisher's Exact Test .753 .430 
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Section two 
The chi-square test for association between EBRT and p53 (positive-negative) shows no 
statistical evidence of that association (Tab. 9a&b). 
Tab. 9a. p53 by response to EBRT. 
Response to radiotherapy Total 
Failed Enduring complete 
treatment response 
Negative 5 10 15 
p53 
Positive 54 32 86 
Total 59 42 101 
Tab. 9b. Chi-Sguare Tests 
Value df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) (1 -sided) 
Pearson Chi-Square 4.562 1 .033 
Continuity Correction 3.430 1 0.064 
Likelihood Ratio 4.515 1 .034 
Fisher's Exact Test .046 .033 
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p53 (positive-negative) has also been tested against stage and grade of tumour by means of 
chi-square but there were no significance (Tab. lOa&b, Tab. lla&b). 
Tab. lOa. p53 by grade of tumour 
Grade of tumour Total 
grade II grade Ill 
Negative 2 13 15 
p53 
Positive 9 77 86 
Total 11 90 101 
Tab. lOb. Cbi-Sguare Tests 
VaLue df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) ( 1-sided) 
IPearson Chi-Square .108 1 .742 
!Continuity Correction .000 1 1.000 
!Likelihood Ratio .103 1 .748 
Fisher's Exact Test .666 .5 12 
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Tab. lla. p53 by stage of tumour 
Stage of Tumour Total 
Stage II Stage III 
Negative 7 8 15 
p53 
Positive 41 45 86 
Total 48 53 101 
Tab. llb. Chi-Sguare Tests 
Value df Asymp. Sig. Exact Sig. Exact Sig. (2-sided) (2-sided) (1-sided) 
IPearson Chi-Square .005 1 .943 
~ontinuity Correction .000 1 1.000 
~ikelihood Ratio .005 1 .942 
!Fisher's Exact Test 1.000 .583 
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Fig. 1. Survival time by p53: p53 has no effect on survival. 
1.2 
1.0 
.8 
.6 
.4 
p53 
.2 0 Positive (ij 
> -~ + Positive-censored 
::J 0.0 
en 
E 
0 Negative 
::J 
-.2 (_) + Negative-censored 
0 1000 2000 3000 4000 
Survival time in days (sig. Log Rank 0.780) 
Fig. 2. Scatter plot ofMIB-1 Vs MVD (CD34): 
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Fig. 3. Scatter plot of haemoglobin level Vs MVD (CDJl): 
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Fig. 4. Scatter plot of p53Vs MVD (CD31): 
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Numb. Age Sex Stage Grade Radio.total Num. Days Cysto Last point Start.Rad. Alive CD 31 CD 34 CD68 bcl-2 p53 M1B1 Hb Site dos. Frac. .Res. review % % % 
1 62 1 2 2 60 30 49 1 28.12.94 25.4.94 1 4 3.6 49.9 1 60.4 93.8 16 3 
2 74 1 2 3 60 30 44 1 23.5.98 5.8.92 2 2.3 5 33.8 2 51.9 81.2 15.2 3 
3 71 1 3 3 54 20 32 1 3.7.95 15.12.94 1 3.3 5.3 30.2 1 59. I 44.2 12.5 2 
4 79 2 2 3 50 20 27 1 29.11.95 18.1.95 1 4.6 3.6 46.9 I 77.I 96.3 12.8 3 
5 53 1 3 3 60 30 42 1 I8.12.94 24.5.93 1 4.6 4.3 47 1 43.9 69 11.4 I 
6 75 1 3 3 54 20 32 1 I0.12.94 7.3.94 1 3 3.3 37.7 1 88.3 51.4 10.1 1 
7 55 2 3 3 54 20 30 1 4 .4.1995 1.3.94 1 2.6 3.6 40 I 64.5 68.2 13.4 2 
8 73 2 3 3 50 25 38 1 22.3.94 28.9.93 l 4 3.3 30.4 1 81.6 96.9 11 2 
9 76 1 3 3 50 25 32 1 28.2.94 16.11.92 1 3.3 3.6 32.1 1 21 64.2 11.1 3 
10 76 1 3 3 54 20 27 1 30.9.92 3.6.92 1 5.3 4.6 34.9 2 95.9 72.8 12.9 3 
11 75 2 3 3 54 20 27 1 30.9.94 8.7.92 1 6.6 6.6 47.7 I 96.2 91 9.8 2 
12 50 2 3 3 54 20 32 1 17.9.98 7.5.92 2 5.6 5 25 I 85.4 67.8 14.4 1 
13 78 1 3 2 60 30 43 1 15.8.93 9.3.92 1 5.6 5.3 30.2 1 41.5 33.8 11.1 1 
14 76 1 2 3 54 20 25 I 20.11.98 24.2.92 2 3.3 3.3 34.9 2 37.7 34.1 15.4 3 
15 81 1 2 3 60 30 41 1 1.3.93 13.6.91 1 5.6 6 67.2 1 63.5 54.3 13 2 
16 70 1 2 3 54 20 28 1 25.1.94 10.6.91 1 5 5.3 35.6 1 85.5 74.5 12.9 2 
17 70 1 3 3 60 30 49 1 28.9.91 19.2.90 1 5 3.6 57.9 2 59 40.6 13.8 2 
18 56 2 3 3 58 29 42 1 19.11.93 16.11.89 1 3 3.3 60.8 2 51.9 76.2 13 3 
19 74 2 3 3 60 30 44 1 6.10.89 21.3.89 1 4 4.6 36.7 2 59.7 69.9 9.6 3 
20 64 1 3 3 60 30 44 1 19.10.97 16.8.89 1 5 5 48.6 2 63.3 79.3 13.8 3 
21 74 1 2 3 54 20 29 1 10.2.92 19.9.89 1 6.3 4.6 50.2 2 99.8 82.1 13.2 2 
22 55 2 3 3 58.8 29 31 1 19.11. 93 16.11.89 1 5.3 4.3 41.8 2 82.5 59.4 13 1 
23 64 1 3 3 60 30 45 I 24.11.88 I5.8.88 1 3.6 4.3 32.1 2 56.4 71.9 13.2 3 
24 74 1 3 2 60 30 45 1 24.1.90 10.3.89 I 3.3 2.6 26.5 2 0 46.2 14.4 1 
25 46 1 2 3 60 30 43 1 18.9.91 27.4.89 1 3.6 4.6 39.8 2 98.8 80.4 13.4 2 
26 73 1 2 3 52 20 28 1 12.4.1992 3.1.1990 1 3 5 41 1 52.8 70.6 10.9 3 
27 69 1 2 2 52.5 20 25 1 3.5.99 24.1.1990 2 4 3.3 so 1 80.8 90 12.7 2 
28 70 1 3 3 50 20 38 1 15.11 .1 990 28.3.1990 1 4.3 5.6 26 2 67.5 60.1 11.3 2 
29 65 1 3 2 55 20 27 1 14.4.99 5.6.1990 2 3 4.3 37.6 1 70 50.4 9.3 3 
30 61 1 2 3 52 20 27 1 22.4.1993 8.8.1991 1 5 4.6 40 1 74.5 52.2 13.4 2 
31 52 1 3 3 55 20 33 1 26.5.99 18.9.1991 2 4.3 3.6 58.2 2 81 .5 80.8 13.5 2 
32 80 1 2 3 52 20 26 1 14.12.1993 27.9.1991 1 5 5.6 32.1 2 51.9 69.8 14.3 3 
33 66 1 2 3 52 20 32 1 11.9.1992 5.12.1991 1 3.6 4.6 42 2 42.2 73.6 10.4 2 
34 80 1 2 3 52 20 34 1 5.12.1996 28.1.1992 1 4.6 4.3 45.6 2 69.9 54.1 12.2 1 
35 68 1 3 3 55 20 25 1 13.6.1994 20.2.1992 1 3 3 .3 39.3 1 86.4 70.3 10.5 3 
36 76 2 3 3 52 20 38 1 15.3.99 4.3.1992 2 5 6 31.1 2 54.1 66.7 12.2 3 
37 72 1 2 3 52 20 32 1 4.12.1994 9.4.1992 1 6.6 5.6 23.8 2 37.6 69.4 11.5 1 
38 74 1 2 3 52 20 35 1 9.2.1994 17.6.1992 1 3 3.3 45.5 1 64.8 59.5 14.3 1 
39 73 2 3 3 52 20 35 1 16.4.1993 3.1 2.1992 1 5.3 4.6 44.3 2 72.7 49.2 12.3 2 
40 86 1 3 3 50 20 29 1 16.2.1994 26.5.1993 1 4 5 51.9 1 80 78.9 12.8 3 
41 85 1 2 2 50 20 27 1 7.3.1996 7.6.1993 1 5.3 5.6 59.7 1 80.1 83.4 11.4 3 
42 73 1 2 3 52 20 29 1 30.5.99 7.7.1993 2 3.3 4.6 31.1 1 57.4 52.8 11.8 2 
43 59 2 3 3 52 20 33 1 24.4.99 26.8.1994 2 6 3.6 56.5 2 32.7 85.9 12.2 3 
44 76 1 3 3 52 20 29 1 8.3.1996 10.9.1994 1 7 5 37.8 1 31.1 55.8 14.8 3 
45 75 1 2 3 50.2 20 27 1 3.5.99 19.9.1994 2 3.3 4 41 .3 1 70.3 45.6 10.2 1 
46 59 1 2 3 55 20 25 1 12.2.99 22.12.1995 2 5.6 7 46.5 1 0 69.2 8.6 1 
47 89 2 2 3 50 20 27 2 28.6 .96 2.11 .94 1 3 3 .6 51 .7 1 0 76.7 12 2 
48 71 1 2 3 54 20 32 2 24.8.98 14.5.92 2 4.3 3.6 42.6 1 45.5 51 .9 14.3 2 
49 67 1 3 3 54 20 27 2 17.10.98 7.1.93 2 5.3 4.6 32.4 1 85.5 80 15.4 2 
50 74 1 2 2 54 20 29 2 25.11 .98 25.3.91 2 4.6 5.3 42.7 1 99.8 80 14.4 1 
51 68 1 3 3 60 30 48 2 10.5.97 23.5.89 1 5.3 4.3 61 .2 2 74.1 67.7 13.7 3 
52 75 2 3 3 60 30 52 2 4.8.92 13.11.89 1 5.3 4 47.5 2 41 .3 72.9 14.1 3 
53 56 2 2 2 52 20 28 2 2.5.99 23.11 .89 2 3 2 50.8 2 34.2 63.3 13.5 1 
54 34 1 2 3 57.5 23 32 2 8.3.91 3.7.89 2 5.6 4.6 36.3 2 61 .8 80.1 11 .5 2 
55 72 1 3 3 52 20 34 2 23.8.93 2.1.92 1 3.3 3.3 39 2 70.7 56.9 14.2 3 
56 68 1 3 3 60 30 41 2 10.4.94 8.2.89 1 5.3 5 30.3 1 0 97.5 10.5 3 
57 55 1 2 3 52 20 32 2 3.9.97 18.2.92 1 3.3 5.6 49.5 2 87.4 76.6 13 1 
58 79 1 2 3 52 20 36 2 26.1.97 3.12.91 1 3.3 5.6 26.7 1 84.8 67.3 11 .6 3 
59 77 1 3 3 52 20 35 2 22.5.94 12.3.93 1 4.3 4.6 34.8 2 54.5 68.3 12.3 2 
60 75 1 2 3 54 20 28 2 2.5.98 10.2.94 1 4.3 5.6 57.5 2 35.2 74 12.7 1 
61 64 1 2 3 54 20 29 2 5.4.96 26.4.94 1 3.6 3.3 26.5 2 90.7 74.8 13.6 2 
62 70 1 3 3 54 20 32 2 23.4.94 12.8.93 1 3 2.3 20 1 99.3 84.3 12.7 3 
63 52 1 2 3 54 20 28 2 26.7.95 26.7.94 1 3 2 .6 54.2 1 0 54.7 14 3 
64 74 1 3 3 54 20 32 2 19.2.97 21 .12.94 1 4 2.6 25.8 2 43.4 62.2 13.1 3 
65 76 1 2 3 60 30 43 2 20.10.98 23.2.95 2 3.3 4 21 1 0 69 13.9 1 
66 77 1 2 3 50 20 28 2 3.11 .96 8.2 .95 1 4.3 3.3 36.1 2 15 55.2 14.3 1 
67 78 1 2 3 50 20 29 2 2 .6 .96 31 .3.93 1 3.6 2.6 44.1 1 63.5 65.5 10.1 3 
68 69 1 3 3 54 20 29 2 10.8.98 12.8.93 2 2.6 3 31.4 2 68.3 65.3 12.7 3 
69 76 1 3 3 50 20 27 2 24.1 .94 10.6.93 1 4.6 2 .6 44.6 2 99.8 98.6 12.7 1 
70 69 1 3 3 50 20 27 2 4.11 .94 4.6 .92 1 3 2.6 31 .2 2 20 41 .4 13.9 3 
71 60 1 2 2 54 20 29 2 7.11.98 19.8.92 2 5 .6 7.6 30 1 96 73.1 12.2 1 
72 56 1 2 3 54 20 30 2 3.2.99 14.12.92 2 6.6 5.6 31.9 1 64.8 32.7 13.1 3 
73 85 1 2 3 54 20 28 2 11 .12.91 8.5.90 1 3.6 4.3 49 2 0 60 11.8 1 
74 86 2 3 3 60 30 46 2 21 .9.92 20.12.90 1 4.3 3.6 59.1 1 31.1 40 13.3 3 
75 79 1 3 3 58 26 37 2 10.5.95 8.1 1.88 1 4.3 4.6 42.1 2 63.6 50.6 11 .8 2 
76 36 1 2 3 60 30 43 2 3.4.99 22.2.89 2 5.6 6 .6 56.2 2 72.6 34.6 15.3 1 
77 72 1 3 3 54 20 31 2 5.1.99 19.12.89 2 5 4.3 55.4 1 0 66.3 14.8 3 
78 54 1 3 3 60 30 43 2 26.4 .94 25.4.89 1 3.3 3.3 50.8 2 35.5 52.8 13.4 3 
79 71 1 3 3 60 30 43 2 7.1 1 .1 994 12.7.1989 1 4.3 5.6 56.5 1 85.7 88 9.4 3 
80 75 1 3 2 52 20 29 2 7.7 .1994 24.1 0.1989 1 3.3 3.6 42.2 2 0 33.2 12.5 3 
81 62 1 3 3 60 30 42 2 30.10.98 31 .1.1990 2 4 4.6 43.4 2 56.1 75.2 14.7 3 
82 72 1 3 3 52 20 31 2 8.3.1991 2.5 .1990 1 5.3 5 35.2 2 59.4 82.4 13.7 2 
83 78 1 3 3 52 20 25 2 31 .8.1 995 15.5.1990 1 4.3 5.3 45.8 1 74.7 93.3 12.5 3 
84 66 2 3 3 52 20 27 2 28.12.1993 15.5.1990 1 3.3 4.3 40.5 2 20 60.6 13.1 3 
85 67 1 3 3 52 20 30 2 10.2.1 995 11 .6 .1990 1 6.6 5.6 65.4 2 80 65.9 12 2 
86 76 1 3 3 52.5 20 30 2 12.5.1 991 1.8 .1990 1 4 5.3 35.5 1 66.1 69.7 12.4 2 
87 72 1 2 3 52 20 29 2 4.2.99 14.2 .1992 2 5.6 6 47.6 1 42.2 70.2 14.3 2 
88 77 1 2 3 52 20 29 2 2.3.99 24.2 .1992 2 5.3 5.3 55.8 2 89.8 64.7 14.1 3 
89 64 1 3 3 52 20 35 2 13.2.99 4.9 .1992 2 3.6 5.6 51.2 2 0 81 16.7 1 
90 64 1 2 3 52 20 25 2 15.3.99 3.6 .1993 2 5.6 6 .6 49.2 2 70.2 49.2 13.4 2 
91 59 1 2 3 50 20 30 2 30.1.99 28.11.1 993 2 5 6.6 47.3 2 89.3 88.4 14.5 2 
92 69 1 2 3 52 20 27 2 22.3.99 20.1.1994 2 6 .3 6 .6 52.3 2 67.5 78 .6 13 3 
93 69 1 2 3 50 20 33 2 12.8.1995 30.3.1994 1 6 7.6 40 2 65.9 75.1 10.5 3 
94 68 1 2 3 52 20 27 2 24.3.99 27.4.1 994 1 3.6 3.3 30 2 0 78.7 14.1 2 
95 76 1 2 3 52 20 29 2 10.2 .99 15.9.1 994 2 7 8.6 44 1 84.2 77.5 13.6 3 
96 81 1 2 2 59 20 27 2 2.2 .99 23.9.1 994 2 4.3 2 .6 57.9 1 87.9 76.6 13.9 3 
97 84 1 2 3 52 20 31 2 20.5.1 996 14.12.1994 1 3.6 5.6 57.4 1 64 56 10.1 1 
98 73 1 3 3 55 20 26 2 16 .3.99 3.5.1 995 2 4.3 5 38 1 53.7 72.5 13.8 3 
99 66 1 2 3 52 20 29 2 22.2.99 5.9.1995 2 5.6 5 56.1 1 42.2 72 13.1 1 
100 63 1 3 3 60 30 44 2 3.1 .90 27.7.88 1 5 5 48.1 2 34.9 45.6 10.2 3 
101 67 1 3 3 54 21 49 2 23.3.99 22.9.1992 2 4 5.3 34.1 2 39.4 55.2 14.7 1 
Numb. Age Sex Stage Grade Radio.total Nwn. Days Cysto.Res. Last point dos. Frac. review 
1 62 I 2 2 60 30 49 I 28.12.94 
2 74 1 2 3 60 30 44 1 23.5.98 
3 7I 1 3 3 54 20 32 l 3.7.95 
4 79 2 2 3 50 20 27 I 29.11.95 
5 53 I 3 3 60 30 42 1 18.12.94 
6 75 I 3 3 54 20 32 1 10.12.94 
7 55 2 3 3 54 20 30 1 4.4.1995 
8 73 2 3 3 50 25 38 1 22.3.94 
9 76 1 3 3 50 25 32 1 28.2.94 
10 76 1 3 3 54 20 27 1 30.9.92 
11 75 2 3 3 54 20 27 1 30.9.94 
12 50 2 3 3 54 20 32 1 17.9.98 
13 78 1 3 2 60 30 43 1 15.8.93 
14 76 1 2 3 54 20 25 1 20.11.98 
15 81 1 2 3 60 30 41 1 1.3.93 
16 70 1 2 3 54 20 28 1 25.1.94 
17 70 1 3 3 60 30 49 1 28.9.9 1 
18 56 2 3 3 58 29 42 1 19.11.93 
19 74 2 3 3 60 30 44 1 6.10.89 
20 64 1 3 3 60 30 44 1 19.I0.97 
21 74 1 2 3 54 20 29 1 10.2.92 
22 55 2 3 3 58.8 29 31 l 19.11.93 
23 64 1 3 3 60 30 45 1 24.11.88 
24 74 1 3 2 60 30 45 I 24.1.90 
Start.Rad Alive CD 31 CD 34 CD68 
25.4.94 l 4 3.6 49.9 
5.8.92 2 2.3 5 33.8 
15.12.94 l 3.3 5.3 30.2 
I8.1.95 1 4.6 3.6 46.9 
24.5.93 1 4.6 4.3 47 
7.3.94 1 3 3.3 37.7 
1.3.94 1 2.6 3.6 40 
28.9.93 l 4 3.3 30.4 
16.11.92 1 3.3 3.6 32.1 
3.6.92 1 5.3 4.6 34.9 
8.7.92 1 6.6 6.6 47.7 
7.5.92 2 5.6 5 25 
9.3.92 1 5.6 5.3 30.2 
24.2.92 2 3.3 3.3 34.9 
13.6.91 1 5.6 6 67.2 
10.6.91 1 5 5.3 35.6 
19.2.90 1 5 3.6 57.9 
16.11.89 1 3 3.3 60.8 
21.3.89 1 4 4.6 36.7 
16.8.89 1 5 5 48.6 
19.9.89 1 6.3 4.6 50.2 
16.I l.89 1 5.3 4.3 41.8 
15.8.88 1 3.6 4.3 32.1 
I0.3.89 1 3.3 2.6 26.5 
bcl-2 P53 MIB1 
1 60.4 93.8 
2 51.9 81.2 
1 59.1 44.2 
1 77.1 96.3 
1 43 .9 69 
I 88.3 51.4 
1 64.5 68.2 
1 81.6 96.9 
1 21 64.2 
2 95.9 72.8 
1 96.2 91 
1 85.4 67.8 
1 4l.5 33 .8 
2 37.7 34.1 
1 63.5 54.3 
1 85.5 74.5 
2 59 40.6 
2 51.9 76.2 
2 59.7 69.9 
2 63.3 79.3 
2 99.8 82.I 
2 82.5 59.4 
2 56.4 71.9 
2 0 46.2 
Hb 
16 
15.2 
12.5 
12.8 
11 .4 
10.1 
13.4 
11 
11.1 
12.9 
9.8 
14.4 
1l.L 
15.4 
13 
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13.8 
13 
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13.8 
13.2 
13 
13.2 
14.4 
Site 
3 
3 
2 
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1 
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2 
2 
3 
3 
2 
1 
1 
3 
2 
2 
2 
3 
3 
3 
2 
1 
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00 
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C'l 
25 46 1 2 3 60 30 43 1 18.9.91 27.4.89 1 3.6 4.6 39.8 2 98.8 80.4 13.4 2 
26 73 1 2 3 52 20 28 1 12.4.1992 3.1.1990 1 3 5 41 1 52.8 70.6 10.9 3 
27 69 1 2 2 52.5 20 25 1 3.5.99 24.1.1990 2 4 3.3 50 1 80.8 90 12.7 2 
28 70 1 3 3 50 20 38 1 15.11.1990 28.3.1990 1 4.3 5.6 26 2 67.5 60.1 11.3 2 
29 65 1 3 2 55 20 27 1 14.4.99 5.6 .1990 2 3 4.3 37.6 1 70 50.4 9.3 3 
30 61 1 2 3 52 20 27 1 22.4.1993 8.8.1991 1 5 4.6 40 1 74.5 52.2 13.4 2 
31 52 1 3 3 55 20 33 1 26.5.99 18.9.1991 2 4.3 3.6 58.2 2 81 .5 80.8 13.5 2 
32 80 1 2 3 52 20 26 1 14.12.1993 27.9.1991 1 5 5.6 32.1 2 51.9 69.8 14.3 3 
33 66 1 2 3 52 20 32 1 11.9.1992 5.12.1991 1 3.6 4.6 42 2 42.2 73.6 10.4 2 
34 80 1 2 3 52 20 34 1 5.1 2.1996 28.1.1992 1 4.6 4.3 45.6 2 69.9 54.1 12.2 1 
35 68 1 3 3 55 20 25 1 13.6 .1994 20.2.1992 1 3 3.3 39.3 1 86.4 70.3 10.5 3 
36 76 2 3 3 52 20 38 1 15.3.99 4.3.1 992 2 5 6 31 .1 2 54.1 66.7 12.2 3 
37 72 1 2 3 52 20 32 1 4 .1 2.1994 9.4 .1 992 1 6 .6 5.6 23.8 2 37.6 69.4 11.5 1 
38 74 1 2 3 52 20 35 1 9.2.1994 17.6.1992 1 3 3.3 45.5 1 64.8 59.5 14.3 1 
39 73 2 3 3 52 20 35 1 16.4.1993 3.12.1992 1 5.3 4.6 44.3 2 72.7 49.2 12.3 2 
40 86 1 3 3 50 20 29 1 16.2.1994 26.5.1993 1 4 5 51 .9 1 80 78.9 12.8 3 
41 85 1 2 2 50 20 27 1 7.3.1 996 7.6 .1993 1 5.3 5.6 59.7 1 80.1 83.4 11.4 3 
42 73 1 2 3 52 20 29 1 30.5.99 7.7 .1993 2 3.3 4.6 31 .1 1 57.4 52.8 11.8 2 
43 59 2 3 3 52 20 33 1 24.4 .99 26.8.1 994 2 6 3.6 56.5 2 32.7 85.9 12.2 3 
44 76 1 3 3 52 20 29 1 8.3.1996 10.9.1994 1 7 5 37.8 1 31 .1 55.8 14.8 3 
45 75 1 2 3 50.2 20 27 1 3.5.99 19.9.1994 2 3.3 4 41 .3 1 70.3 45.6 10.2 1 
46 59 1 2 3 55 20 25 1 12.2.99 22.12.1995 2 5.6 7 46.5 1 0 69.2 8.6 1 
47 89 2 2 3 50 20 27 3 28.6 .96 2.11 .94 1 3 3.6 51.7 1 0 76.7 12 2 
48 71 1 2 3 54 20 32 3 24.8.98 14.5.92 2 4.3 3 .6 42.6 1 45.5 51.9 14.3 2 
49 67 1 3 3 54 20 27 3 17.10.98 7 .1.93 2 5.3 4.6 32.4 1 85.5 80 15.4 2 
50 74 1 2 2 54 20 29 3 25.11 .98 25.3.91 2 4.6 5.3 42.7 1 99.8 80 14.4 1 
51 68 1 3 3 60 30 48 3 10.5.97 23.5.89 1 5.3 4.3 61.2 2 74.1 67.7 13.7 3 
52 75 2 3 3 60 30 52 3 4.8.92 13.11 .89 1 5.3 4 47.5 2 41.3 72.9 14.1 3 
53 56 2 2 2 52 20 28 3 2.5.99 23.11 .89 2 3 2 50.8 2 34.2 63.3 13.5 1 
54 34 1 2 3 57.5 23 32 3 8.3.91 3.7.89 2 5.6 4.6 36.3 2 61 .8 80.1 11.5 2 
55 72 1 3 3 52 20 34 3 23.8.93 2.1.92 1 3.3 3.3 39 2 70.7 56.9 14.2 3 
56 68 1 3 3 60 30 41 3 10.4.94 8.2.89 1 5.3 5 30.3 1 0 97.5 10.5 3 
57 55 1 2 3 52 20 32 3 3.9.97 18.2.92 1 3.3 5.6 49.5 2 87.4 76.6 13 1 
58 79 1 2 3 52 20 36 3 26.1.97 3.1 2.91 1 3.3 5.6 26.7 1 84.8 67.3 11 .6 3 
59 77 1 3 3 52 20 35 3 22.5.94 12.3.93 1 4.3 4.6 34.8 2 54.5 68.3 12.3 2 
60 75 1 2 3 54 20 28 2 2.5.98 10.2.94 1 4.3 5.6 57.5 2 35.2 74 12.7 1 
61 64 1 2 3 54 20 29 2 5.4.96 26.4.94 1 3.6 3.3 26.5 2 90.7 74.8 13.6 2 
62 70 1 3 3 54 20 32 2 23.4.94 12.8.93 1 3 2.3 20 1 99.3 84.3 12.7 3 
63 52 1 2 3 54 20 28 2 26.7.95 26.7.94 1 3 2.6 54.2 1 0 54.7 14 3 
64 74 1 3 3 54 20 32 2 19.2.97 21 .12.94 1 4 2.6 25.8 2 43.4 62.2 13.1 3 
65 76 1 2 3 60 30 43 2 20.10.98 23.2.95 2 3.3 4 21 1 0 69 13.9 1 
66 77 1 2 3 50 20 28 2 3.11 .96 8.2.95 1 4.3 3.3 36.1 2 15 55.2 14.3 1 
67 78 1 2 3 50 20 29 2 2.6.96 31 .3.93 1 3.6 2.6 44.1 1 63.5 65.5 10.1 3 
68 69 1 3 3 54 20 29 2 10.8.98 12.8.93 2 2.6 3 31 .4 2 68.3 65.3 12.7 3 
69 76 1 3 3 50 20 27 2 24.1.94 10.6.93 1 4.6 2.6 44.6 2 99.8 98.6 12.7 1 
70 69 1 3 3 50 20 27 2 4.11.94 4.6 .92 1 3 2.6 31 .2 2 20 41 .4 13.9 3 
71 60 1 2 2 54 20 29 2 7.11.98 19.8.92 2 5.6 7.6 30 1 96 73.1 12.2 1 
72 56 1 2 3 54 20 30 2 3.2.99 14.12.92 2 6 .6 5.6 31 .9 1 64.8 32.7 13.1 3 
73 85 1 2 3 54 20 28 2 11 .12.91 8.5.90 1 3.6 4 .3 49 2 0 60 11 .8 1 
74 86 2 3 3 60 30 46 2 21 .9.92 20.1 2.90 1 4.3 3.6 59.1 1 31.1 40 13.3 3 
75 79 1 3 3 58 26 37 2 10.5.95 8.11 .88 1 4.3 4 .6 42.1 2 63.6 50.6 11.8 2 
76 36 1 2 3 60 30 43 2 3.4.99 22.2.89 2 5.6 6.6 56.2 2 72.6 34.6 15.3 1 
77 72 1 3 3 54 20 31 2 5.1 .99 19.12.89 2 5 4 .3 55.4 1 0 66.3 14.8 3 
78 54 1 3 3 60 30 43 2 26.4 .94 25.4.89 1 3.3 3.3 50.8 2 35.5 52.8 13.4 3 
79 71 1 3 3 60 30 43 2 7.11.1994 12.7.1989 1 4.3 5.6 56.5 1 85.7 88 9.4 3 
80 75 1 3 2 52 20 29 2 7 .7.1994 24.1 0.1 989 1 3.3 3.6 42.2 2 0 33.2 12.5 3 
81 62 1 3 3 60 30 42 2 30.10.98 31 .1.1990 2 4 4 .6 43.4 2 56.1 75.2 14.7 3 
82 72 1 3 3 52 20 31 2 8.3.1991 2.5.1990 1 5.3 5 35.2 2 59.4 82.4 13.7 2 
83 78 1 3 3 52 20 25 2 31 .8.1 995 15.5.1990 1 4.3 5.3 45.8 1 74.7 93.3 12.5 3 
84 66 2 3 3 52 20 27 2 28.12.1 993 15.5.1990 1 3.3 4.3 40.5 2 20 60.6 13.1 3 
85 67 1 3 3 52 20 30 2 10.2.1995 11.6.1990 1 6.6 5.6 65.4 2 80 65.9 12 2 
86 76 1 3 3 52.5 20 30 2 12.5.1991 1.8.1990 1 4 5.3 35.5 1 66.1 69.7 12.4 2 
87 72 1 2 3 52 20 29 2 4.2.99 14.2 .1 992 2 5.6 6 47.6 1 42.2 70.2 14.3 2 
88 77 1 2 3 52 20 29 2 2.3.99 24.2.1 992 2 5.3 5.3 55.8 2 89.8 64.7 14.1 3 
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